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Abstract
Abstract
Epstein-Barr Virus (EBV) is associated with several human cancers including 
Burkitt’s lymphoma (BL), Hodgkin’s disease and nasopharyngeal carcinoma amongst 
others. In these cancers, a different subset of the viral latent genes are expressed, but all 
express the EBV small encoded RNAs: EBER1 and EBER2. The EBERs are polymerase 
III (pol HI) genes but do not fall neatly into any of the 3 promoter types as they combine 
both pol II (Spl, ATF and TATA-like box) and pol III elements (A and B boxes). The 
EBERs have been shown to confer resistance to interferon (IFN)--a-induced apoptosis via 
binding of the IFN-inducible, double-stranded (ds) RNA-activated protein kinase PKR and 
inhibition of its activation by phosphorylation. Evidence has also suggested an oncogenic 
role of the EBERs in BL cells, indicating their possible contribution to the disease process 
of EBV-associated tumours.
In order to investigate the potential role of EBER1 as an oncogenic RNA in vivo, 
13 lines of transgenic mice designed to express EBER1 in lymphoid cells using three 
variant transgenes were generated. The transgenes incorporate a novel combination of 
tissue-specific RNA pol II and pol HI elements. The efficacy of transgene expression was 
confirmed in culture. Mice of 10 of the transgenic lines were shown to express EBER1 in 
lymphoid tissues and the expression varied between the lines. The phenotypic 
consequences of EBER1 expression in vivo were examined and lymphoid expansion in 
mice of several lines was observed at a young age as well as the development of B-cell 
lymphoma in one of the lines. Cross-breeding programmes were undertaken and have 
shown that EBER1 does not cooperate in lymphomagenesis with EBNA1. However 
cooperation was observed in B-cell lymphomagenesis between EBER1 and N-myc 
although not with c-Myc. This might suggest that the oncogenic mechanism is elicited 
through cell survival.
The role of EBER1 in response to dsRNA stimulation was analysed in vivo and 
results indicate an inhibition of Statl expression and activation by EBER1, This might 
reflect downstream actions of blockade of the IFN pathway or a new pathway.
The results in this study support the hypothesis that EBER1 has oncogenic 
properties, the first pol III RNA described as such. This implicates the RNA in the 
pathogenesis of EBV associated lymphoma in addition to its role in immune evasion.
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ISGF3 IFN-stimulated gene factor 3
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LB Luria broth
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LN Lymph node
mA Milli Ampere
mg Milligram
Mg Magnesium
MLNs Mesentheric lymph nodes
miRNA MicroRNA
ml Millilitre
\d Microlitre
mM millimolar
MMLV Moloney Murine Leukemia Virus
MOPS 3-N-morpholinopropanesulphonic acid
mRNA Messenger RNA
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1.1. Epstein-Barr Virus
1.1.1. Discovery of the virus
Members of the herpesviridae family are classified into three subfamilies: alpha, 
beta and gamma on the basis of their biological properties. Epstein-Barr virus (EBV), also 
called Human Herpesvirus 4, is a ubiquitous gamma-herpes virus, which was discovered in 
1964 in B lymphocytes cultured from an African Burkitt’s lymphoma. Its presence was 
detected by electron microscopy (Epstein et al., 1964) and it was the first time that this 
technique was used to confirm the presence of a virus.
EBV has a large double-stranded DNA genome, which encodes 87 genes (Kieff 
and Rickinson, 2001, Young and Rickinson, 2004, for reviews), including 11 latent genes 
(Figure 1.1). Two EBV types circulate in most populations, which are designated type 1, 
which is the most common type, and type 2. The main difference between the 2 genomes 
lies in the genes which encode the EBV nuclear proteins.
1.1.2. Primary infection, latent and lytic viral life cycles
More than 90 % of the world-wide population is estimated to be infected by EBV. 
The virus is normally contracted asymptomatically at an early age, via saliva and persists 
as a life-long infection in a latent state.
EBV infection takes place in the oropharynx of an individual. The virus infects 
naive B cells in the lymphoid tissue of Waldeyer’s ring. However, there is increasing 
evidence that the epithelium at the site of infection has a role in primary infection and in 
virus shedding (Borza and Hutt-Fletcher, 2002). EBV enters the B cells via CD21, the 
EBV receptor. Monoclonal antibodies directed against CD21 can block EBV infection. 
The infection correlates with the expression of CD21 during B cell development (Fingeroth 
et al.y 1984). The crystal structure of CD21 has now been determined and a possible region
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Figure 1.1: The EBV genome and the latent genes
This figure is a schematic diagram of the double stranded EBV episome showing the location 
of the different latent genes. The open reading frames o f the latent proteins are indicated with 
block arrows (EBNA in light orange, LMP in blue) showing the transcriptional orientation of 
each gene. BamA region signifies BamW\ A region and includes the BARFO and BARF1 
genes. The EBNA genes include: EBNA-LP, EBNA2, EBNA3A, EBNA3B, EBNA3C and 
EBNA1. The LMP genes include LMP1, LMP2A and LMP2B. The terminal repeats are 
shown in the yellow box and the origin of replication (oriP) in a red box. The location and 
orientation o f the EBERs (EBER1 and EBER2) are shown with green arrows. The figure is not 
to scale. EBNA: EBV nuclear antigen, LMP: latent membrane protein, EBER: EBV encoded 
RNA. This figure was modified from Murray and Young, 2001.
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for EBV attachment was identified (Prota et al., 2002). The most abundant glycoprotein of 
EBV, gp350/220, was shown to be the CD21 ligand (Nemerov etal., 1987, Nemerov et ah, 
1989) (Kieff and Rickinson, 2001, for review). Adsorption of gp350/220 to CD21 on the 
B-lymphocyte plasma membrane initiates infection of primary B lymphocytes. The 
interaction between gp42 and HLA class II, which functions as a co-receptor, is also 
required for infection (Wang and Hutt-Fletcher, 1998, Li et ah, 1997a). This step is 
followed by aggregation of CD21 in the plasma membrane and internalization of EBV into 
cytoplasmic vesicles (Carel et ah, 1990).
Once the virus enters the naive B cells, it switches on the growth programme 
leading to the activation of B cells, which can enter germinal center reactions without the 
presence of an antigen. Germinal center B cells will then differentiate into memory B cells 
(Thorley-Lawson and Gross, 2004, for review). Through the differentiation process, 
different sets of the latent genes are expressed (Babcock et ah, 2000). For instance, during 
the growth programme all of the latent genes are expressed (Joseph et ah, 2000), whereas 
germinal center B cells express only EBNA1, LMP1 and LMP2A. In the memory B cells, 
the virus enters the latency programme where it is thought that no viral protein is expressed 
(Hochberg et ah, 2004), unless the memory cell divides in which case EBNA1 will be 
expressed to ensure viral DNA replication. The replication of viral DNA during the latent 
phase occurs only once per cell cycle (Adams, 1987). Memory B cells are the perfect hosts 
for the virus as they are long lived cells and therefore EBV can persist for long periods of 
time and also remain undetected by the immune system as no viral proteins are expressed.
Reactivation and replication occur within healthy carriers in order to produce new 
virions, which can then infect new hosts (Amon and Farrell, 2005 for review). In tissue 
culture assays, it was shown that the virus can be induced to enter the lytic cycle by cross- 
linking IgG to the B cell receptor (BCR). In order to induce reactivation, the virus needs a 
latency programme where no LMPs are expressed as LMP2A has been shown to block 
reactivation of the lytic cycle following IgG cross-linking (Miller etal., 1994). During lytic 
replication several rounds of replication are initiated from the origin (oriLyt) 
(Hammerschmidt and Sugden, 1988). Lytic gene expression follows a specific order 
starting first with the immediate early genes, BZLF1 and BRLF1 (Biggin etal., 1987), then 
the early genes and finally the late genes (Tsurumi et ah, 2005, for review). It was shown 
that the expression of BZLF1 alone can transactivate the early promoter and therefore
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induce the lytic cycle (Rooney et al., 1989). BZLF1 was shown to activate its own 
expression as well as that of BRLF1 (Speck et al., 1997). The gene product of BRLF1 is 
also a transactivator and activates various viral and cellular promoters. BRLF1 was shown 
to bind the retinoblastoma protein in vivo early after reactivation (Zacny, etal., 1998). This 
interaction initiates cell cycle progression and thus production of viral DNA during the 
lytic cycle. The early genes are involved in DNA replication whereas the late genes encode 
the viral structural proteins.
1.1.3. The different diseases associated with EBV
As mentioned previously, infection usually occurs at an early age. However, if the 
primary infection occurs post-puberty, this can result in infectious mononucleosis (IM), 
also called glandular fever (Steven, 1996, for review).
EBV is also associated with several malignancies (Rickinson and Kieff, 2001, 
Baumforth etal., 1999, Kuppers, 2003, for reviews) including Hodgkin’s disease (HD) 
(about 50% of cases) (Kuppers and Rajewsky, 1998, for review), Burkitt’s lymphoma (BL) 
(Magrath, 1990, for review), nasopharyngeal carcinoma (NPC) (Raab-Traub, 1992, Spano 
et al., 2003, for reviews) and some rare T cell lymphomas (Meijer et al., 1996, for review). 
In immune-deficient individuals EBV can cause lymphoproliferative disease (Gaidano et 
al., 1998). EBV has also been linked to post-transplant lymphoproliferative disease 
(PTLD) (Nalesnik, 1998).
Different subsets of the latent genes are expressed in the different EBV associated 
tumour cells. For instance, in BL only EBNA1 and the EBERs, are expressed, which is 
termed latency I, whereas in HD and NPC, EBNA1, LMP1, LMP2 and the EBERs are 
expressed, which is termed latency II (Table 1.1).
1.1 A. Burkitt’s lymphoma
Denis Burkitt, who was a surgeon working in East Africa, identified a new tumour 
occurring in children, which is now known as Burkitt’s lymphoma (BL) (Burkitt, 1962). 
There are two forms of BL an endemic form (eBL), which is 100% associated with EBV,
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Latency stage EBV latent genes expressed Associated malignancies
I EBNA1, EBERs and BamHl A Burkitt’s lymphoma
n
EBNA1, LMP1, LMP2A, LMP2B, 
EBERs and BamHl A
Nasopharyngeal carcinoma, 
Hodgkin’s disease, 
Peripheral T-cell lymphoma
m
EBNA1, EBNA3, EBNA4, EBNA5, 
EBNA6, LMP1, LMP2A, LMP2B, 
EBERs and BamHl A
Lymphoproliferative disease, 
Post-transplant 
lymphoproliferative disease, 
infectious mononucleosis
Table 1.1: The latent genes expressed in the different EBV associated malignancies
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and a sporadic form (sBL). The endemic regions include equatorial Africa and coastal New 
Guinea and are coincident with the malaria belt. It has been suggested that the 
immunosuppression resulting from the malarial infection increases the chances of BL 
occurring. The sBL form is found world-wide at an incidence 50 to 100 times lower than 
the eBL. In Europe and the United States 15% to 25% of sBL tumors are EBV genome 
positive. A third form of BL is found in AIDS patients and 30% to 40% are associated with 
EBV.
Both eBL and sBL are characterised by chromosome translocations of chromosome 
8 and either chromosomes 2, 14 or 22. The translocation results in the juxtaposition of the 
c-myc locus (on chromosome 8) to one of the immunoglobulin (Ig) heavy or light chain 
loci and leads to the abnormal overexpression of c-Myc in B cells. The most common 
translocation in BL is t(8; 14) and the break points were shown to be different in eBL and 
sBL forms. In eBL, the breaks in chromosome 8 occur outside the c-myc locus whereas in 
sBL the breaks occur either 5’ to the first non-coding exon, within the first exon or within 
the first intron of myc (Pelicci et al., 1986). The breaks in chromosome 14 occur 5’ to or 
within the heavy chain joining region for eBL whereas in sBL the breaks occur near the \i 
switch region (Neri et al., 1988). The t(8;14) translocation is found in 80% of cases, the 
remaining translocations t(8;2) and t(8;22) account for 10% each and result in translocation 
of the light chain genes to the 3’ region of the c-myc sequence.
Other genetic and epigenetic changes are observed in BL following tumour 
progression (Lindstrom and Wiman, 2002, for review). p53 is often mutated in BL (Farrell 
et al., 1991) and the mutations are clustered in the core domain of p53 (Vousden et al., 
1993). In other cases of BL, MDM2 is overexpressed which leads to inactivation of wild- 
type p53 (Capoulade et al., 1998). \i\6INK4a  was found inactivated by promoter 
methylation in 42% of the primary BL tumours and 89.5% of the BL cell lines examined 
(Klangby et a l , 1998). This leads to the inactivation of the retinoblastoma protein (pRb) 
pathway. pl4ARF loss has been detected in BL at a much lower frequency (6%), which 
leads to inactivation of p53, as pl4ARF was shown to stabilise p53. Some of these tumours 
carried wild-type p53 and overexpression of MDM2 (Klangby et al., 1998, Lindstrom et 
al., 2001).
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In BL, EBV appears to be a contributing factor rather than an essential factor as 
sBL can arise without the presence of EBV. Only two of the latent genes are expressed in 
this B cell malignancy and these are EBNA1 and the EBERs. The expression of LMP1 and 
EBNA2 has been reported in less than 1% of eBL (Niedobitek et al., 1995) and in more 
than 1% of non-endemic BL (Carbone and Gloghini, 1996). EBNA1 was first suggested to 
supply an oncogenic function following the generation of EpEBNAl transgenic mice 
(Wilson and Levine, 1992, Wilson et a l, 1996). A subsequent study on the EpEBNAl 
suggested a survival function for EBNA1 in this model (Tsimbouri et al., 2002). It has 
been shown that inhibition of EBNA1 using a dominant negative approach in cultured BL 
cells leads to decreased survival and induction of apoptosis in EBV positive BL cells. It 
was therefore suggested that EBNA1 is a critical factor for survival of EBV positive BL 
(Kennedy et al., 2003). The EBERs could also provide a survival factor as they have been 
reported to confer resistance to apoptosis (Komano e ta l, 1999). This will be described in 
more detail in section 1.3.5.
1.2. The different latent protein encoding genes of EBV
1.2.1. The EBV nuclear antigens
1.2.1.1. EBV nuclear antigen 1
EBV nuclear antigen 1 (EBNA1) is the only viral protein expressed in all the 
disease states of EBV. However, it has been shown that EBNA1 is not essential for 
transformation of B-cells in culture but enhances this process (Humme et al., 2003). 
EBNA1 is a sequence specific DNA binding protein (Rawlins et al., 1985) and has a 
critical role in the maintenance and replication of the EBV genome (Yates et al., 1985). 
This is achieved by binding to the episomal origin of replication, oriP (Kieff ard 
Rickinson, 2001, for review). OriP is composed of 20 copies of the EBNA1 binding site in 
tandem repeats, called the family of repeats (FR), localised lkb away from the dyed 
symmetry element (DS), which comprises four copies of the EBNA1 binding site. Upcn 
binding to DNA, EBNA1 brings FR and DS in close proximity. Using a yeast two-hybrid 
approach, it was shown that a human cellular protein, termed EBNA1 binding protein 2 
(EBP2), binds EBNA1 and is important for plasmid maintenance (Shire et a l, 1999). [t
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was recently demonstrated that repression of EBP2 expression lead to a decrease in the 
EBNA1 capacity to bind mitotic chromosomes and that EBP2 was regulated by a kinase 
from the Aurora B kinase family (Kapoor et al., 2005). Aurora kinases phosphorylate 
hi stone H3 providing a direct path to the nucleosome and are regulators of cytokenesis 
during mitosis.
EBNA1 is composed of three different domains: a short N-terminal domain 
followed by a glycine-alanine (gly/ala) repeat domain and a C-terminal domain. The 
gly/ala domain varies in its number of repeats depending upon the EBV strain, which leads 
to a variation in the size of the protein (Kieff and Rickinson, 2001). This domain stabilises 
the mature protein preventing it being degraded by the proteasome (Levitskaya et al., 
1997) and also enables the protein to escape from immune surveillance. It does this by 
preventing antigen processing and thus presentation through MHCI; as a consequence the 
protein cannot be recognised through cytolytic CD8+ interactions (Levitskaya et al., 1995). 
Furthermore, this region limits “self’ expression also helping in immune detection by 
limiting protein levels. The C-terminal domain of EBNA1 comprises the dimerisation 
domain, as EBNA1 binds to DNA as a dimer (Bochkarev et al., 1995), the DNA binding 
domain, a transcriptional activation domain and a nuclear localisation domain.
1.2.1.2. EBV nuclear antigen 2
EBV nuclear antigen 2 (EBNA2) is a transcription factor of both viral genes 
(LMP1 and LMP2B) and cellular genes (CD21, CD23 and others) (Wang et al., 1987, 
Wang et al., 1990, Abbot et al., 1990, Cordier et al, 1990). EBNA2 does not bind to DNA 
directly, instead it interacts with a sequence-specific DNA binding protein RBP-Jk to 
regulate gene expression (Grossman etal., 1994).
EBNA2 plays a crucial role in the transformation process of B-cells in vitro by 
EBV. This was demonstrated by the EBV P3HR-1 strain, which has a deletion in the 
EBNA2 gene and the last two exons of EBNA-LP and is unable to transform B cells in 
vitro (Cohen etal., 1989). Cellular proteins whose expression was up or down regulated by 
EBNA2 were recently identified using a proteomics approach and were shown to be 
similar to those observed following EBV infection (Schlee et a l, 2004). c-Myc was also
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shown to be directly activated by EBNA2 (Kaiser et al., 1999) and thus could be an 
important factor for EBV induced B cell proliferation.
1.2.1.3. EBV nuclear antigen 3 family
The EBNA3 genes are adjacent on the viral genome (figure 1.1) and are termed 
EBNA3A (or EBNA3) (Hennessy etal., 1986), EBNA3B (or EBNA4) and EBNA3C (or 
EBNA6). EBNA3A and 3C have been shown to have an essential role in B cell 
transformation in vitro using EBV recombinant viruses (Tomkinson et al., 1993) whereas 
EBNA3B was found to be dispensable (Tomkinson and Kieff, 1992). However, EBNA3B 
has been shown to induce expression of CD40 and vimentin when stably transfected into 
EBV negative B cells (Silins and Sculley, 1994). EBNA3A was also shown to be important 
for the growth maintenance of LCLs (Maruo et al., 2003, Maruo etal., 2005). EBNA3C 
functions as a transactivator (Subramanian et al., 2002, for review) as its expression in Raji 
cells (which have a deletion in EBNA3C) increases the expression of LMP1 (Allday and 
Farrell, 1994). EBNA3C was also shown to repress the Cp promoter, and therefore can 
negatively regulate the expression of EBNA proteins including itself (Radkov et al., 1997). 
In vitro translated EBNA3C binds pRb, which is dependent on the pocket domain of pRb 
(Parker et al., 1996). The EBNA3 proteins (like EBNA2) interact with RBP-Jk (Robertson 
et ah, 1996). This disrupts RBP-Jk binding to EBNA2 thus repressing EBNA2 mediated 
transactivation. The binding of EBNA3A to RBPJk was shown to be important for LCL 
growth (Maruo et al., 2005).
1.2.1.4. EBV nuclear antigen leader protein
EBNA-leader protein (LP) is also termed EBNA5. It is encoded by the 5’ leader of 
each of the EBNA mRNAs (Kieff and Rickinson, 2001), and thus is a protein of variable 
size. Along with EBNA2 it is one of the first latent proteins expressed. EBNA-LP in 
cooperation with EBNA2 induces the G0 to Gi transition of resting B cells, which is 
measured by an increase in cyclin D2 expression (Sinclair et al., 1994). EBNA-LP also 
cooperates with EBNA2 in upregulating transcriptional targets of EBNA2, including 
LMP1 (Nitsche et al., 1997). EBNA-LP has been shown to co-localise with the 
retinoblastoma protein (pRb) in LCLs and it was shown in vitro that it binds both pRB and
7
Chapter I. Introduction
p53 (Szekely et al., 1993). EBNA-LP is not required for immortalisation of cultured B- 
cells; however mutants of EBNA-LP genes show an impaired ability to transform primary 
B cells (Mannick£/#/., 1991, Allan etal., 1992).
1.2.2. The latent membrane proteins
1.2.2.1. Latent membrane protein 1
Latent membrane protein 1 (LMP1) is thought to be the main transforming protein 
of EBV due to its classic oncogene activity in the ability to transform rodent fibroblasts in 
culture and lead to a tumourigenic phenotype of these cells in nude mice (Wang et al., 
1985). LMP1 is essential for EBV immortalisation of B cells in culture (Kaye etal., 1993). 
Furthermore in transgenic mice, LMP1 expression under the control of a polyomavirus or 
viral L2 promoter leads to the early stages of epithelial neoplasia (Wilson et al., 1990, 
Stevenson et al., 2005) and with an IgH enhancer predisposes mice to B cell neoplasia 
(Kulwichit et al., 1998, and our laboratory unpublished observations). LMP1 is a 
transmembrane protein composed of a short cytoplasmic N-terminal domain, six 
hydrophobic transmembrane domains and a long C-terminal domain (Eliopoulos and 
Young, 2001, Li and Chang, 2003, for reviews). LMP1 is a constitutively active receptor­
like molecule, which simulates an activated CD40 (Gires et al., 1997, Kilger et al., 1998). 
LMP1 exerts its function via its C-terminal domain, which encompasses three different 
regions termed C-terminal-activating regions (CTAR) 1, 2 and 3. CTAR1 binds the 
complex of cellular proteins belonging to the family of tumour necrosis factor receptor 
associated factors (TRAFs) whereas CTAR2 binds tumour necrosis factor-receptor death 
domain proteins (TRADDs). Through these associations, several signaling pathways are 
activated including the NFkB pathway (Huen et al., 1995), MAPK pathways (Eliopoulos 
et al, 1999b), JNK pathway (Eliopoulos et a l, 1999a), and PI3K, Akt pathways (Dawson 
et a l, 2003). The Jak-Stat pathway is activated via CTAR3 (Gires et a l, 1999). The 
oligomerisation of LMP1 at the plasma membrane is essential for activation of cell 
signaling (Liebowitz et al., 1992) and it has recently been shown that LMP1 is associated 
with lipid rafts (Rothenberger et a l, 2002).
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1.2.2.2. Latent membrane proteins 2A and 2B
Two distinct proteins are encoded by the latent membrane protein 2 (LMP2) gene: 
LMP2A and LMP2B (Sample et al., 1989). With differential promoter usage LMP2A 
incorporates an additional 5’ exon and hence N-terminal sequence compared to LMP2B. 
They both have 12 transmembrane domains and a short C-terminal domain. LMP2A also 
has a long Nt domain (Longnecker and Kieff, 1990). The use of EBV recombinants with 
mutations in different LMP2 parts demonstrated that the LMP2 proteins are not essential 
for EBV transformation of B-cells (Longnecker et al., 1993a, Longnecker et al., 1993b, 
Longnecker, 2000). They were also shown to be dispensable for in vivo growth of EBV 
infected B-cells following injection in SCID mice (Rochford et al., 1997). LMP2A was 
shown to associate with LMP1 in the plasma membrane of latently infected cells 
(Longnecker et al., 1991) and like LMP1, LMP2A associates with lipid rafts (Dykstra et 
al., 2001). The N-terminal domain of LMP2A contains an immunoreceptor tyrosine-based 
activation motif (ITAM) (Fruehling and Longnecker, 1997), which can be phosphorylated 
and is usually found on the B cell receptor (BCR) complex. The Src family of protein 
kinases (PTKs) and Syk interact with phosphorylated ITAM, usually following BCR 
stimulation, and with LMP2A. As mentioned previously, in tissue culture assays the virus 
can be induced to enter the lytic cycle by cross-linking IgG to BCR. As LMP2A was 
shown to mimic BCR signalling in transgenic mice (Caldwell et al., 1998), it was thought 
that LMP2A could also induce the lytic cycle. Unexpectedly, following IgG cross-linking, 
LMP2A prevented activation of the lytic cycle in B-cells. This was shown to occur via 
blocking of BCR-stimulated calcium mobilization and phosphorylation of signalling 
molecules through LMP2A’s association with Lyn and Syk (Miller et al., 1994, Miller et 
al., 1995). LMP2A was also shown to block BCR from entering lipid rafts and thus 
subsequent signalling from the receptor (Dykstra et al., 2001). Recently, a dual role for 
LMP2A in reactivation was suggested. In permissive B-cells, LMP2A was shown to 
induce the lytic cycle when acting alone, whereas following stimulation of BCR LMP2A 
was shown to inhibit reactivation (Schaadt et al., 2005).
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1.3. The EBV encoded RNAs
The EBV encoded RNAs (EBERs) encode two small non-polyadenylated RNAs 
called EBER1 and EBER2 (Clemens, 1993, Clemens, 2006, for reviews). The EBERs are 
transcribed by RNA polymerase HI (RNA pol HI) (Rosa e ta l , 1981, Howe and Shu, 1989) 
and are the most abundant viral transcripts in some latently EBV-infected cells; for 
instance the EBER1 level has been estimated to be as high as 107 molecules per cell 
(Lemer et a l, 1981). EBER1 is usually more abundant by 10 fold than EBER2, which is 
due to a faster turnover of EBER2 (0.75 hours) compared to that of EBER1 (8-9 hours) 
(Clarke et a l , 1992). Their abundance varies in different cell lines and may be related to 
the copy number of EBV DNA (Lemer et a l, 1981, Arrand and Rymo, 1982). Their 
abundance allows them to be readily used as target molecules for detection of EBV- 
infected cells in tissues by in situ hybridization, and their detection is considered a highly 
reliable marker of the presence of EBV (Wu et a l, 1991).
1.3.1. Structure of the EBERs
The EBERs are encoded by the right-hand 1000 base pairs of the EcoRI J fragment 
(Figure 1.2) of the EBV genome (Lemer et a l, 1981, Arrand and Rymo, 1982) and are 
transcribed from left to right on the EBV genome map (Arrand and Rymo, 1982). The 
EBER1 and EBER2 transcripts are 167 and 172 nucleotides long respectively and are 
separated in the genome by 161 bp (Rosa et a l, 1981).
The primary sequence of the EcoRl J fragment has been compared between five 
different EBV strains, which were isolated from different pathologies and in different 
geographical locations. No variation in the EBER1 sequence was observed between the 
different strains, whereas two single base pair changes were observed for the EBER2 gene 
at positions 68 (G to A) and 168 (A to G). Several base pair changes were observed in the 
region between EBER1 and EBER2 (Arrand et a l, 1989). A single base pair change was 
observed in the region 5’ of the EBER1 promoter and two substitutions were observed in 
the region 3’ of the EBER2 gene. These minor changes grouped the strains into two 
families, which corresponds with the two EBV types. This study suggests that a precise
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Figure 1.2: Diagrammatic representation o f the EBER genes
The top line indicates the linear EBV genome (172kb) with the relative location o f the EcoRl J 
fragment (see also figure 1.1). The bottom line indicates the EBER1 and EBER2 genes along 
with their promoter elements. The c-Myc binding sites (E boxes) on the EBER1 promoter is 
shown in green and white. The upstream elements are shown in yellow and in yellow and red 
for the TATA-like element. The internal elements are shown in red. The transcriptional 
regions o f the EBERs are shown in blue and the transcriptional direction of the two genes is 
indicated by an arrow. This diagram is not to scale. The figure is modified from Clemens 
1993.
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sequence is important for the function of these RNAs. This could be needed for the 
secondary structure of the EBERs, since both EBER1 and EBER2 are predicted to form 
extensively base-paired structures containing a number of short stem loops (Figure 1.3) 
(Rosa et al., 1981, Glickman et al., 1988). Herpesvirus Papio (HVP) is a baboon virus 
whose genome is co-linear with that of EBV and its small RNAs were shown to cross- 
hybridise with the EBER sequence. The secondary structure of the HVP RNAs is also 
conserved (Howe and Shu, 1988). Therefore, the structure of the EBERs is likely to be 
critical for their interaction with specific proteins and thus for their function in vivo.
1.3.2. Expression of the EBERs by RNA polymerase III
1.3.2.1. The RNA polymerase HI
The eukaryotic RNA pol HI synthesizes 5s rRNA, tRNAs, 7 spliced leader (SL) 
RNA, U6 small nuclear (Sn) RNA and a few other small stable RNAs and small viral 
RNAs such as the EBERs and the virus-associated (VA) RNAs of Adenovirus (Mathews 
and Shenk, 1991, for review). The VA RNAs are two small highly structured pol III 
RNAs. One of the features of pol IH action is that some of the promoters of pol ID genes 
require sequence elements downstream of the transcription start within the transcribed 
region (Paule and White, 2000, for review). The promoters of pol HI genes are divided into 
three types (Figure 1.4). Type I promoter is unique to 5s RNA and is composed of three 
internal elements: an A block, an intermediate element and a C block. The type II promoter 
is the most common type and is found in tRNA genes. This promoter contains two internal 
elements, the A and B blocks. The A blocks from type I and II promoters are homologous 
and interchangeable (Ciliberto etal., 1983). The location of block B is variable as well as 
the space between A and B blocks. On type II promoters, the transcription complex 
assembly first involves binding of transcription factor (TF) IIIC to A and B blocks. TFIIIC 
then recruits TFIIIB, containing the TATA-binding protein (TBP), which in turn recruits 
pol III (Geiduschek and Kassavetis, 2001, for review). In Saccharomyces cerevisiae, it was 
shown that TFIIIB alone recruits pol m  (Kassavetis et al., 1990). It was recently shown 
that c-Myc is also involved in activation of pol III transcription by binding to TFIIIB 
(Gomez-Roman et al., 2003). With type I promoters, the transcription complex assembly is 
similar to that of type II promoters, except for the binding of TFIILA on A and C blocks, 
which then recruits TFIIIC. The third promoter type (type III) does not require internal
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Figure 1.3: The protein binding sites o f EBER1 and EBER2
The EBER1 and EBER2 secondary structures are presented (as modified from Howe and Shu, 
1988) in this figure along with their identified protein binding sites. The La-antigen (La-Ag) 
binding site o f both EBER1 and EBER2 is presented in a blue box. The PKR binding site of 
EBER1 is presented in an orange circle. The L22 major binding site is presented as a green 
circle and the minor binding site as a dashed green circle. The stem-loop number o f EBER1 is 
presented in red and with Roman characters.
Type
Type II
B
Type III
PSEDSE TATA
Figure 1.4: The three types of promoters used by RNA polymerase III
The arrow on each promoter indicates the transcription start. The positions o f the various 
promoter elements are also indicated and include the A (orange), B (blue) or C (pink) blocks, 
the intermediate element (IE) (light blue), TATA box (light orange), proximal sequence 
element (PSE) (light yellow) and distal sequence element (DSE) (light green).
The figure was adapted from Paule and White, 2000.
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promoter elements, instead it has three upstream elements: a TATA box, a proximal 
sequence element (PSE) and a distal sequence element (DSE). The factors that bind these 
elements are different from types I and II except for the binding of TFIIIB on the TATA 
box. Proximal element transcription factor (PTF) binds PSE and Octl binds DSE. Both 
these factors interact and this interaction stabilises their binding to DNA. PTF also 
interacts with TBP (Geiduschek and Kassavetis, 2001, for review). RNA pol ID, unlike pol 
I and n, does not require the presence of various factors to terminate transcription. Instead, 
pol III recognizes a stretch of T (four or more) as the termination signal. The polymerase 
then releases the transcript.
1.3.2.2. The EBER promoter
The EBER genes are pol in genes but do not fall neatly into any of the 3 promoter 
types as they combine both pol II and pol HI elements (Figure 1.5). They have internal A 
and B blocks which are characteristic of type II promoters and are essential for pol III 
transcription (Figure 1.5A, red) (Howe and Shu, 1989). However, the efficient 
transcription of the EBER genes also requires 3 upstream elements: a TATA-like box 
(TGTA, -28 to -23, relative to the start site for transcription for EBER1), activating 
transcription factor (ATF) binding site (-51 to -47 for EBER1) and Spl binding site (-65 to 
-60 for EBER1) which are usually associated with sequences transcribed by RNA 
polymerase II (Howe and Shu, 1988, 1989) (Figure 1.5A, in yellow and in yellow and 
orange).
The deletion of all three upstream elements from either the EBER1 or EBER2 
promoter reduces transcription levels by more than 95% compared to a wild-type promoter 
in transfection assays (Howe and Shu, 1989). The deletion of both Spl and ATF elements 
showed a similar reduction in EBER2 transcription. However, sequences upstream of Spl 
in the EBER2 promoter are not essential for transcription, as their deletion did not affect 
the transcription of EBER2. The promoter of EBER2 was studied in more detail by testing 
mutated promoters in transfection assays. A mutation in the ATF binding sequence 
decreased transcription by 50% compared to a wild-type promoter, whereas mutation in 
either Spl or the TATA-like box decreased transcription by 80%. The authors also showed 
that the internal elements (A and B box) were essential for transcription of EBER2 as 
deletion of either element led to a drastic decrease in EBER2 expression.
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A
-136-122 -65 -60 -51 -47 -28 -23 +9+24 +66 +78 +167
Splmyc ATF TGTA
B
6301 gaaaggtcag cctgcaaggt ggatggcgtg ttttctgagg ttatccccgc tacgtgcagt
6361 gctgggtgat agagacccta gaatgtgtcg aaatgaccaa gcgtccccgc agcggggctc
6421 ccaacacggg ttcccagaga gggtaaaaga gggggccata aagcccaggg tgtaaaacac
6481 cgaccgcgcc accagatggc acacgtgggg gaaatgaggg ttagcatagg caacccccgc
6541 ctacacacca actatagcaa accccgcccc gtcacggtga cgtagtctgt cttgaggaga
6601 tgtagacttg tagacactgc aaaacctcag gacctacgct gccctagagg ttttgctagg
6661 gaggagacgt gtgtggctgt agccacccgt cccgggtaca agtcccgggt ggtgaggacg
6721 gtgtctgtgg ttgtcttccc agactctgct ttctgccgtc ttcggtcaag taccagctgg
6781 tggtccgcat gtttt
Figure 1.5: The EBER1 promoter and sequence
A diagram of the EBER1 promoter is presented in panel A. The c-Myc E boxes (myc) are 
shown in green and white. The three upstream elements are shown in yellow (Spl and ATF 
sites) and in yellow and orange (TATA-like box). The A and B boxes are shown in red. The 
nucleotide position of the different promoter elements is indicated where +1 is the start o f the 
EBER1 gene. Panel B shows the nucleotide sequence of the EBER1 promoter and gene. The 
Spl and ATF binding sites are shown in blue and bold. The TATA-like box is shown in dark 
purple and bold and the A and B boxes are in red and bold. The EBER1 transcribed sequence 
is underlined. The nucleotide position is indicated on the left hand-side and is relative to the 
B95.8 sequence.
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A study similar to this was undertaken to characterise the EBER1 promoter further 
(Wensing et a l , 2001). Successive deletion mutants of the different upstream elements of 
the EBER1 promoter were transiently transfected into 293 cells and EBER1 expression 
was compared to wild-type by northern blot. The results showed that like EBER2, the 
sequences upstream of the Spl site are not required for efficient transcription in this 
system. Deletion of the Spl site reduced transcription by 50%. Deletion of both Spl and 
ATF resulted in very little EBER1 expression. No additional effect was observed when the 
three upstream elements were deleted. The authors also showed that the presence of oriP 
(the sequence immediately 3’ to the EBER2 gene) and EBNA1 (which binds to and 
transactivates this sequence) increased EBER1 expression by two to four fold.
Several new binding sites were identified on the EBER promoters by genomic 
footprinting: one additional Spl site and two other binding sites (W and X) for EBER1, 
and two additional binding sites (Y and Z) for EBER2. Site X of EBER1 has two E boxes 
and it was demonstrated that c-Myc binds this element (Figures 1.2 and 1.5A) (Niller etal.,
2003). This finding suggests a direct role and contribution between EBER1 and c-Myc.
The TATA-like box of EBER2 was studied in more detail and was termed EBER 
TATA box or ETAB (Howe and Shu, 1993). The ETAB element is located at a pol II 
TATA box position (-28 -23). However, its consensus sequence is different from that of a 
TATA box (TGTAGA compared to TATAA). The ETAB promoter element does not 
function as a pol II TATA box and does not substitute for a TATA box in vitro. Different 
nucleotides in the EBER2 ETAB were mutated and the constructs were transfected into 
BJAB cells (an EBV negative BL cell line). When ETAB was mutated to a consensus 
TATA box, EBER2 transcription was inhibited. The results from the various ETAB 
mutants suggested that the correct ETAB sequence is necessary for EBER2 transcription. 
In in vitro transcription assays, it was shown that by replacing the ETAB element by a 
consensus TATA box followed by two G nucleotides instead of a thymidine doublet 
EBER2 could be transcribed by both pol II and pol HI. This suggested that the ETAB 
confers pol HI specificity for EBER2 transcription. As EBER1 and EBER2 have similar 
ETABs, one can hypothesise that this also applies for the EBER1 TATA-like box and that 
the presence of this element is necessary for EBER1 transcription by RNA pol III.
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1.3.3. Subcellular localisation of the EBERs
Low resolution in situ hybridisation data initially suggested that these RNAs have a 
nuclear location in Raji cells (Howe and Steitz, 1986). However, high resolution confocal 
laser scanning microscopy combined with in situ hybridisation using fluorescent probes 
has shown that both RNAs occur abundantly in both the cytoplasm and the nucleus of 
exponentially growing Raji cells (Schwemmle et al., 1992). The nuclear localisation of the 
La antigen was also confirmed (an EBER1 binding protein, section 3.4.1), suggesting that 
this protein does not interact with the EBERs in the cytoplasm. It was also demonstrated 
that in the cytoplasm DAI (also known as PKR, another EBER1 binding protein, section
3.4.3) co-localises with EBER1 in the rough ER region. However, during mitosis, the 
staining generated with the EBER probes was different than that obtained during 
interphase, and showed that during this phase the EBERs are not associated with either the 
La antigen or PKR. It seems likely that the EBERs exist in both nucleus and cytoplasm.
1.3.4. Interaction of the EBERs with cellular and viral proteins
To date, the EBERs has been shown to bind four host cell proteins: the La antigen, 
the small EBER-associated protein (EAP)/L22, the interferon-inducible protein kinase 
PKR, 2’5’ oligoadenylate synthase (2’5’OAS) and one viral protein: EBNA1.
1.3.4.1. The La antigen
The La protein was first identified as an autoantigen from patients with Systemic 
lupus erythematosus and Sjogren’s syndrome. Anti-La antibodies were used to 
immunoprecipitate La ribonucleoproteins (RNPs) from radioactive cell extracts, which 
showed that La was associated with a number of small RNAs (Maraia and Intine, 2001, for 
review). The La antigen was also shown to associate with viral small RNAs, such as 
adenovirus VAI and VAII (Rosa et al., 1981), the EBERs (Lerner et al., 1981) and the 
HVP RNAs (Howe and Shu, 1988).
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The La antigen is a phosphoprotein, whose main function is to bind the 
oligouridylate stretch at the 3’ termini of all mammalian RNA pol HI transcripts (Mathews 
and Francoeur, 1984). The binding is usually transient and is thought to stabilise the 
nascent RNAs from 3’ exonuclease degradation before they undergo maturation. However, 
for the EBERs the association was shown to be stable (Howe and Shu, 1988). The La 
antigen is also thought to be implicated in internal ribosome entry site-mediated translation 
in mammalian cells and in the processing of a subset of pol II 3’-processed snRNA 
containing a uridylate stretch. The La binding site on the EBER transcripts has been 
identified (Glickman et al., 1988) and is shown in figure 1.3. The findings confirmed that 
La binds to the U stretch at the 3’ end of the EBERs. The functional significance of this 
interaction remains to be determined. It has been hypothesised that the binding of La to 
EBERs could act to retain the EBERs in the nucleus as it is a nuclear protein.
1.3.4.2. The small EBER-associated protein/ L22
A second protein was shown to be present in the EBER-RNP and was termed the 
small EBER-associated protein (EAP) (Toczyski and Steitz, 1991). This protein was also 
shown to be associated with the HVP RNAs (Toczyski and Steitz, 1991). In patients 
suffering from different forms of leukemia, a chromosomal translocation t(3;21) was 
shown to result from the joining of the acute myeloid leukemia (AML) 1 gene and the EAP 
gene (Nucifora et al., 1993); however the joining of the two genes did not maintain the 
reading frame of EAP. EBER1 stem loop in  was later identified as the EAP binding site 
and nearly all the nucleotides in the stem loop were shown to be important for binding 
(Figure 1.3). Stem loop IV was identified as a weaker binding site using EBER1 deletion 
mutants (Toczyski and Steitz, 1993). It was subsequently demonstrated that EAP was the 
same protein as the ribosomal protein L22 (Toczyski et al., 1994). L22 is a component of 
the ribosome and is thought to have a role in organising the ribosome. Toczyski et al., 
(1994) indicated that in addition to the cytoplasmic and nucleolar localisation of L22, it 
also exhibited a nucleoplasmic signal in EBV positive cells unlike negative cells. As 
EBER1 also exhibits a strong nuclear signal (Howe and Steitz, 1986), it was concluded that 
the redistribution of L22 to the nucleus was due to the presence of EBER1 in EBV positive 
cells. This association was thought to occur before ribosome assembly. Therefore this 
could lead to a depletion of L22 from ribosomes and could alter translation.
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1.3.4.3. The inteiferon-inducible, double-stranded RNA-activated protein kinase PKR
The interferon (IFN)-inducible, double-stranded (ds) RNA-activated protein kinase 
PKR (previously known as p68, DAI, dsl, PI and PK<is) is one of the first proteins to be 
activated following any viral infection. Upon binding of dsRNA, PKR becomes activated 
and undergoes autophosphorylation. Once activated it can phosphorylate the a  subunit of 
protein synthesis initiation factor eIF2 (eIF2a) leading to inhibition of translation at the 
level of initiation (Clemens, 1997, Williams, 1999, for reviews). This and the role of PKR 
will be described in more detail in section 1.5.3.1. In this section the EBER1-PKR 
interaction is described.
In vitro assays have demonstrated that EBER1 binds to PKR (Clarke et al., 1991) 
and inhibits activation of PKR (Sharp et al., 1993). EBER2 was also shown to bind to PKR 
but was less efficient than EBER1 at rescuing protein synthesis following dsRNA 
treatment (Sharp et al., 1993). The interaction between the EBERs and PKR was also 
demonstrated in vivo (Nanbo et al., 2002). Different EBV positive BL cell lines were 
transfected with a flag tagged PKR plasmid. Immunoprecipitation with a flag tag antibody 
was followed by an RT-PCR using EBER1 or EBER2 primers and the results showed that 
EBERs co-precipitated with PKR. No signal was observed following transfection of a 
mutant PKR lacking dsRNA binding activity. The secondary structure of EBER1 was 
shown to be important to mediate this effect (Clarke et al., 1990, Clarke et al., 1991). Stem 
loop IV (nucleotides 87-123) of EBER1 was identified as the binding site for PKR (Figure
1.3) (Vuyisich et al., 2002). It was recently determined that PKR and L22 compete for 
EBER1 binding, suggesting that they bind the same or an overlapping site (Elia et al.,
2004), which is in agreement with the observation of Toczyski and Steitz (1993) where 
two binding sites for L22 were identified, one of which was stem loop IV. Elia et al., 
(2004) also showed that L22 rescued the inhibitory effect of EBER1 on PKR activation 
following binding to dsRNA. L22 was also suggested to be a substrate for PKR in vitro, as 
the ribosomal protein was found to be phosphorylated by PKR upon dsRNA treatment.
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1.3.4.4. The interferon-inducible 2’5’ oligoadenylate synthase
2’5’ OAS, like PKR, is involved in the primary response against viral infection and 
is also activated upon binding of dsRNA. 2’5’OAS is activated by dsRNA and in turn 
activates endoribonuclease (RNAse L), which leads to mRNA degradation, but its role will 
be described in more detail in section 1.5.3.2. EBER1 was reported to bind 2’5’OAS in 
vitro (Sharp et al., 1999). Surprisingly, like VAI of Adenovirus, EBER1 was shown to be 
an activator of 2’5’OAS in a concentration dependent manner. As shown for other 
proteins, the secondary structure of EBER1 might be critical for this interaction as no 
binding of 2’5’OAS was observed following digestion with RNase Tl. The interaction 
between EBER1 and 2’5’OAS is of a lower affinity than that of 2’5’OAS with dsRNA.
1.3.4.5. Interaction with the viral protein EBNA1
It had been suggested that EBNA1 binds to RNA through its RGG motifs (Snudden 
et al., 1994) and more recently was demonstrated that this is the case. Binding was 
increased when the RNA G U content was increased or when the RNA had extensive 
secondary structure (Lu et al., 2004). A recombinant EBNA1 protein was also able to bind 
an in vitro transcribed EBER1 probe. The complex was supershifted following the addition 
of an anti-EBNA 1 antibody, suggesting that the interaction was specific between EBNA1 
and EBER1. This interaction was also observed in Akata cells using a ribonucleoprotein 
immunoprecipitation assay (Lu et a l , 2004). However, the significance of the interaction 
between the viral protein and viral RNA in EBV infected cells is not clear.
1.3.5. Role of the EBERs in transformation and growth support
To date the possible contribution of the EBERs to transformation remains unclear. 
The EBERs are present in the majority of EBV cell lines and EBV positive tumours, with 
the exception of hepatocellular carcinoma (Sugarawa et al., 1999), which could suggest a 
possible role in growth transformation. However, this remains controversial. The EBERs 
are the last latent genes to be expressed following immortalisation of B-cells in culture, 36 
hours post-infection, therefore suggesting that they are not required during the early stages
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of infection. Moreover, an EBER-deleted EBV recombinant virus was reported to 
transform primary B lymphocytes into LCLs and was able to replicate like a wild-type 
EBV (Swaminathan et al., 1991). The recombinant virus was also able to reactivate its 
lytic cycle and infect other B lymphocytes. However, Yajima et al., (2005) recently 
revisited these findings and they reported that the previous group failed to produce large 
quantities of pure EBER-deleted recombinant virus, which they obtained using EBV 
negative Akata cells. Akata cells were isolated from an EBV positive BL and retained a 
latency I phenotype (Takada et al., 1991). EBV negative Akata cells spontaneously arose 
and were also isolated (Shimizu et al., 1994). Yajima et a l, (2005) also showed that the 
EBER-deleted EBV was able to infect B cells but had a much lower transforming ability 
than that of a wild-type virus. The LCLs harboring the EBER-deleted EBV grew more 
slowly than wild-type cells with EBV. This recent finding supports the hypothesis that the 
EBERs contribute to the transforming process of EBV.
The EBERs share similar properties with the VA RNAs of Adenovirus (Rosa et al., 
1981). The EBERs can functionally replace the VAs in mutant Adenovirus lacking VA 
genes (Bhat and Thimmappaya, 1983, Bhat and Thimmappaya, 1985). Therefore it was 
hypothesised that they have similar functions. For instance, the EBERs can bind and 
inhibit PKR in vitro, like VAI, suggesting that they can rescue protein synthesis. This 
could be important especially during the later stages of infection to help synthesise growth 
factors needed to support growth. Moreover, both the VAs and EBERs bind and activate 
2’5’OAS, which could lead to the mRNA degradation of anti-viral cellular genes and 
therefore support growth of the infected cells.
IL10 was shown to support growth of activated B-cells (Rousset et al., 1992). The 
EBERs have been suggested to support growth by inducing the expression of different 
autocrine growth factors. For example, IL10 expression was reported to be upregulated in 
EBV positive Akata and Mutu cells compared to their EBV negative counterparts. 
Following transfection of EBV negative Akata cells with the different latent genes of EBV 
it was concluded that the EBERs were responsible for the increased IL10 expression in 
these cells. This was confirmed using an EBER-deleted EBV. The addition of IL10 to the 
medium of EBV negative cells enabled their growth under low serum conditions and the 
growth of EBV positive cells was inhibited following the addition of anti-DL10 antibody to 
the medium. This suggested that in BL, IL10 acts as an autocrine growth factor, which is
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further supported by the finding that in BL biopsies IL10 is also detected (Kitagawa et al., 
2000). The same experiments in T cell lymphoma and in NPC have identified IL9 and 
IGF 1 to be acting as autocrine growth factors respectively (Yang et al., 2004, Iwakiri et al.,
2005).
The EBV positive BL cell line Akata, when selected for EBV negative subclones, 
lose the ability to grow under low serum conditions and to form colonies in soft agar and 
tumours in SCID mice (Shimizu etal., 1994). Several reports have suggested an oncogenic 
role of the EBERs in BL using this cell line (Takada and Nanbo, 2001, Nanbo and Takada, 
2002, for reviews). Studies have reported that high expression of EBERs, following 
transfection of EBV negative Akata cells, seemed to protect the cells from apoptosis under 
certains conditions (cycloheximide, glucocorticoid treatment or hypoxic stress) but not 
under serum deprivation (Komano e ta l, 1999, Ruf et al., 2000). Both studies showed that 
the injection of EBV negative Akata cells transfected with EBERs into SCID mice can lead 
to tumourigenesis. Komano et al., (1999) also reported that EBV negative Akata cells 
transfected with EBERs were able to form colonies in soft agar and that Bcl2 protein was 
found upregulated upon introduction of EBERs. Another group has reported that 
transfection of EBERs into an EBV negative BL cell line, BJAB, rendered the cells more 
malignant and resistant to apoptosis. It was shown that this transfection caused inhibition 
of PKR phosphorylation upon polyl polyC (pIC) stimulation (Yamamoto et a l, 2000). 
However, it was not tested whether resistance to apoptosis was due to inhibition of PKR 
phosphorylation. This was demonstrated using a dominant negative PKR. A catalytically 
inactivated PKR mutant, which could block phosphorylation of endogenous PKR, was 
transfected into EBV negative BL. These cells were rendered resistant to IFNa-induced 
apoptosis compared to untransfected cells. A second PKR mutant, which was catalytically 
active but lacked dsRNA binding activity, was transfected into EBV positive cells and 
shown to be able to be phosphorylated. This mutant did not bind the EBERs (Nanbo et al., 
2002). These results suggest that in BL, resistance to IFNa-induced apoptosis is conferred 
by EBERs via binding of PKR and inhibition of its phosphorylation. Taken together, these 
results suggest that the EBERs are implicated in the disease process of EBV-associated 
malignant disorders. However, one report showed that expression of EBERs in NIH3T3 
(rodent fibroblasts) cells enhanced growth in soft agar but failed to confer a consistent 
malignant phenotype following injection of the cells into SCID mice, suggesting that the
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presence of EBERs only is not sufficient to confer a tumourigenic phenotype in these cells 
(Laing et al., 2002).
Transfection of EBERs in an NPC cell line did not lead to either formation of 
colonies on soft agar or a tumourigenic phenotype in SCID mice despite the cells having a 
higher growth rate compared to cells transfected with the vector control. However, the 
cells exhibited lower PKR phosphorylation in response to pIC, increased Bcl2 expression 
and a decreased expression of apoptosis markers (Wong et a l, 2005). This suggests that 
the EBERs lead to resistance to apoptosis in NPC.
1.4. Transgenic mice
1.4.1. Introduction to transgenic mice
In the early 1900s the mouse became one of the mammals of choice for genetic 
studies due to its small size, ease of reproduction in captivity, large litter size and relatively 
fast generation time. The use of mice is now widespread and one of the most common uses 
is to study disease processes in vivo and especially to identify if a gene has any oncogenic 
properties by generating transgenic mice (Palmiter and Brinster, 1986, Jaenisch, 1988 for 
reviews). The first attempt at pronuclear microinjection was performed in 1966, where 
bovine gamma globulin protein was injected into mouse pronuclei. The zygotes were 
reported to have survived the mechanical stress of insertion of a glass needle into their 
pronuclei (Lin, 1966). It was not until the early 1980s that the generation of transgenic 
mice following pronuclear microinjection of DNA was described (Gordon et a l, 1980, 
Brinster et a l, 1980). Several reports then showed that the gene of interest was expressed 
and transmitted in the germline (Brinster et al., 1981, Wagner et a l, 1981, Gordon and 
Ruddle, 1981).
1.4.2. Generation of transgenic mice expressing myc genes
The myc family of genes are involved in several cell growth processes including 
cell proliferation and differentiation (Adhikary and Eilers, 2005, for review). A number of 
genes from this family have been implicated in the development of malignancies. The myc
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family of genes includes c-myc, N-myc, L-myc and S-myc. The myc genes encode nuclear 
helix-loop-helix phosphoproteins which dimerise with Max. The Myc-Max dimers bind E 
box DNA sequences and activate target linked genes (Marinkovic et al., 2004). However, 
Max also dimerises with other helix-loop-helix proteins, including members of the Mad 
family and Mnt, which limit supply of Max to heterodimerise with Myc. The Mad-Max 
and Mad-Mnt dimers act as transcriptional repressors, which antagonize c-Myc functions 
(Walker e ta l, 2005, Luscher, 2001, Hurlin and Dezfouli, 2004, for reviews). c-Myc was 
also shown to be involved in the activation of transcription by RNA polymerase I and HI 
(Grandori e ta l,  2005, Gomez-Roman e ta l, 2003), thus suggesting that deregulation of c- 
Myc could enhance cell growth by increasing the transcriptional activity of both pol I and 
III complexes and maybe lead to tumourigenesis.
The expression level of c-Myc was shown to be altered in many malignancies 
including BL. To gain more insight into the oncogenic properties of c-Myc transgenic mice 
overexpressing c-Myc were generated (Adams et a l, 1985). The expression was directed 
to the lymphoid compartment using the immunoglobulin heavy chain intronic enhancer 
(Ep). The mice succumbed to pre-B and B cell lymphoma at an early age. The phenotype 
was similar in the different lineages generated showing a massive enlargement of the 
lymph nodes, which was described as a “water wings” phenotype. The spleen also showed 
signs of enlargement as did the thymus (Harris et a l, 1988, for review). The tumours were 
monoclonal and of B cell origin as indicated by their IgH rearrangement. Several new lines 
of c-Myc mice have been reported since the publication of the original paper describing the 
generation of Epc-myc mice (Butzler e ta l,  1997, Kovalchuk et al, 2000, Cheung et a l, 
2004, Park et a l, 2005, Wang and Boxer, 2005). These c-Myc mice show a variability in 
their tumour onset (ranging from several weeks to several months) and pathologies 
indicating that the generation of transgenic mice with the same gene can lead to slightly 
different results depending on the construct used. However, the generation of these animals 
provides a tool to gain more insight into the mechanism of action of c-Myc in the 
development of lymphomas.
N-myc was discovered as a homologue of c-myc in neuroblastoma. EpN-myc mice 
succumbed to pre-B and B cell lymphoma; however the latency was longer than that of 
Epc-myc animals (Dildrop et a l, 1989). The phenotype was also similar to that of Epc-
21
Chapter 1. Introduction
myc animals with enlargement of the lymph nodes, spleen and sometimes the thymus. The 
tumours were of B cell origin (15/16) and clonal except for one tumour (1/16) which 
showed a T cell receptor rearrangement.
L-myc was identified in small cell lung carcinoma. EpL-myc mice in contrast to 
Epc-myc and EpN-myc preferentially developed T cell neoplasias and had a much slower 
onset of tumour development compared to E^c-myc animals (Moroy et al., 1990). Some 
animals developed B lymphomas. In both cases the tumours were of clonal origins.
1.4.3. Generation of transgenic mice expressing some of the latent genes of 
EBV
Transgenic mice have also been used to determine if viral genes have oncogenic 
properties in vivo. For instance SV40 T-antigen transgenic mice develop brain tumours 
(Brinster et a l, 1984). Therefore the use of transgenic mice could be a powerful tool to 
gain more insight into the function of the different latent genes of EBV (Wilson, 1997, for 
review).
1.4.3.1. LMP1 transgenic mice
LMP1 is regarded as the primary transforming protein of the virus. EpLMPl and 
Polyoma early promoter (Py)LPMl transgenic mice were generated in the laboratory 
(Wilson et al., 1990). High expressing E^LMPl mice died very quickly (post natal lethal 
for some) and no viable progeny or poor viability for others suggested that widespread 
expression of the transgene is lethal. However, those with expression in the skin displayed 
the phenotype of epidermal hyperplasia, seen in the PyLMPl mice (described below). 
Those EpLMPl lines of mice with either low enough or restricted LMP1 expression to 
survive showed lymphoid pathologies and one line studied over an extended period 
developed long latency lymphoma (described in Wilson, 1997). Similarly another group 
also reported the generation of EpLMPl mice. These mice show very low level expression 
and succumb to B cell lymphoma with a late onset (mainly after 18 months) (Kulwichit et 
al., 1998). Directing expression of LMP1 to skin in both PyLPMl (Wilson et al., 1990) 
and L2LMP1cao mice (Stevenson etal., 2005) revealed that this protein induces epithelial
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hyperplasia, a first step in carcinogenesis. Moreover, progression of the phenotype to 
papilloma and carcinoma was observed in mice expressing the NPC derived variant 
LMP1ca0 Taken together these results indicate that LMP1 is oncogenic in vivo in both B- 
cells and epithelial cells. Therefore LMP1 expression is thought to be directly implicated in 
the development of several EBV associated-malignancies such as HD and NPC.
1.4.3.2. EBNA1 transgenic mice
The use of this technique was of particular interest for EBNA1 as no oncogenic 
activity had been attributed in tissue culture assays. EpEBNAl mice were generated and 
mice expressing the protein succumbed to B cell lymphoma (Wilson and Levine, 1992, 
Wilson et al., 1996). Two of the lines (lines 26 and 59) developed a phenotype which was 
characterised by a massive enlargement of the spleen and liver. The lymph nodes were 
enlarged in some animals. The tumour latency and penetrance was different between lines 
26 and 59. The line 26 mice developed lymphomas between 4-12 months whereas the 
onset of line 59 was much later. The tumours in both lines were characterised and shown to 
be of B cell origin with IgH rearrangement and not T cell receptor rearrangement. A 
subline arose spontaneously from line 26, called line 26A, which had lost part of the 
transgene and was shown not to express EBNA1. Animals carrying this transgene do not 
develop tumours (Wilson et al., unpublished results). These results suggest that EBNA1 
has oncogenic properties in vivo. However, one cannot exclude at present that sequences at 
the site of insertion of the transgene contribute to influence the tumour phenotype. 
However the insertion has been found to be complex. This is currently under study in the 
laboratory.
In a recent publication a different series of EpEBNAl mice have been described. 
Unlike the mice described above (Wilson and Levine, 1992, Wilson et al., 1996) the Ep,- 
EBNA1 mice reported in this paper do not succumb to lymphoma even after 26 months 
(Kang et al., 2005). These mice were generated in the FVB background and importantly 
were maintained under specific pathogen free (spf) conditions, whereas the mice 
established in our laboratory are in a C57B1/6 background and maintained under 
conventional conditions (ie, not spf). If the reaction of the immune system plays a role in 
tumour development, as has been hypothesised by our group with respect to T-cell
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production of IL2 (Tsimbouri et al., 2002) then the pathogen status of the environment 
may be all important. The background of strains of mice can play a role in the development 
of tumours. For instance Epc-myc mice in a C57B1/6 background develop B cell 
lymphoma, whereas in a C3H/HeJ they also develop T cell lymphomas (Yukawa et al., 
1989). Mice of line 26 were backcrossed to FVB background in the laboratory and they 
also developed lymphoma (Drotar and Wilson, unpublished results).
1.4.3.3. EBNA2 and EBNA-LP transgenic mice
EBNA2 is one of the first genes of EBV to be expressed following B-cell infection 
in vitro. SV40 promoter and enhancer (SV)EBNA2 transgenic mice have been generated 
(Tomell et al., 1996). The animals succumb to kidney adenocarcinoma following a very 
long latency period. The expression of the transgene was low in kidney, spleen and liver 
and even lower in other tissues. EpEBNA2 lines of mice were generated (J.B. Wilson, 
personal communication) but these lines of mice showed no phenotype and it was 
suspected that expression levels were very low or negative and these studies were not 
pursued.
EBNA-LP transgenic mice have been reported and showed a phenotype of 
congestive heart failure (Huen et a l, 1993). In these constructs EBNA-LP was under the 
control of the metallothionein promoter, which would be expected to drive expression in 
the liver of the animal. To date, no EpEBNA-LP mice have been reported (or generated in 
this group).
1.4.3.4. LMP2A transgenic mice
LMP2A is a transmembrane protein, which has been shown to inhibit B cell 
receptor (BCR) induced apoptosis in BL cells (Fuduka and Longnecker, 2005). EpLMP2A 
transgenic mice were generated and no oncogenic phenotype was detected in vivo 
(Caldwell et al., 1998). However, expression of LMP2A in the B cells abrogates normal B 
cell development enabling IgM negative cells (cells lacking a BCR) to amass in the 
peripheral lymphoid organs. This result suggests that LMP2A provides a signal in the 
absence of the BCR, which supports the survival of the cells.
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1.4.4. Cooperation studies in mice
The activation of an oncogene is one of several steps involved in tumour 
development and progression. However, in order to fully develop a phenotype, the “pre- 
tumour” cell must undergo secondary events. Therefore to investigate the mechanism of 
cooperation between two genes in lymphomagenesis, cross-breeding studies have been 
undertaken with transgenic mice expressing the genes of interest. A cooperation between 
the two genes in tumourigenesis can be observed by an acceleration of the phenotype or a 
change of the pathology.
1.4.4.1. Cooperation between cellular genes
Several genes have been shown to cooperate with c-myc in tumourigenesis. For 
instance, a cooperation between c-myc and bcl2 was reported (Strasser et al., 1990). Epc- 
myc transgenic mice were crossed with EpBcl2 mice and the bi-transgenics developed 
tumours somewhat faster than the Epc-myc mice and with a more immature B-cell 
phenotype. This suggests a complementary role between c-Myc and Bcl2 where c-Myc 
activates proliferation and Bcl2 inhibits apoptosis. A cooperation was also demonstrated 
between between c-myc and pim l. EpPiml mice are slightly predisposed to lymphoma 
developing after a very long latency period; however when crossed with Epc-myc mice bi- 
transgenic mice develop pre-B cell lymphoma (Verbeek et al.y 1991). A strong synergy 
between the two genes was observed, as the bi-transgenic mice die in utero or just post­
natal. To date this is one of the strongest synergisms observed in vivo,
A synergy between piml and N-myc and L-myc was reported (Moroy et al.y 1991). 
In both cases an acceleration of the tumour onset was demonstrated. EpPim 1/EpN-myc bi- 
transgenic mice succumbed to pre-B cell lymphoma at an average age of 5 weeks 
compared to the 13 to 16 weeks observed for EpN-myc animals. E^Piml/EpL-myc bi- 
transgenic mice succumbed to T cell lymphoma at an average age of 3 months compared to 
9 months observed for EpL-myc animals.
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1.4.4.2. Cooperation between cellular genes and viral latent genes of EBV
Cooperation studies have been described for EBNA1. A synergy between EBNA1 
and Myc was reported (Drotar et al., 2003). E^EBNAl animals were crossed with Epc- 
myc or EpN-myc animals. In both cases a cooperation was observed between the two 
genes due to an acceleration of the tumour onset. However, the cooperation was more 
pronounced between EBNA1 and N-myc. This is likely due to the fact that EpN-myc 
animals have a longer latency for tumour development compared to Epc-myc animals and 
acceleration is more easily observed rather than any difference in the basis of the 
cooperation. This cooperation can give further insight into the mechanism of eBL, where 
both EBNA1 and c-Myc are expressed.
EpEBNAl animals were also crossed with EpBcl2 animals. No cooperation in 
lymphomagenesis was observed between the two genes, as the age of tumour onset from 
the bi-transgenic animals was the same as that of EpEBNAl animals and no difference in 
tumour pathology was noted from the EpEBNAl mice (Tsimbouri et al., 2002). This 
suggests that the two genes are redundant in lymphomagenesis and provides an insight into 
the mechanism of EBNA1 in this system, that it may act through anti-apoptotic (or 
survival) pathways. Evidence in support of this idea was provided by the observation that 
BCIxl is upregulated in pre-tumour transgenic samples, and subsequently EBNA1 has been 
shown to have a survival function in BL cells (Kennedy et al., 2003).
Therefore cooperation studies can reveal, in addition to cooperative action, the 
possible mechanism of action of an oncogene through the redundancy with oncogenes with 
known functions.
1.5. The interferon response
1.5.1. Introduction on the interferon response
The interferons (IFNs) are part of a large family of secreted proteins, which are 
involved in different processes such as cellular growth, hematopoiesis, immunoregulation
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and antiviral defense (Goodboum et al., 2000, Samuel, 2001, Malmgaard, 2004, for 
reviews). There are two types of IFNs termed type I and type II. Type I IFNs are induced 
directly by a virus and are composed of IFNa and IFNp. The former is predominantly 
expressed by leucocytes whereas the latter is synthesised by most cell types but mainly by 
fibroblasts. Type II IFN (EFNy) is induced by mitogenic and antigenic stimuli and is 
produced by natural killer (NK) cells, Thl CD4+ cells and CD8+ cytotoxic suppressor cells. 
Therefore, IFNa and p are the main cytokines for the innate immune response whereas 
IFNy is a regulator of the adaptive immune response (Schindler and Brutsaert, 1999).
1.5.2. First steps of the IFN response
1.5 .2.1. The interferon regulatory factors 3 and 7 and induction of IFNa and IFNp
The interferon regulatory factor (IRF) 3 and IRF7 are transcription factors located 
in the cytoplasm of un-stimulated cells (Sato et al., 2000, Zhang and Pagano, 2002, for 
review, Hiscott and Lin, 2005). IRF3 is constitutively activated whereas the expression of 
IRF7 is induced by the IFNa and p signalling pathway as it is under the control of EFN- 
stimulated gene factor 3 (ISGF3) (described in section 1.5.3). Following a virus infection, 
both factors become phosphorylated by IkB kinase epsilon and TANK-binding kinase 1 
(Fitzgerald et a l, 2003, Sharma et al., 2003) and translocate to the nucleus (Figure 1.6). 
Phosphorylated IRF3 forms a complex with CBP/p300 and binds to the promoters of IFNa 
and IFNp genes with phosphorylated IRF7. NFkB also binds to the promoter of IFNp but 
not of IFNa. IFNa and IFNp are then secreted from the cells and bind to their receptors in 
an autocrine and paracrine manner.
In non-stimulated cells a weak constitutive signal of IFNa and p was shown to be 
present (Taniguchi and Takaoka, 2001, for review). The spontaneous expression of IFNa 
and p occurs by an unknown mechanism. This weak constitutive signal is thought to allow 
a stronger response when the cells encounter a viral infection, which could be due to the 
pre-accumulation of IRF7 in the cytoplasm.
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1.5.2.2. Induction of IFNy
IFNy is not induced following a viral infection but mediates the second wave of 
cytokines and is induced by early cytokines or antigen stimuli. The main cytokine 
responsible for induction of IFNy production is IL12. Several other cytokines can induce 
IFNy expression and include IL2, IL18, IL21, IL23, IL27, IFNa and p and TNFa. In NK 
cells and CD4+ cells induction of IFNy involves Stat4 activation (Thierfelder et al., 1996, 
Nguyen et al., 2002). It also involves NFkB and nuclear factor activating transcription 
(NFAT) following stimulation by IL18 (Tsuji-Takayama et al., 1999).
1.5.2.3. EFNa-inducible genes: PKR and 2’-5’oligoadenylate synthetase
Following a viral infection, dsRNA is produced from the viral replication and 
protein synthesis. Two IFNa and pinducible genes, PKR (Der and Lau, 1995) and 
2’5’OAS (Goodbourn et a l, 2000, Samuel, 2001, for reviews) are activated following 
binding of dsRNA (Figures 1.6 and 1.7). Both PKR and 2’5’OAS are induced by ISGF3.
1.5.2.3.1. Characteristics and functions of dsRNA-activated protein kinase PKR
PKR is a ubiquitously expressed kinase, which is composed of two functional 
domains (Clemens, 1997, Williams, 1999, for reviews). The N-terminal domain contains 
the dsRNA binding domain, which is divided into two dsRNA binding sites. The structure 
of this domain has been determined and a model was proposed for its interaction with 
dsRNA (Nanduri et a l, 1998). The C-terminal domain is composed of the kinase catalytic 
domain. Following binding of dsRNA, PKR undergoes a conformational change which 
exposes the catalytic domain of PKR. Homodimerisation of PKR was shown to be 
important for autophosphorylation. It was suggested that one molecule of PKR would be 
phosphorylated by the other one (Williams, 1999). A cellular protein, p58, was identified 
as an inhibitor of PKR (Lee et a l, 1994). Using co-immunoprecipitation Polyak et a l, 
(1996) have shown that p58 binds PKR. The binding of p58 to PKR leads to inhibition of 
its autophosphorylation.
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Figure 1.7: PKR and 2 ’5’OAS signalling following an interferon response 
Following binding o f IFN to its receptor signal transduction pathways are induced leading to 
the expression of PKR and 2 ’5’OAS. Upon viral infection, viral dsRNA is produced. Binding 
of viral dsRNA leads to the phosphorylation of PKR (P-PKR) and the activation o f 2’5’OAS 
(A-OAS). Activated PKR blocks translation through the phosphorylation o f eIF2a and 
releases NFkB to activate transcription o f several target genes. Activated 2’5’OAS generates 
2’5’ oligoadenylate compounds which bind and activate RNAseL leading to mRNA 
degradation. This figure was modified from Goodbourn et al., 2000.
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To date the best characterised substrate of PKR is the alpha subunit of the initiation 
factor eIF2 (eIF2a) (Chong et al., 1992) (Figure 1.8 A). Activated PKR phosphorylates 
eIF2a on serine 51, which results in the sequestration of the recycling factor eIF-2B in an 
inactive complex with eEF-2GDP. The consequence of blocking eEF2 into its inactive form 
is inhibition of protein synthesis (both cellular and viral).
Another substrate of PKR is IkB, which is the specific inhibitor of NFkB. In 
response to dsRNA, PKR phosphorylates IkB (Kumar et al., 1994) by a mechanism 
involving NFkB inducing kinase (NIK) and IkB kinase (IKK) (Zamanian-Daryoush et al., 
2000). This leads to the release of NFkB and thus its translocation to the nucleus to 
activate the transcription of various genes implicated in mediating the anti-proliferative 
and survival effects of IFN such as class I major histocompatibility complex (MHCI) and 
IRF-1, as well as regulating IFNp transcription (Visvanathan and Goodboum, 1989) 
(Figure 1.8 B).
PKR loss of function phenotype in U-937 cells was investigated using two different 
strategies: a dominant negative mutant and overexpression of an antisense PKR transcript 
(Der and Lau, 1995). Suppression of PKR resulted in impaired IFN induction at both 
protein and mRNA levels. Moreover, loss of function of PKR resulted in enhanced 
replication of EMC V.
Mice devoid of functional PKR (PKR'7') were generated (Kumar et al., 1997). The 
mice exhibited a reduced antiviral response following IFNy and pIC treatments. Mouse 
embryo fibroblasts (MEFs) derived from these mice have been used in transfection assays. 
An IFN response was stimulated using different inducers and induction was measured 
using IRF1 reporter gene. Signalling deficiencies in PKR'7'MEFs were observed and the 
defects were rescued when PKR function was restored. A defect in activation of NFkB and 
IRF-1 was also observed in response to IFNy and pIC by electrophoretic mobility shift 
assays (EMSAs), as well as in the induction of several genes, such as the murine Gbp and 
MHCI (which are dependent on IRF1) shown by northern blots.
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Figure 1.8: Role o f PKR on eIF2a and NFkB
Following binding of dsRNA, PKR becomes autophosphorylated. Activated PKR then 
phosphorylates eIF2a (panel A). This leads to inhibition of initiation o f translation. Activated 
PKR also activates IkB kinase (panel B), which will dissociate NFkB from IkB. IkB then 
becomes ubiquitinated and degraded by the proteasome, whereas NFkB translocates to the 
nucleus where it will activate target genes including IFNp.
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1.5.2.3.2. Characteristics and functions of 2’5’ oligoadenylate synthetase and 
endoribonuclease L
2 ’5’ oligoadenylates are small active compounds, which are synthesized from 
adenosine triphosphate by activated 2’5’OAS (Kerr and Brown, 1978). The enzyme 
becomes activated upon binding of dsRNA. The newly synthesised 2’5’oligoadenylates 
bind to the inactive monomeric endoribonuclease (RNase) L, inducing its activation and 
dimerisation. Once activated, RNAse L degrades single-stranded RNA, including mRNA, 
which leads to inhibition of protein synthesis (Goodboum et a l, 2000, Samuel, 2001, for 
reviews). It was also shown that RNase L cleaves 28S ribosomal RNA which inhibits 
translation (Iordanov etal., 2000).
RNase L*7' transgenic mice have been generated and showed an impaired antiviral 
effect following IFNa treatment (Zhou et al., 1997). The RNase L 7' thymocytes and 
fibroblasts exhibited resistance to apoptosis when compared to wild-type thymocytes and 
fibroblasts following treatment with different apoptotic agents.
1.5.3. The signalling response pathway of IFNa and {3
The signalling pathway of IFNa and p is mediated by interferon activated receptor 
(IFNAR), which has 2 subunits denoted IFNAR1 and IFNAR2 (Kim et a l, 1997). IFNAR1 
and IFNAR2 are associated with Tyk2 (a member of the Jak family of kinases) and Jakl 
respectively in un-stimulated cells (Figure 1.9). IFNAR2 was also shown to be pre­
associated with the signal transducer and activator of transcription (Stat) 2 (Li et al, 
1997b). Upon ligand binding, IFNAR1 and IFNAR2 form a complex leading to the cross­
phosphorylation of Tyk2 and Jakl. The activated Jaks phosphorylate IFNAR1 creating a 
docking site for Stat2, which is then phosphorylated by Tyk2  on tyrosine 690 (Qureshi et 
al., 1996). This favours the recruitment of Statl, which becomes phosphorylated on 
tyrosine (Tyr) 701 by the activated Jaks. Two isoforms of Statl have been described and 
are generated by alternative splicing and denoted Statla and Statl p. Statlp lacks an exon 
encoding the last amino acids of Statl (Horvath, 2000, for review) and therefore cannot 
induce transcriptional activation of target genes. Thus the transcriptional activation domain 
of Statl resides in the 38 amino acids unique to the a  isoform. The activated Stats are
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released from the receptor and form two complexes termed IFN-a-associated factor (AAF) 
and IFN-stimulated gene factor 3 (ISGF3). The former is a homodimer complex composed 
of activated Statl whereas the latter is composed of both activated Statl and Stat2  and 
IRF9 (also known as p48) (Figure 1.9) (Horvath et al., 1996). Both Statla and p can 
functionally dimerise with Stat2 in ISGF3 complexes as Stat2 retains its transcriptional 
activity (Muller et al., 1993). The two complexes are translocated to the nucleus where 
they bind specific sequences and stimulate transcription. ISGF3 activates the IFN- 
stimulated response element (ISRE) (Li et al., 1998), which is present on the promoter of 
genes including IRF7, 2’5’OAS and PKR. AAF binds to the IFNy-activated site (GAS) 
element, which is present on the promoter of IRF1.
The phosphorylation of Tyr 701 is important for the dimerisation of Statl and also 
for its translocation and retention in the nucleus. The dephosphorylation of Statl on Tyr 
701 is required for it to leave the nucleus (Meyer et al., 2003). For maximal induction of 
IFN-responsive genes the phosphorylation of Statl on serine (Ser) 727 is also required 
(Wen et al., 1995). Several serine kinases are involved in this process including mitogen 
activated protein kinase (MAPK) p38. This kinase was shown to be activated in HeLa S3 
cells following treatment with either IFNa or IFNy (Goh et al., 1999) The authors also 
showed that following the pre-treatment of HeLa S3 cells with a p38 inhibitor prior to 
stimulation with either IFNa or IFNy Statl Ser 727 phosphorylation was reduced and that 
the antiviral activities of IFNs were diminished.
Balb-c mice with a null mutation in the IFNAR1 gene were generated and showed 
no sign of abnormal foetal development or morphological changes in adults. Male and 
female IFNARl'7' were fertile suggesting that type I IFNs are not important for 
development and reproduction (Hwang et al., 1995). However, these mice succumb to 
infection with Semliki Forrest Virus and Encephalomyocarditis Virus very quickly 
following injection, indicating that type I IFNs are involved in antiviral defence. 
Stimulation with IFNa or IFNp failed to induce 2*5*0AS activity, suggesting that IFNAR1 
is essential for transducing signals responsible for induction of 2’5’OAS activity in 
response to IFNa and p stimulation. The mice also showed elevated levels of myeloid 
lineage abnormalities of hemopoietic cells.
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A different group also generated IFNAR1 KO mice. The mice were unresponsive 
to type I IFNs, and extremely susceptible to viral infection by Vesicular Stomatitis Virus 
(Muller et al., 1994). Functional inactivation of the receptor was confirmed by analysis of 
different IFN-inducible genes, including MHC class I gene, 2’5’OAS, IRF1 and Mx-1 (a 
type I specific response marker in mouse cells).
1.5.4. The signalling response pathway of IFNy
The IFNy receptor is composed of 2 subunits: interferon gamma receptor (IFNGR) 
1 and IFNGR2, which are dissociated in unstimulated cells (Bach et a l, 1996). IFNAGR1 
is associated with Janus protein tyrosine kinase (Jak) 1 and IFNAGR2 is associated with 
Jak2 through their intracellular domains (Figure 1.10). Upon binding of IFNy, the two 
subunits associate bringing Jakl and Jak2 closer. Jak2 becomes phosphorylated and in turn 
phosphorylates Jakl (Briscoe etal., 1996). The activated Jaks phosphorylate IFNGR1 on 
specific tyrosine residues leading to the generation of a Stat docking site. Following its 
binding to the receptor, Statl becomes phosphorylated by the Jaks on Tyr 701. The 
phosphorylated Statl proteins (Horvath, 2000, Shuai and Lui, 2003, for reviews) then 
dissociate from the receptor and dimerise. The Statl homodimers, termed y-activated factor 
(GAF), translocate to the nucleus and bind to GAS promoter elements, thus stimulating 
transcription of IFNy-inducible genes.
1.6. Aims and approaches of the project
1.6.1. Aims of the project
This project was designed to test hypotheses in relation to the action of the EBERs 
and more specifically of EBERl. It was decided to study EBER1 and not EBER2 in the 
first instance due to the fact that EBERl is more abundant than EBER2 in most EBV- 
infected cells and because knowledge of die involvement of EBERl in the inhibition of the 
IFN response is more detailed. Moreover, both EBERl and EBER2 have been shown to 
have similar properties so far and therefore studying only EBERl may provide an 
hypothesis from which to test EBER2.
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The role of the EBERs in viral pathogenesis remains unclear. Recent evidence has 
suggested an oncogenic role of the EBERs in BL cells, thus indicating that they may 
contribute to the disease process of EBV-associated disorders. This led to the hypothesis of 
this project which was that EBERl contributes to the pathogenesis of EBV associated 
disorders either through or in addition to its role in inhibiting the anti-viral effect of IFN. 
Therefore the aim of this project was to examine and investigate the phenotypic 
consequences of expression of EBERl in vivo by generating transgenic mice expressing 
EBERl in their B cell compartment.
1.6.2. Approaches and summaries of the project
1.6.2.1. Chapter 3 Generation of EBERl transgenic mice
In order to approach our hypothesis, the first step of this study involved the design 
of the transgene and the generation of EBERl transgenic mice. As EBERl is a pol III 
transcript, it was decided to construct three different transgenes, which encompassed 
different sections of the promoter fused to the immunoglobulin heavy chain intronic 
enhancer (Ep) to direct expression to the B cells. This was a completely novel approach as 
no transgenic mice had been reported in the literature with both pol II and pol III elements. 
As the unusual EBERl promoter already contained pol II motifs, it was speculated that a 
tissue specific pol II motif could be functional. The different transgenes were tested for 
expression in culture using reverse transcriptase- polymerase chain reaction (RT-PCR) and 
northern blotting and then used for pronuclear microinjection to generate several EBERl 
positive founders. The transgenic status of the founders and their offspring was analysed 
by Southern blotting. Several lines were established (127, 131, 132, 133, 134, 135, 136, 
137, 138, 141, 142, 143, 144 and 145) and their inheritance pattern discerned, X-linkage or 
autosomal integration and transgene copy number were determined.
1.6.2.2. Chapter 4 Expression of EBERl in the different lines generated
In the generation of transgenic mice, once the lines have been established, the next 
step is to determine if the transgene is expressed and in which tissue expression is detected. 
This step is of importance for this study, as expression of the transgene is needed for any
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phenotype to develop and it was hoped to achieve tissue specific expression. The 
expression of the transgene was determined for each line generated using RT-PCR in all 
the lymphoid tissues and in selected lines (127, 131, 136, 137, 145) in non-lymphoid 
tissues.
To determine if in this transgenic system EBERl was transcribed by RNA pol HI, 
as it is in Burkitt’s lymphoma cell lines, an RT-PCR assay was developed. This was of 
importance as the transgene contains both pol n  and pol m  promoter elements as well as a 
pol II enhancer, which could lead to a distorted pol II expression. Therefore, RNAs from 
the highest expressing tissue of lines 127, 131, 134, 136 and 137, were used as template for 
different RT-PCRs.
In Raji cells, the presence of a minor species of EBERl was observed with a 5’ 
upstream start (Jat and Arrand, 1982, Arrand and Rymo, 1982). Therefore the possible 
presence of an upstream start for EBERl and a minor species was also investigated in the 
transgenic EBERl system of lines 127, 131, 134, 136 and 137. This gives further insight 
into the transcription of EBERl from the different EBERl constructs in the transgenic 
system.
1.6.2.3. Chapter 5 Phenotype analysis of the different expressing lines
The main aim in the generation of transgenic mice is to study their phenotype. For 
this purpose developmental defects, abnormal behaviour, abnormal immune response, or 
tumour formation can be analysed. A cohort of animals from the main expressing lines 
(127, 131, 136, 137, 142 and 145) was placed under a phenotype watch. To determine the 
origins of the tumour phenotype in animals of line 127, the protein level of different 
oncogenes and tumour suppressor genes from tumour tissues was analysed by western 
blotting. The binding activity of Myc was also determined by mobility shift assays.
An in vivo assay was developed to determine if EBERl was able to block a 
response to dsRNA induced in lines 127 and 137 animals. For this purpose polylC, which 
mimics double-stranded RNA, was injected in the tail vein of the animals and tissues were 
collected and analysed for expression and activation of different proteins involved in the 
interferon pathway by western blotting.
To further investigate the phenotypic effect of EBERl expression at the cellular 
level, FACS analyses were performed on cells isolated from the different lymphoid tissues 
of mice of lines 127 and 131. The different antibody combinations were designed to test if
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expression of EBERl modified the proportions of B and T cells or their differential status. 
Similarly, the levels of secreted IgM antibodies and of different cytokines were 
investigated in serum samples from mice of lines 127, 131 and 137 by enzyme-linked 
immunosorbent assay (ELISA).
1.6.2.4. Chapter 6  Cooperation study between EBERl and EBNA1 or Myc
In EBV positive Burkitt’s lymphoma cells, EBNA1 and EBERl are expressed and 
c-Myc deregulated (Magrath, 1990), suggesting a possible cooperation between these 
genes. Therefore, the aim of this chapter was to investigate the possible cooperation of 
EBERl in lymphomagenesis with EBNA1 and/or Myc (both N-myc and c-Myc were 
tested) using transgenic mice expressing these genes. This could give further insight into 
the mechanism leading to the development of eBL. For this purpose, EpEBERl and 
EpEBNAlmice were cross-bred and monitored for the development of lymphomas. 
Similarly, EpEBERl and EpN-myc or Epc-myc mice were cross-bred and monitored. To 
determine the B or T cell origin of the tumour cells immunoglobulin heavy chain and T 
cell receptor rearrangements were investigated. To understand the cooperative mechanism 
between EBERl and Myc, tumour tissues were collected and analysed using western 
blotting, to monitor changes in the expression levels of different genes, and by EMSA to 
test the binding activity of Myc.
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Chapter 2. Materials and Methods
2.1. Materials
2.1.1. Cell lines
Cell line Transgene EBV status Latency Reference
39.415 LMP1 Dabbagh and Wilson 
Unpublished
BJAB Negative Menezes etal., 1975
AK31 Negative Jenkins et al., 2 0 0 0
AK2003 Positive I From Prof Farrell’s lab 
Takada, 1984
Raji Positive m Pulvertaft, 1965
IB4 Positive m King et al., 1980
Table 2.1: The different cell lines used
2.1.2. Bacterial strains
All transformations were performed using the Escherichia coli (E. coli) DH 5a-F’ 
bacterial strain.
2.1.3. Mice strains and mouse lines for cross-breeding
The following strains of mice were purchased from HarlanOlac: C57B1/6, B6D2.F1 
(C57Bl/6x DBA/2), ICR.
Line
number
Transgene Strain Reference
26 EBNA-1 C57B1/6 Wilson and Levine, 1992; Wilson eta l., 1996
96 N-myc Balb-c Dildrop etal., 1989
97 c-myc C57B1/6 Adams etal., 1985, Jackson laboratories 
Stock number: 002728 
http://jaxmice.jax.org
Table 2.2: Mouse lines for cross-breeding experiments
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2.1.4. pcDNA 3.1 vector for cloning of the different EBERl constructs
pcDNA3.1 version A (Invitrogen) was used to clone EBERl PCR products and the 
Eg enhancer (appendix 1). It is a 5.5kb vector which contains a CMV promoter, an 
ampicillin gene for selection in bacteria and a neomycin gene for selection in mammalian 
cells.
2.1.5. Enzymes and primers
All enzymes were provided by Invitrogen or New England Biolabs (NEB) except 
for Pfu Turbo polymerase (Stratagene), Taq polymerase, T4 DNA ligase, DNAse I 
(Promega) and the reverse transcriptase MMLV (Invitrogen). All the primers used for 
PCRs, genotyping, sequencing and EMSA oligos were obtained from Sigma Genosys.
2.1.6. Chemicals, tissue culture and microinjection reagents
All chemicals were provided by Sigma unless otherwise indicated. Tissue culture 
reagents were purchased from Invitrogen. The hormones and buffers used for 
microinjections were purchased from Sigma.
2.1.7. Probes used for Southern and northern blotting
Probe fragment Plasmid number Expected size of insert Digest/PCR primers
EBERl P670 501bp CR1-CR4
EgEBERl p670 1995bp Xbal
EBNA1 p ll4 966bp EcoRl/BstXI
N-myc p75 800bp Pstl
IgH, J region p79 900bp XbaVXhol
TCR, Jpl p463 3300bp EcdRl/BaniHL
rpL32 p92 1600bp Sacl
Table 2.3: Probe fragments
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2.1.8. Antibodies used for FACS analysis, western blots and ELISA
Antibody name Stage FITC/PE Supplier Catalog number
B220 Pro-B to mature FITC eBioscience 11-0452-85
B PE Caltag RM 2604-3
CD43 Immature B FITC Pharmigen 553270
slgs Mature B FITC Caltag M 30901
CD5.2 Subtype B1 
Mature
FITC
PE
Caltag
eBioscience
MM 3201 
12-0051-83
CD2 Pre-B to B FITC Caltag RM 7801
CD23 Mature B FITC Caltag MCD 2301
CD80 B activation FITC Pharmigen 553768
CD8 6 B activation FITC Pharmigen 553691
MHCI FITC Pharmigen 553579
MHCII FITC Pharmigen 553605
RatIgG2a Isotype control FITC
PE
Serotec MCA 1212F 
MCA 1212PE
Table 2.4: B cell FACS antibodies
Antibody name Stages FITC/PE Supplier Catalog number
CD3 Mature T FITC
PE
Caltag HM 3401-3 
RM 3404
CD90.2 Immature T PE Caltag MM 2004
CD4 Mature T 
(T helper)
FITC
PE
Caltag RM 2501 
RM 2504
CD8 a Mature T 
(T killer)
PE Caltag RM 2204
Table 2.5: T cell FACS antibodies
Antibody Catalog
number
Supplier Expected 
size in kDa
Dilution 
factor used
Species
Id2 (C20) 
Blocking 
peptide
sc 489 
sc 489P
Santa Cruz 
Santa Cruz
15 1 /1 0 0 0  
5x excess 
weight
Rabbit
c-Myc (Cl 9) sc 788 Santa Cruz 67 1 /1 0 0 0 Rabbit
P-tubulin sc 9104 Santa Cruz 55 1 /1 0 0 0 Rabbit
Nmyc (Cl 9) 
Blocking 
peptide
sc 791 
sc 791P
Santa Cruz 
Santa Cruz
67 1 /1 0 0 0  
5x excess 
weight
Rabbit
Statl 9172 Cell signaling 84,91 1 /1 0 0 0 Rabbit
P- statl 
(Tyr 701)
9171S Cell signaling 84,91 1 /1 0 0 0 Rabbit
P- statl 
(Ser727)
9177 Cell signaling 91 1 / 1 0 0 0 Rabbit
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Antibody Catalog
number
Supplier Expected 
size in kDa
Dilution 
factor used
Species
PKR 3072 Cell signaling 74 1 /1 0 0 0 Rabbit
P-PKR 
(Thr 446)
07532 Upstate 74 1 /1 0 0 0 Rabbit
eIF2a 9722 Cell signaling 40 1 /1 0 0 0 Rabbit
P-eIF2a 
(Ser51)
972 IS Cell signaling 40 1 /1 0 0 0 Rabbit
Rb (C l5) 
Blocking 
peptide
sc 50 
sc 50P
Santa Cruz 
Santa Cruz
1 1 0 1 /1 0 0 0 Rabbit
P-Rb 
(Ser780)
9307 Cell signaling 1 1 0 1 /1 0 0 0 Rabbit
p53 (Ml 9) 
Blocking 
peptide
sc 1312 
sc1312P
Santa Cruz 
Santa Cruz
53 1 / 1 0 0 0 Goat
Table 2.6: Primary antibodies used for western blotting
The different antibodies used to detect a phophorylated form are labeled P followed by the 
antibody name. The phosphorylated residue is indicated.
Antibody Catalog
number
Supplier Dilution 
factor used
Species
Goat anti-rabbit 
IgG-HRP
sc 2030 Santa Cruz 1/4000 Goat
Donkey anti-goat 
IgG-HRP
sc 2 0 2 0 Santa Cruz 1/4000 Donkey
Table 2.7: Secondary antibodies used for western blotting
Antibody Catalog number Supplier
c-Myc (N262) sc 764X Santa Cruz
N-myc sc 791 Santa Cruz
Table 2.8: Antibodies used for supershifts in mobility shift assays
Antibody type Antibody name Catalog number Company
Coating Rat anti-mouse IgM heavy chain MCA 199 Serotec
Detection Goat anti-mouse IgM-HRP 1021-05 Southern 
biotechnology 
associates inc
Standard curve Mouse IgM kappa chain M-3795 Sigma
Coating anti-mouse IL10 14-7101-81 eBioscience
Detection Biotin conjugated anti-mouse 
IL10
13-7102-81 eBioscience
Standard curve Recombinant Mouse IL10 BMS347 Bender
MedSystem
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Antibody type Antibody name Catalog number Company
Coating Rat anti-mouse IgG lheavy chain MCA 336 Serotec
Detection Goat anti-mouse IgG l-H RP 1070-05 Southern 
biotechnology 
associates inc
Standard curve Rat anti-mouse IgG l kappa M-9035 Sigma
Table 2.9: Antibodies used for the ELISA
2.1.9. The different PCR primers used 
IgHF CR1 CR2
Ep Spl
CR3
ATF TATA
CR8
------------
EBERl
CR16 CR20 CR9 CR4
CR25
Figure 2.1: Diagram o f the different EBERl primers
Schematic representation o f the different primers used for EBERl PCRs, RT-PCRs and 
quantitative PCRs. For the primer sequence see table 2.10.
Primer name 5’ to 3’ primer sequence Tm °C
CR1 g tg tg tg tg a a ttc q tc a q c c tq c a a q q tq 78.8
CR2 g tg tg tg tg a a ttc a c ta ta q c a a a c c c c q 73.1
CR3 g tg tg tg tg a a t tc tc t tq a q q a q a tq ta q 68.4
CR4 g tg tg tg tc tc g a q a a a a q a tq c q q a c c a c 78
CR8 ag g a c c tac g c tg c 51.8
CR9 ta c ttg a c c g a a g a c 44.8
CR16 c tc a g a a a a c a c g c c a tc c 63.3
CR20 tc ta g g g c a g c g ta g g 57.4
CR25 g ta g a c a c tg c a a a a c c tc 54.6
Table 2.10: PCR primers for EBERl
Table o f the sequence o f the different EBERl primers used for cloning, PCRs, RT-PCRs 
and QPCRs. The primer sequences (5’ to 3 ’) along with the melting temperatures (Tm) are 
shown. For primers CR1, CR2, CR3 and CR4 the EBERl specific sequence is underlined.
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Primer name Forward 
or reverse
5’ to 3* primer sequence Tm °C
Cmyc-F Forward c a g c tg g c g ta a ta g c g a a g a g 66.9
Cmyc-R Reverse c tg t g a c t g g tg a g ta c tc a a c c 62.6
G3PDH5’ Forward t c c a c c a c c c t g t t g c t g t a 66.6
G3PDH3’ Reverse a c c a c a g tc c a tg c c a tc a c 66
Irhf Forward c g a g g a a tg g g a g tg a g g c 67.1
tRNALeu-F Forward g a g g a c a a c g g g g a c a g ta a 63.8
tRNALeu-R Reverse tc c a c c a g a a a a a c tc c a g c 64.1
Table 2.11: Other primers used for PCR
For the Cmyc primers the sequence was obtained from the Jax laboratory website. For the 
tRNALeu primers the sequence was obtained from Gomez-Roman et al., 2003.
Primer name Forward or reverse 5’ to 3* primer sequence
EMSAMvcF Forward g a g c g g a a g c a g a c c a c g tg g tc tg c t tc c
EMSAMycR Reverse g ta g g g a a g c a g a c c a c g tg g tc tg c t tc c
SplF Forward g a g c a ttc g a tc g g g g c g g g g c g a g c
S plR Reverse g ta g g c tc g c c c c g c c c c g a tc g a a t
NF-kB F Forward g a g c a g t tg a g g g g a c t t tc c c a g g c
NF-kB R Reverse g ta g g c c tg g g a a a g tc c c c tc a a c t
Table 2.12: Oligonucleotides used for the different electromobility shift assays
The nucleotides in bold in the forward oligonucleotide sequence indicate the consensus 
binding motifs.
2.1.10. Formulation of frequently used solutions
TE. pH7.5:
lOmM Tris HC1, pH 7.5 
lmMEDTApH8
lOx loading buffer DNA: 
0.42% (w/v) bromophenol blue 
50% (v/v) TE 
50% (v/v) glycerol 
0.42% (w/v) xylene cyanol
lOxTBEGLV 
55g Boric acid 
40(xl 0.5M EDTA pH8 
108g Tris base
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5Ox TAE (1L):
57.1ml glacial acetic acid 
372gNa2EDTA.2H20 
242g Tris base pH 8.5
Church buffer:
1% (w/v) BSA 
ImMEDTA 
500mM NaP04 
7% (w/v) SDS 
pH 7.2
Denaturing solution:
0.6MNaCl 
0.4M NaOH
STE:
ImMEDTA 
lOmMNaCl 
lOmM Tris HCL pH 7.5
SSC:
150mM NaCl 
15mM Sodium citrate 
pH 7.5
Tail solution:
1 OOmM EDT A pH8  
150mM NaCl 
1% (w/v) SDS 
lOmM Tris-HCl pH7.5
2FC:
49.45% (v/v) chloroform 
0 .1% (w/v) 8 -hydroxy quinoline 
1% (v/v) isoamyl alcohol
49.45% (v/v) buffered phenol saturated with 1M Tris pH 8.0 
Wrap with foil and keep at 4°C]
Loading buffer RNA: 
lx MOPS
17.8% (v/v) formaldehyde
50% (v/v) pure, deionised formamide
Loading dve RNA:
50% (v/v) glycerol 
0 .1% (w/v) bromophenol blue 
0 .1% (w/v) xylene cyanol 
50% (v/v) TE pH 7.5
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lOx MOPS buffer:
200mM MOPS 
lOmMEDTA 
50mM NaOAc 
pH, NaOH, 7
High salt buffer:
20mM Hepes pH 7.9 
0.4M NaCl 
ImMEDTA pH8  
lmMEGTApH8  
ImMDTT 
ImMPMSF
Protein 4x loading dve:
1M Tris pH 6 .8
8 % (v/v) SDS
30% (v/v) glycerol
1 0 % (v/v) 2 p mercaptoethanol
Bromophenol blue trace
Phosphate buffered saline fPBSV 
80mM Na2HP0 4  
20mM NaH2P 0 4 
lOOmM NaCl 
pH 7.5
Protein blocking buffer: 
lxPBS
0 .0 0 1 % (v/v) tween 
5% (w/v) non-fat dried milk
Protein wash buffer: 
lxPBS
0 .0 0 1 % (v/v) tween
Protein stripping buffer: 
lOOmM Pmercaptoethanol 
2% SDS
62.5mM Tris HC1 pH 6 .8  
NELC1 solution:
9 volumes of NH4CI [0.83% (w/v) in H20]
1 volume of Tris [2.06% (w/v) in H20 , pH 7.65] 
pH to 7.2 and filter sterilise
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5x Tris/glvcine buffer (3LV 
337.5g glycine 
90.6g Tris 
30ml 0.5MEDTA 
make up to 3L and pH 8.7
2.2. Methods
2.2.2. DNA techniques
2.2.2.1. Small scale plasmid DNA preparation
The procedure was performed using the Sigma miniprep kit and is based on the 
alkaline lysis of bacterial cells, followed by adsorption of DNA on to a silica membrane (in 
a column) in the presence of high salt (this protocol was adapted from the method of 
Bimboim and Doly, 1979). The DNA is then eluted from the column. Single-plasmid 
transformed bacterial colonies were inoculated in 5ml of L-Broth usually containing 
50pg/ml of Amp (unless otherwise stated) and incubated overnight with shaking at 37°C. 
1.5ml of the bacterial suspension was transferred into a microfuge tube and centrifuged for 
3 minutes at 13000g. Each sample was resuspended in 2 0 0 pl of suspension buffer and 
subjected to a modified alkaline-SDS lysis by the addition of 2 0 0 pl of lysis buffer, mixed 
and left for 5 minutes at room-temperature. Following lysis, the samples were neutralised 
by adding 350pl of neutralisation buffer. The cell debris, proteins, lipids, SDS and 
chromosomal DNA form a white viscous pellet after centrifugation at 13000g for 10 
minutes. The clear lysate was transferred to a GenElute miniprep binding column 
containing a silica membrane, which was centrifuged at 13000g for 1 minute in order to 
bind the plasmid DNA. The column was washed once with 750pl of wash solution and 
centrifuged at 13000g for 1 minute. This step removes any traces of contaminants which 
were introduced during the column load. The flow-through was discarded and the column 
was centrifuged an additional time to ensure that the excess of ethanol from the wash 
solution was removed. The elution step was performed with lOOpl of elution solution or 
with 1 0 0 pi H2O if the products were to be used for sequencing. The plasmid DNA was 
then kept at 4°C or -20°C.
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2.22.2. Large scale plasmid DNA preparation
An endofree plasmid preparation maxi kit (Qiagen) was used for the preparation of 
plasmid DNA for transfection of mammalian cells or for zygote microinjection. The purity 
of the plasmid DNA is one of the requirements for these 2 techniques. Bacterial 
endotoxins, also known as lipopolysaccharides, strongly influence transfections by 
reducing the transfection efficiency. Moreover, in B cells, the endotoxins can cause non­
specific activation of immune responses. The endotoxins are released during lysis of 
bacterial cells. LPS molecules are lipids and thus can form micellar structures leading to 
their co-purification with plasmid DNA. During the procedure, an endotoxin removal 
buffer is used which inhibits the LPS from binding to the resin of the QIAGEN-tips. Two 
different types of columns are used in this procedure: a QLAfilter maxi cartridge, which is 
used for clearing the bacterial lysates by filtration instead of centrifugation, and the 
QIAGEN anion-exchange tip, which is used for the plasmid DNA purification step.
The procedure is based on the same principle as the small scale preparation. A 
single plasmid-transformed colony was inoculated into 5ml of L-Broth usually 
supplemented with 50pg/ml of Amp (unless otherwise stated) and incubated with shaking 
at 37°C for 6  to 8  hours. 200p.l of this starter culture was transferred to 200ml L-Broth 
containing the required antibiotic and incubated overnight with shaking at 37°C. The 
bacterial cells were harvested by centrifugation at 6000g for 15 minutes at 4°C (in a 
Beckman JA-17 rotor). The preparation was performed following the manufacturer’s 
instructions using endotoxin-free plastic-ware. The pellet was resuspended in 10ml of PI 
buffer [50mM Tris.Cl (pH 8.0), lOmM EDTA, lOOpg/ml RNase A], lysed with 10ml of 
P2 buffer [200mM NaOH, 1% SDS (w/v)] and incubated for 5 minutes at room 
temperature. During this incubation the syringe format of the QLAfilter maxi cartridge was 
assembled. 10ml of Pre-chilled neutralisation buffer (P3) [3.0M potassium acetate (pH 
5.5)] was added to the sample and mixed. The lysate was poured into the barrel of the 
QIAfilter maxi cartridge and incubated for 10 minutes at room temperature. The white 
precipitate containing proteins, genomic DNA (gDNA), cell debris and detergent floats and 
forms a layer on top of the solution; this avoids clogging of the column. The lysate was 
filtered through the column by pushing the liquid through the filter with the plunger; 2.5ml 
of ER buffer [composition not given in the manufacturer’s instructions] was added to the
45
Chapter 2. Materials and Methods
sample and incubated for 30 minutes on ice. This step removes any traces of endotoxins. 
The QIAGEN anion-exchange tip column was equilibrated using 10ml of QBT buffer 
[750mM NaCl, 50mM MOPS (pH 7.0), 15% isopropanol (v/v), 0.15% Triton® X- 1 0 0  
(v/v)], which contains a detergent. This column is an anion-exchange resin composed of 
defined silica beads coupled with positively charged DEAE groups. The negatively 
charged phosphates of the DNA backbone will interact with the positively charged DEAE 
group and will only be eluted with the presence of high-salt. The filtered lysate was applied 
to the column and the flow-through removed. The column was washed twice with 30ml of 
buffer QC [1.0M NaCl, 50mM MOPS (pH 7.0), 15% isopropanol (v/v)], which will 
remove the majority of contaminants, such as RNA, protein, carbohydrates and small 
metabolites. The plasmid DNA was eluted in 15ml of the high salt QN buffer [1.6M NaCl, 
50mM MOPS (pH 7.0), 15% isopropanol (v/v)] and precipitated using 10.5ml of 
isopropanol (0.7 volumes). The sample was centrifuged at 15000g, 4°C for 30 minutes (in 
a Beckman JA-14 rotor). The supernatant was carefully decanted as the isopropanol pellet 
is fairly loose. The pellet was washed by adding 5ml of endotoxin-free 70% ethanol and 
centrifuged at 15000g, 4°C for 10 minutes (in a Beckman JA-14 rotor). The 70% ethanol 
removes any traces of salt and replaces isopropanol with a more volatile solvent. The pellet 
was air-dried for 5 to 10 minutes, resuspended in 50pl or lOOpl of endotoxin-free HjO 
depending on the size of the pellet and transferred to a microfuge tube. The concentration 
was determined using a spectrophotometer and also by loading an aliquot on a gel. 
Different digestions were performed to check the profile of the plasmid.
2.22.2. Genomic DNA preparation
Genomic DNA (gDNA) extraction was performed on mouse tail fragments and 
tissues and on cell pellets. The tail tissues were digested with 700pl of tail solution [50mM 
Tris (pH 8.0), lOOmM EDTA (pH 8.0), lOOmM NaCl, 1% SDS] plus freshly added 35pl of 
proteinase K (lOmg/ml). Non-tail tissues were first minced with a scalpel blade before the 
addition of tail solution and proteinase K. For the cell pellets, 300(iil of tail solution and 
15pi of proteinase K were used. The samples were placed overnight at 55°C with shaking 
in an Eppendorf thermomixer. The proteins were separated by adding an equal volume 
(700pl or 300pi) of Tris-HCl buffer-saturated phenol pH 7.5. The samples were thoroughly 
mixed and microfuged for 5 minutes at 13000g at room-temperature. After the
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centrifugation step DNA and RNA are in the upper aqueous phase whereas the proteins 
and cell debris are in the lower hydrophobic layer. Using cut yellow tips, the upper phase 
was transferred to a new microfuge tube without disturbing the interphase. An equal 
volume of 2FC was added to each sample and thoroughly mixed before being microfuged 
for 5 minutes at 13000g. This step further ensures the purification of the DNA from any 
residual proteins. The upper aqueous phase containing the DNA and RNA was transferred 
to a fresh microfuge tube. To preferentially precipitate the gDNA, lOOpl of 10M NH40Ac 
and 750pl ice-cold 100% ethanol (43pi and 321 pi respectively for cell pellets) was added 
to each sample and mixed until a white precipitate was observed. The tubes were 
microfuged at 8000g for 2 minutes to collect the gDNA. The supernatant was removed and 
the pellet was washed once with 750pl of 70% ethanol to remove excess salt. The samples 
were centrifuged at 8000g for 2 minutes. After removing the supernatant, the pellet was 
air-dried and resuspended in lOOpl of TE pH7.5, using 15pl to quantify by optical density 
(OD). To ensure that the gDNA was resuspended the samples were heated at 55°C for up 
to one hour and then stored at 4°C indefinitely.
2.2.2.4. Quantification of DNA and RNA
The concentration of a sample was determined by measuring the OD at 260nm. 
After large scale plasmid DNA preparation 5pl of DNA was added to 295pi of H2O 
(dilution factor of 60), whereas after a gDNA preparation 15pi of gDNA was added to 
285pi of H20  (dilution factor of 20). The sample was transferred to a quartz cuvette and 
the OD read on a spectrophotometer (Molecular Devices, Spectra Max plus). The 
concentration was determined using the following formula:
DNA concentration of the sample = OD260 x 50* x dilution factor x 1/light path (cm)
* For a double stranded DNA an OD26o of 1 equals a concentration of 50pg/ml.
* For a single stranded DNA an O D ^  of 1 equals a concentration of 33pg/ml.
* For a single stranded RNA an OD260 of 1 equals a concentration of 40pg/ml.
For large scale plasmid preparation the concentration was subsequently checked by 
electrophoresing an aliquot on an agarose gel along with a marker of a known 
concentration.
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For plasmid DNA preparation the samples were adjusted to a concentration of 
lp g /p l and stored at -20°C. For gDNA the different samples were adjusted to a 
concentration of 0.33pg/pl or 0.5pg/pl and stored at 4°C.
2 .2.2.5. Sequencing DNA fragments
An in house sequencing service was used (MBSU-DNA sequencing, Joseph Black 
Building, Department of Infection and Immunity). The sequencing primers were used at a 
concentration of 3.2pmoles. The sequences were analysed using Editview software.
2.2.2.6. DNA agarose gel electrophoresis
Agarose gels were prepared using either Ultrapure agarose (Gibco) for checking 
digests, PCR products or Southern blots, or low melting agarose (Nusieve) for gel 
extraction or making probes, in lx TAE buffer or lx TBE buffer. The agarose in buffer 
was melted in a microwave oven for 2 to 3 minutes. After slight cooling, ethidium bromide 
(EtBr) was added to a final concentration of 0.5pg/ml to the gel prior to casting. Samples 
were loaded and electrophoresed at 120V for 1 to 5 hours depending on the size of the 
expected fragments and the gel. The DNA fragments in the gel were visualised using a 
short wave (280nm) UV transilluminator. However the DNA fragments were visualised 
using a long wave UV for probe fragments and fragments for collection for construct 
generation.
2.22.1. Restriction digests
Restriction digestion of gDNA was performed according to Wilson et al., (1990). 5 
to 1 0 pg of gDNA was digested with a restriction enzyme (usually 3 units/pg of DNA) 
along with the manufacturer’s recommended buffer, in a total volume of 30 to 60pi. The 
samples were digested overnight at 37°C (or other recommended temperature). The 
following day, a further lpl of enzyme was added and the samples were placed at 37°C for 
2 to 3 hours. The reactions were then stopped by heating the samples at 65°C for 10 
minutes.
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Diagnostic digests were performed after each small and large scale plasmid 
preparation. For this, 1 to 3 pg of DNA was used with lpl (lunit/pl) of enzyme (up to 3 
units) along with the manufacturer’s recommended buffer. The samples were usually 
digested for 2  hours at 37°C (unless otherwise stated by the manufacturer). The reactions 
were stopped by heating the samples at 65°C for 10 minutes. For preparative digests, more 
DNA was used (10 to 50pg) with suitably increased enzyme quantities and time.
2.2.2.8 . DNA modification by ligation
Ligations were usually performed with a molar ratio of 1:3 to 1:10 (vector: insert). 
The following formula was used to determine the quantity of insert to add for the reaction 
(in ng):
ng of vector x kb size of insert insert
-------------------------------------  x molar ratio o f -------  = ng of insert
kb size of vector vector
Usually between 50 to 200ng of purified vector DNA was used for the reaction. 
The reaction was set up in a PCR tube with the appropriate amounts of vector and insert 
and H2O and lOx ligase buffer. 1 unit (lpl) of T4 DNA ligase was then added and mixed 
and the tube was placed in the PCR machine and incubated overnight at 16°C. Self-ligation 
of the vector was also performed as a control and in that case 50ng of vector was used. The 
reaction was performed in the same way as above.
Ligations of vector and insert were also performed in low melting agarose. For this 
purpose, the appropriate gel fragments were extracted from the low melting agarose and 
the concentration was determined (as described in section 2 .2 .2 .9.1). The molar ratio of 1:3 
to 1:10 (vector: insert) was also used for this type of ligation. Both the vector and the insert 
tubes were heated at 70°C for 5 minutes and the appropriate amounts of vector and insert 
were added and mixed in a PCR tube which was then cooled down to 37°C before adding 
the required amount of lOx ligase buffer and 1 unit of T4 DNA ligase. The tube was 
quickly placed on ice as the buffer contains ATP and both ATP and the T4 DNA ligase are 
heat labile. The PCR tube was placed in the PCR machine and incubated overnight at 
16°C. The following day the PCR tube was heated at 70°C for 5 minutes and the DNA was
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diluted in 2 0 0 jil of TE to dilute the agarose, which could “inhibit” the transformation into 
bacteria.
2.2.2.9. DNA fragment isolation and purification
2.2.2.9.1. Isolation of DNA fragments in low melting agarose
DNA fragments to be used as a probe, for Southern blots or northern blots, or to be 
used for cloning were eiectrophoresed through low melting agarose gels. The DNA 
fragments in the gel were visualised using a long wave UV transilluminator and the 
appropriate DNA fragments were collected with a scalpel and placed in a microfuge tube. 
The quantity of the DNA fragment (in ng) was also estimated visually against a known 
quantity standard. The tube containing the appropriate DNA fragment was heated at 70°C 
for 5 minutes and the volume was checked in order to determine the concentration of the 
sample. The sample was then kept at -20°C until further use.
2.2.2.9.2. Gel extractions
DNA fragments to be used for cloning or as a standard for the quantitative PCR 
reaction were eiectrophoresed through 1% agarose gels. The DNA fragments in the gel 
were visualised using a long wave UV transilluminator and the appropriate DNA 
fragments were collected with a scalpel and placed in a microfuge tube. The quantity of the 
DNA fragment (in ng) was also estimated in the gel against a known quantity standard. 
Qiagen gel extraction kit was used for the procedure. The first step consists of the 
solubilisation of the gel slice which is followed by the absorption of the DNA fragment to 
a silica membrane column and an elution step. The tube containing the appropriate DNA 
fragment was weighed and 3 volumes of QG buffer was added to 1 volume of gel (lOOmg 
of DNA/gel fragment to lOOpl of the kit’s solutions). The sample was heated at 50°C for 
10 minutes and mixed every 2 minutes. The QG buffer solubilises the agarose gel slice and 
also provides appropriate conditions for binding of the DNA to the silica membrane. 1 
volume of isopropanol was then added to the sample and mixed. The sample was applied 
to the QIAquick column and centrifuged for 1 minute at 13000g. The flow-through was 
discarded and 0.5ml of buffer QG was added to remove all traces of agarose. The column 
was centrifuged for 1 minute at 13000g and the flow-through was discarded. The bound 
DNA was washed with 0.75ml of buffer PE, which contains ethanol, and centrifuged for 1
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minute at 13000g. The flow-through was discarded and the sample was centrifuged for an 
additional 1 minute in order to remove any traces of residual ethanol. The DNA was then 
eluted in an appropriate volume (usually 50p,l) of filter sterilised H2O. The quantity of the 
DNA fragment recovered after the elution step was estimated by electrophoresing l^il 
through a gel against a known quantity standard.
2.2.2.9.3. NA45 isolation and purification of DNA fragments
This procedure was used for the isolation of DNA fragments for use in the 
microinjection of embryos. 20pg of plasmid DNA was digested with the appropriate 
restriction enzyme (60 units of enzyme were used). For the different EBER1 transgenes the 
Xbal restriction enzyme was used to generate the linear transgene fragment.
The NA45 paper (Schleicher and Schuell), which is a Diethylaminoethyl (DEAE )- 
Dextran paper, was cut into strips of the correct size and activated by placing it in a 
solution of ImM EDTA (pH 8.0) for 10 minutes at room-temperature. The strips were 
transferred to a solution of 0.5M NaOH for 5 minutes at room-temperature. The NA45 was 
then washed several times with sterile water and could be kept at 4°C indefinitely in this 
state.
The different digested plasmids were eiectrophoresed through a 1% agarose gel at 
100V for 1 hour or longer if further separation was required. A strip of activated NA45 
was inserted below the desired fragment into a slot cut into the gel. To prevent 
contamination from the vector DNA or other larger fragments, the gel above the desired 
fragment was cut off and discarded. The gel was eiectrophoresed for a further hour to 
allow transfer of the fragment on to the paper. The complete transfer was assessed by 
examination of the gel and paper on a long wave UV light box. Once the transfer was 
complete, the paper was trimmed into several small pieces and placed in a microfuge tube. 
The paper was washed with NET solution [0.15M NaCl, O.lmM EDTA (pH 8.0), 20mM 
Tris (pH 8.0)] by vortexing and removing all the NET solution. The wash step was 
repeated. The DNA was then eluted from the paper in 2 0 0 pl of high salt solution [1M 
NaCl, O.lmM EDTA (pH 8.0) and 20mM Tris (pH 8.0)] at 6 8 °C for 15 minutes. The eluate 
was transferred to a new microfuge tube and a further 2 0 0 jul of high salt solution was 
added to the NA45 paper. The second elution was performed at 6 8 °C for 20 minutes or as 
required to elute all DNA. This can be monitored by examining the NA45 paper under long 
wave UV light. The eluates were pooled and precipitated overnight at -20°C by adding
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50|ml of H2O and 1ml of EtOH. The following day the sample was centrifuged at 13000g, 
4°C for 15 minutes and washed once with 70% EtOH. The pellet was air-dried and 
resuspended in 40pl of H2O.
The quality of the fragment was checked and quantity estimated by electrophoresis 
of 1^ 1 and 5pi through an agarose gel against a known quantity standard. The volume of 
remaining sample was then made up to 360pl with H2O and the sample was precipitated 
overnight at -20°C by the addition of 40pl 3M NaOAc (pH 4.5) and 1ml of EtOH. The 
following day the sample was centrifuged at 13000g, 4°C for 15 minutes and washed once 
with 70% EtOH. The pellet was air-dried and resuspended in filter sterilised injection 
buffer [5mM Tris (pH 7.4), 5mM NaCl, O.lmM EDTA (pH 8.0)] at a concentration of 
5pg/ml. A dilution to 2 pg/ml was also made. The concentration was checked by running 
an aliquot on a gel along with an appropriate standard.
Prior to using for microinjection, the DNA solution was centrifuged at 13000g for 
15 minutes at room-temperature. The top 2/3 was transferred to a new microfuge tube, 
leaving behind the lower part with any particulate matter, which could clog the injection 
needle. The lower part was kept and used as a fragment to generate a probe for Southern 
blot analysis.
2.2.2.1 0 . Southern blot
The DNA samples used for the Southern blot analysis were eiectrophoresed 
through a 0.8 to 1.6% agarose gel in lx TAE buffer. The gel was eiectrophoresed for 5 to 7 
hours at 120V or overnight at 30V. The EtBr stained DNA was visualised using a short 
wave UV transilluminator and the gel trimmed of any excess and the ladder track. The gel 
was placed in denaturing solution shaking for 30 minutes at room-temperature. The gel 
was washed 3 times 10 minutes in 0.5x TAE buffer. The DNA was transferred onto a 
Nytran supercharge membrane (Schleicher and Schuell) by electroblotting at 1500mA for 
3 hours in 0.5x TAE in a Hoeffer electroblotting tank. The DNA was UV crosslinked to the 
membrane using a Stratalinker at 1200kJ and either kept at -20°C until used or probed as 
described by Wilson etal. (1990).
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2 .2 .2 .1 1 . Slot blot
The slot blots were performed using either gDNA or plasmids as test samples. For 
each sample lOpg of gDNA was used and the volume was made up to 120pl with H2O. For 
plasmid DNA 20, 100 and 500pg were used. The DNA was denatured by the addition of 
40pi of 1M NaOH and vortexed for 10 minutes at room-temperature. 160pi of lOx TAE 
was added to the samples, which were vortexed briefly, microfuged for 1 minute at 13000g 
and placed on ice. Positively charged Nytran membrane (Schleicher and Schuell) was pre­
soaked in lx TAE and the apparatus was assembled. The samples were then loaded onto 
the slots and then the vacuum was switched on so that the samples could pass through the 
membrane. One drop of 5x TAE was loaded onto the slots and the vacuum was stopped 
when all liquid had passed through the membrane. The apparatus was dismantled and the 
membrane was UV cross-linked in a Stratalinker at 1200kJ. The blots were then kept at 
room-temperature until probing. The probing conditions, hybridising and washing 
conditions of the probe were the same as for Southern blots.
2.2.2.12. Probing of Southern blots, slot blots and northern blots with 32P labelled DNA 
fragments
The membranes were rolled up in perspex tubes with the DNA loaded side facing 
the inside of the tube. 10 to 15ml of Church buffer were added and the tubes were placed 
in a rotary hybridisation oven to pre-hybridise for at least 2  hours at the appropriate 
temperature. This step was performed to block any non-specific binding sites of the probe 
on the membrane.
The probes were generated using Stratagene’s Primelt labelling kit following the 
manufacturer’s instructions. 25ng of the appropriate DNA fragment (Table 2.3) isolated on 
low melting point agarose gel was added to random primers and the DNA was denatured at 
95°C for 5 minutes. 5x buffer lacking dCTP, 40 to 50pCi of 32P adCTP and 5 units of 
Klenow enzyme were added to the sample in this order. The reaction was incubated at 
37°C for 30 minutes to 4 hours. The probe was purified from unincorporated nucleotides 
using the NucTrap push columns system (Stratagene) according to the manufacturer’s 
instructions. The radiolabelled sample was applied on to a prewet column and the probe
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was eluted from the column by pushing down a syringe. The column was rinsed once with 
lx STE and pushed down using a syringe. The liquid from the sample and rinse were 
combined in the same collection tube. The probe was then denatured at 95°C for 5 minutes 
and added to the membrane in Church buffer. Hybridisation was carried out overnight at 
the appropriate temperature (Table 2.13). For Southern blots, the following day the 
membranes were washed 4 times for 1 0  minutes in 2x SSC, 0 .1% SDS, shaking at room- 
temperature. A hot wash was also carried out at the appropriate temperature (Table 2.13), 
shaking for 30 minutes to 1 hour in pre-heated O.lx SSC, 0 .1% SDS. For northern blots, 
the following day hot washes were carried out at the appropriate temperature, shaking for 
15 minutes in pre-heated 2 x SSC, 0 .1% SDS, for 15 minutes in pre-heated (60°C) lx SSC, 
0.1% SDS and for 15 minutes in pre-heated (60°C) 0.5x SSC, 0.1% SDS. The membranes 
were then sealed in plastic bags and visualised by autoradiography. The exposure time 
varied depending on the intensity of the bands.
Probe Hybridisation temperature Hot wash temperature
EBER1 60°C 60°C
EpEBERl 65°C 65°C
EBNA1 6 8 °C 6 8 °C
N-myc 65°C 65°C
IgH 65°C 65°C
TCR 65°C 65°C
Table 2.13: Hybridisation and wash stringencies of Southern blot probes
2.2.2.13. Polymerase chain reaction
Polymerase chain reaction (PCR) is a method for selectively and repeatedly 
replicating defined DNA sequences from a DNA mixture. The technique is based on the 
annealing of two short oligonucleotides (primers) to the opposite strands of a denatured 
target DNA molecule, thereby providing free 3’OH ends for DNA polymerase-mediated 
chain primer elongation. With each cycle (of 20-40 cycles in total) the DNA present after 
the previous cycle serves as a template; therefore the quantity of DNA is doubled. Cycling 
was performed in a PCR thermal cycler (MJ Research).
The PCRs were performed using either Pfu Turbo DNA polymerase or Taq DNA 
polymerase and plasmid DNA or gDNA as a template. The reactions were carried out in 25 
or 50pl final volume with lng to 300ng of template DNA as indicated. The figure below 
shows an outline of the different steps of the reaction:
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denaturing step: 95°C for 5 minutes 
denaturing step: 95°C for 30 seconds 
annealing step: X°C for 30 seconds f  Y cycles 
elongation step: 72°C for Z minutes > 
final elongation step: 72°C for 10 minutes 
X, Y and Z are different with the different sets of primers as detailed in figure 2.2.
Reagents Concentrations
DNA or gDNA Between lng and 300ng
lOx buffer, supplied with the enzyme 1/ 10 th of the final volume
MgCh if not included in buffer 1.5mMto2mM
dNTPs (dATP, dCTP, dGTP, dTTP) 0.4mM
Forward primer 0.2pM
Reverse primer 0.2pM
Enzyme (Taq or Pfu) 2.5 units
Table 2.14: Composition of a PCR
To clone the three EBER1 fragments into pcDNA3.1, three different PCRs were 
performed using Pfu Turbo DNA polymerase and pLEXIII as template for the EBER1 
gene (kind gift from Prof M. Clemens). The reaction was performed in 50pl final volume 
with lng of template DNA. The following reagents were used: 5pl of lOx buffer, lpl of 
20mM (stock concentration) dNTPs, 1 ptl of lOpM (stock concentration) forward and 
reverse primers (CR1-CR4, CR2-CR4 and CR3-CR4) and 2.5units of Pfu Turbo DNA 
polymerase. The cycling conditions were the following: 
denaturing step: 95°C for 5 minutes 
denaturing step: 95°C for 30 seconds 
annealing step: 60°C for 30 seconds r  30 cycles 
elongation step: 72°C for 1 minute > 
final elongation step: 72°C for 10 minutes
To check for the presence of the c-myc transgene, PCRs were performed using Taq 
DNA polymerase and tail gDNA as template. The reaction was performed in 25pi final 
volume with 300ng of template gDNA. The following reagents were used: 2.5pl of lOx 
buffer, 2 pi of 25mM (stock concentration) MgCb, 0.5 pi of 20mM (stock concentration)
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CR1-CR4
CR2-CR4
CR3-CR4
95°C, 5min 
95°C, 30sec 
60°C, 30sec 
72°C, lmin 
72°C, lOmin
^ 95°C, 5min 
95°C, 30sec
3Ox IgH-CR16 y  53°C, 30sec
72°C, lmin 
72°C, lOmin 
Only for 670 constructs
3 Ox
CR8-CR9
CR8-CR4
Cmyc-F
Cmyc-R
95°C, 5min 
95°C, 30sec 
40°C, 30sec 
72°C, 30sec 
72°C, lOmin
95°C, 5min 
95°C, 30sec 
50°C, 30sec 
72°C, 30sec 
72°C, lOmin
94°C, 3min 
94°C, 20sec 
64°C, 30sec 
72°C,35sec 
94°C, 20sec 
58°C, 30sec 
72°C, 3 5sec 
72°C, lOmin
25x
25x
1 2 x
25x
95°C, 5min 
95°C, 30sec ' 
IgH-CR9 y 40°C, 30sec ► 3Ox 
72°C, 30sec ^
72°C, lOmin 
For 670 constructs, elongation time 
is increased to 90sec
95°C, 5min 
95°C, 30sec 
IgH-CR20 f 53°C, 30sec 3Ox
72°C, 30sec 
72°C, lOmin 
For 670 constructs, elongation time 
is increased to 90sec
CR25-CR9
95°C, 5min 
95°C, 30sec 
40°C, 30sec 
72°C, 30sec 
72°C, lOmin
3 Ox
G3PDH5’
G3PDH3’
95°C, 5min 
95°C, 30sec 
55°C, 30sec 
72°C, 30sec 
72°C, lOmin
r 30x tRNALeu-F
tRNALeu-R
95°C, 5min 
95°C, 30sec 
40°C, 30sec ► 30x 
72°C, 30sec , 
72°C, lOmin
Figure 2.2: Cycling conditions for the different primer pairs
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dNTPs, 1.25 pi of lOpM (stock concentration) CmycF and CmycR primers and 2.5units of 
Taq Turbo DNA polymerase. The cycling conditions are shown in figure 2.2.
2.2.3. RNA techniques
2.2.3.1. RNA extraction according to Chomczynski and Sacchi
During the procedure, gloves were worn at all times to avoid any ribonuclease 
degradation via RNases. The bench and the different pieces of equipment were washed or 
soaked with 1%SDS (w/v) and rinsed with 75% EtOH (v/v). All the solutions were made 
up with diethyl-pyrocarbonate (DEPC)-H2 0  or treated directly with DEPC and autoclaved 
to destroy RNases. All the chemicals, solvents, solutions, microfuge and PCR tubes were 
kept in a separate RNA cupboard.
This method is based on the protocol developed by Chomczynski and Sacchi 
(1987). The tissues were kept either on dry-ice or in liquid nitrogen to avoid thawing until 
being processed. The frozen tissues were placed in a 5ml RNase-free falcon tube and 1ml 
of solution D (1ml per 50 to lOOmg of tissue) was added [0.36ml of 20 mercaptoethanol, 
50ml of 4M GT [250g guanidinium thiocyanate (Sigma), 0.75M Na citrate pH7 with citric 
acid and 1 0 % sarcosyl, 350ml dissolved at 65°C and 3 months life shelf], 1 months shelf 
life] and homogenised using a polytron homogeniser. For larger size tissues, they were cut 
on dry ice using a scalpel blade. The tissues were kept on ice until all the tissues were 
homogenised. For cell pellets the procedure was the same except that the cells were 
resuspended in solution D by vortexing. lOOpl of 2M NaOAc (equivalent to 0.1 volume of 
solution D used) was added to the samples and they were mixed thoroughly. 1ml of acid 
phenol (equivalent to 1 volume of solution D used, catalog number P1037, Sigma) was 
added to the samples and they were mixed thoroughly. 2 0 0 pl of CHCh-isoamylalcohol 
(49:1 ratio) (equivalent to 0.2 volume of solution D used) was added and the samples were 
vortexed thoroughly for 10 seconds and placed on ice for 15 minutes. The mixture was 
then centrifuged at lOOOOg (6000rpm in a JA-17 Beckman rotor) for 20 minutes at 4°C. 
This step separates the mixture into three phases: a colourless organic phase containing 
proteins (bottom phase), an interphase containing DNA, and a colourless aqueous phase 
containing RNA (the upper phase). For each sample the colourless aqueous phase was 
transferred to 2 microfuge tubes and 0.5ml of isopropanol was added to each tube
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(equivalent to 1 volume of solution D used). The RNA was then precipitated at -20°C for 
at least 4 hours or longer. The samples were centrifuged in a microfuge at 13000g for 2 0  
minutes at 4°C. The wet pellets were resuspended in 300pl of solution D (for each of the _ 
samples 150pl of solution D was added and the samples were combined in the same tube), 
vortexed and 600pi of EtOH was added. The RNA was precipitated at -20°C for 2 hours. 
The samples were microfuged at 13000g for 2 0  minutes at 4°C and the pellet was washed 
twice in 75% EtOH, air-dried and resuspended in lOOpl DEPC-H2O for small tissues and 
up to 400pl of DEPC-H2O for larger tissues by heating at 65°C and vortexing. The RNA 
was then DNAse I treated if used for RT-PCRs or quantitative RT-PCRs.
2.2.3.2. Analysis and quantitation of RNA
Following RNA extraction the quality of the RNA was checked visually on a 1.4% 
formaldehyde agarose gel. 5pl of RNA was added to 15pi of RNA loading buffer and 
heated at 6 8 °C for 10 minutes. 2pl of lOx loading buffer was added to each sample and 
they were loaded on to a 1.4% formaldehyde agarose gel, as described for the northern blot 
(section 2.2.3.5). The gel was eiectrophoresed at 100V for 1 hour in lx MOPS. The RNA 
was visualised using a short wave UV transilluminator to check for the presence of the 
three ribosomal RNA bands. Degraded samples were discarded.
To measure the RNA concentration, 5pl of each sample was used. Both the OD at 
260 and 280 was measured and the ratio (OD260/OD280) was determined. A good ratio 
was considered to be between 1.8-1.6 and optimal at 2. This ratio provides an estimate of 
the protein content in the sample (below 1.6). The RNA samples were then stored at -20°C 
until further use.
2.2.3.3. DNAse I treatment
Usually lOpg of RNA was treated with 2.5units of DNase I. The volume was made 
up to 50pl with DEPC-H2O and buffer. The samples were incubated at 37°C for 1 hour and 
heated at 75°C for 10 minutes to inactivate the enzyme. To remove any traces of DNA, 
200pl of DEPC-H2O was added to the samples, which were further subjected to an acid 
phenol extraction (see section 2 .2 .3.4).
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2.2.3.4. Acid phenol extraction
250pl of acid phenol (Sigma, phenol citrate, pH 4.7) was added and mixed. The 
samples were centrifuged at 13000g for 2 minutes at room-temperature. The aqueous phase 
was transferred to a microfuge tube and 250pl of chloroform was added and mixed. The 
samples were centrifuged at 13000g for 2 minutes at room-temperature. The aqueous phase 
was transferred to a microfuge tube. 1/10th volume of 3M NaOAC and 2.5 volume of EtOH 
were added and the RNA was precipitated overnight at -20°C. The samples were 
microfuged at 13000g for 20 minutes at 4°C. The pellet was washed in 75% EtOH, air- 
dried and the RNA resuspended in 2 0 pl of DEPC-H2O by vortexing and heating the 
samples at 65°C. The RNA was usually used for RT-PCR.
2.2.3.5. Northern blot
The gel tank, tray and combs were soaked overnight in 1% SDS and rinsed with 
DEPC-H2O in order to remove traces of RNases. Between 10 and 20pg of sample RNA 
was used and usually lpg  of EBV positive cell line (eg Raji) RNA was used for the 
positive control, unless otherwise stated. The samples were aliquoted in microfuge tubes 
and precipitated with 3M NaOAc (l/10th aqueous volume) and 100% EtOH (2.5x total 
aqueous volume) overnight at -20°C. The samples were centrifuged for 30 minutes, 4°C at 
13000g and the pellets washed once with 75% EtOH. The RNA pellets were air-dried and 
resuspended in 4pl of DEPC-H2O by heating to 65°C and vortexing thoroughly. 16pi of 
RNA loading buffer was added and the samples heated at 6 8 °C for 10 minutes to denature 
secondary structures, before being placed on ice and briefly centrifuged to collect the 
sample. Prior to loading the samples on a 1.4% formaldehyde agarose gel, 2pl of lOx 
loading dye was added to each sample. 1.4g of agarose was melted in 84.8ml of DEPC- 
H2O in a microwave. 10ml of lOx MOPS was added to the gel mix and cooled down 
before adding 5.2ml of formaldehyde and poured. Electrophoresis was performed in the 
cold room in lx MOPS buffer at 80V for 2 to 3 hours. A lkb ladder was also loaded as a 
size control after all the RNA samples were loaded and usually a spare well was left 
between the ladder and the first RNA sample. After running, the gel was washed 3 times 
20 minutes in 0.5x TAE buffer and in the third wash EtBr was added to a final
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concentration of 0.5pg/ml. The DNA ladder and RNA were visualised using a short wave 
UV transilluminator and the gel trimmed of any excess and the ladder track. The RNA was 
transferred onto a Nytran supercharge membrane by electroblotting at 1500mA for 2.5 
hours in 0.5x TAE in a Hoeffer electroblotting tank. The RNA was UV crosslinked to the 
membrane using a Stratalinker at 1200kJ and either kept at -20°C until used or probed as 
described by Wilson et al. (1990).
2.2.3.6 . Reverse transcriptase
cDNA synthesis was performed using a gene specific primer for EBER1 (CR4) and 
Moloney murine leukemia virus (M.MLV) reverse transcriptase (RT). For RNA 
polymerase II genes, such as GAPDH, the reaction was performed using the cDNA first 
strand synthesis kit from Abgene and oligodT primers. However, the procedure was 
performed in the same way.
2 pg of total RNA (DNAse I treated or not) was mixed with lpM  of either gene 
specific primer or oligodT, 0.4mM of dNTP and made up to a final volume of 12pi with 
DEPC H2O. The reaction was incubated for 5 minutes at 65°C to denature any secondary 
structures. The buffer was added to the reaction mix (lx  final concentration), plus 0.01M 
DTT and 200 units of RT enzyme. A negative control was also performed without the RT 
enzyme; this was used to check for gDNA contamination in the RNA sample. The samples 
were incubated at 37°C for 1 hour followed by 72°C for 1 0  minutes to stop the reaction. A 
PCR, or QPCR was usually performed using 1/5* of the RT reaction. The RT samples 
were stored at 4°C or -20°C for longer storage.
2.2.3.7. Quantitative reverse transcriptase-polymerase chain reaction
Quantitative PCR (QPCR) is a fluorescence-based method, which allows initial 
quantities of the template to be determined. The bigger the initial template the fewer cycles 
are required before a significant fluorescence signal is detected. The QPCR machine 
records the amount of fluorescence emitted after each cycle. Quantitect™ SYBR Green kit 
(Qiagen) was used along with the DNA engine Opticon™ (MJ research). SYBR Green is a 
fluorescent double stranded (ds) DNA binding dye thought to bind in the minor groove. 
The major drawback using this dye is that false positive signals from secondary structures
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or primer dimers can interfere with accurate quantification of the fragment under test. To 
try and minimise this, a water control with primers was always performed along with a -RT 
control for each sample. A melting curve was also performed at the end of the reaction to 
analyse product homogeneity and help to distinguish between a primer dimer and a PCR 
product.
For each QPCR a standard curve was generated so that an accurate comparative 
quantity of DNA could be determined in the different samples. To generate the standard 
curve, a PCR was first carried out using the appropriate plasmid DNA as template and the 
same primers as the ones used for the QPCR. The PCR product was eiectrophoresed 
through an agarose gel and the correct DNA fragment was cut out of the gel and gel 
isolated using the Qiagen kit. The concentration of the sample was determined by 
measuring the OD at 260nm and subsequently checked by running an aliquot on an agarose 
gel along with a marker of a known concentration. The standard curve template was 
adjusted to lng/pl and stored at -20°C until used. For the standard curve itself, 6  serial 
dilutions ( 1/ 1 0 ) of the standard curve template were performed starting with a 
concentration of O.lng/pl. l^il of each standard template was then used for the reaction. 
The standard reactions were always performed in duplicate. The fluorescence emitted by 
each standard sample was recorded by the machine and as the initial quantity of these 
samples was known a standard curve could be generated and plotted as log quantity versus 
threshold cycle (Ct). The Ct is defined as the cycle at which the sample’s fluorescence 
trace crosses the Ct line. A baseline-subtracted graph of the samples and standard sample is 
displayed as the fluorescence versus the cycle number. It is on this graph that the Ct line is 
positioned such that it intersects the fluorescence traces at a point where the signal 
surpasses the background noise and begins to increase. The following equation describing 
the linear standard curve is presented in the form of:
Y=mX + B
where m is the slope and B is the intercept of the line
An R value is also given and indicates how well the fit of the standard curve describes the 
variation of the data. Values closer to 1 indicate a good fit. The initial quantity in a sample 
can then be determined by replacing the Ct value of the sample in the following equation:
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Q  =  IQ (*“X+B)
where Q is the quantity in ng, m the slope and X the Ct value of the sample
The reactions for the cDNA samples were either performed in duplicate or triplicate. 
The figure below shows an outline of the different steps of the reaction: 
denaturing step: 95°C for 15 minutes (hot start enzyme) 
denaturing step: 95°C for 30 seconds
annealing step: X°C for 30 seconds f  Y cycles, plate read after each cycle 
elongation step: 72°C for Z minutes > 
final elongation step: 72°C for 1 0  minutes 
plate read
melting curve: 70°C to 90°C, increment: 0.3 and hold time: 1 sec 
X, Y and Z values differ with the different sets of primers.
Reagents Concentrations
cDNA Xpl
lOx buffer 1/ 10 th of the final volume
dNTPs (dATP, dCTP, dGTP, dTTP) 0.4mM
Forward primer 0.2pM
Reverse primer 0.2pM
Table 2.15: Composition of a QPCR 
2.2.4. Protein techniques
2.2.4.1. Protein extraction from tissues using a high salt buffer
The proteins were extracted in high salt buffer containing phosphatase inhibitors 
(Sigma, cat. No. P5726, as recommended by the manufacturer’s instructions) and protease 
inhibitors (Sigma, cat. No. P2714, as recommended by the manufacturer’s instructions). 
The phosphatase inhibitor cocktail contains sodium vanadate, sodium molybdate, sodium 
tartrate and imidazole; this cocktail can inhibit acid/alkaline and tyrosine protein kinases. 
The protease inhibitor cocktail contains AEBSF, E-64, bestatin, leupeptin, aprotinin and 
sodium EDTA; this cocktail can inhibit serine, cysteine, aspartic acid and metalloproteases. 
For each sample usually 0.5ml of high salt buffer per 0.1-0.2mg of tissue was added to a
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5ml Falcon tube. The samples were homogenised using a Kinematica polytron 
homogeniser. Before and after each sample was processed the polytron was washed with 
1% SDS, 3 H2O washes and 70% (v/v) ethanol. Once homogenised the samples were 
placed on ice for 1 0  minutes, transferred to a fresh collection tube and microfuged at 
13000g, 4°C for 15 minutes. The supernatant was transferred to a fresh microfuge tube and 
the protein concentration was determined using a Bradford assay. The samples were then 
placed at -70°C until used.
2.2.4.2. Quantification of proteins using a Bradford assay
This method is based on the Bradford dye-binding procedure (Bradford, 1976), 
which is a colourimetric assay. A standard curve was performed with a known 
concentration of BSA as shown in the table 2.16. 5pl of high salt buffer was added to all 
the BSA standards. 5pl of sample was added to 795pl of TE in the appropriate cuvette. 
2 0 0 pl of Biorad dye was added to each sample and standard; the samples were inverted a 
few times and left to stand for 5 minutes for the colour to develop. The optical density of 
each standard and sample was read at 595nm. Using the values obtained for the BSA 
standard a standard curve was drawn (X axis = OD and Y axis = concentration) and the 
protein concentration of each sample was determined.
BSA quantities in pg BSA (lOOpg/ml) added in pi TE in pi
0 0 795
1 1 0 785
2 2 0 775
4 40 755
8 80 715
16 160 635
Table 2.16: Standard protein curve for the Bradford assay
2.2.4.3. Western blot
2.2.4.3.I. SDS polyacrylamide gel electrophoresis of protein samples
The polyacrylamide gels were prepared as described in table 2.17. Different 
percentage gels were performed in order to separate different sizes of proteins. For 
instance, a higher percentage gel was used to resolve small proteins.
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The running gel was poured first and overlaid with a layer of butanol-saturated 
water. Once set (usually after 30 minutes), the water was removed and the stacking gel was 
poured on top and the comb was placed. This was allowed to set for approximately 40 
minutes and then assembled into the electrophoretic apparatus. One litre of running buffer 
was added and the samples were loaded as described in section 2.2.4.3.2.
Reagents 5% stacking gel 
(for 2  gels)
7.5% running 
gel (for 1 gel)
1 0 % tunning 
gel (for 1 gel)
12.5% running 
gel (for 1 gel)
40% Bis- 
Acrylamide
3.75ml 9.375ml 12.5ml 15.63ml
1M Tris pH 6 .8 3.75ml ----- ------
1.5M Tris pH 
8 .8
------ 12.5ml 12.5ml 12.5ml
2 0 % SDS 150*11 250|xl 250*il 250*il
0.5MEDTA 60*il 1 0 0 ^ 1 1 0 0 |il 1 0 0 *il
H20 2 2 ml 27.175ml 24.05ml 20.97ml
TEMED 30*il 50(il 50*il 50*il
20% APS 300*il 500gl 500*il 500*il
Table 2.17: Running and stacking gels for western blots
2.2.4.3.2. Western blotting
Usually between 50 to 1 0 0 *ig of protein extract was loaded on the gel. The samples 
were added to 4x loading buffer and placed at 65°C for 5 minutes. 1 0 *il of either high or 
low molecular weight ladder (catalogue number 756 or 755, respectively, Amersham) was 
also loaded on to the gel. The samples were eiectrophoresed at 200V (0.1 A) for 3 hours 
until the dye reached the bottom. Prior to setting up the western transfer, the membrane 
(Immobilon P, Millipore, cat No. IPVH 00010) was pre-wetted in methanol for 15 seconds, 
then in H2O for 2  minutes and finally left to equilibrate in transfer buffer for 1 0  minutes. 
The gels were also left to equilibrate in transfer buffer for 1 0  minutes. The transfer was 
performed in the cold room at 1200mA for 2 hours and 20 minutes. After transfer, the 
membranes were placed for at least 1 hour in blocking buffer. The membrane was then 
incubated overnight with the appropriate primary antibody at the required dilution (Table 
2.6) in blocking buffer. The following day, the membrane was washed for 3 times 15 
minutes in wash buffer. The appropriate secondary antibody fused to horseradish 
peroxidase (HRP) was added at the required dilution (Table 2.7) in blocking buffer and 
usually incubated for 1 hour at room-temperature. The membrane was washed for 3 times 
15 minutes in wash buffer. Amersham’s ECL™+ kit (Amersham) was used for the
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detection of antibody binding. The process converts acridan into acridinium ester 
intermediates with the use of peroxide and HRP. These intermediates react with peroxide 
under slight alkaline conditions to produce a high intensity chemoluminescence, which can 
be detected using autoradiography film. The solution was left for 5 minutes and then the 
excess of solution was drained and the membrane was placed in a plastic bag and sealed. 
The membrane was then exposed to X-AR Kodak film for various exposure times 
depending on the intensity of the signal and the film was developed using an X-Omat 
developer. To determine if the proteins were loaded equally, a ponceau (Sigma) stain was 
sometimes performed, which stains all the proteins. 1 0 0 ml to 2 0 0 ml of ponceau was added 
to the membrane and placed on a rocking platform for 1 0  minutes at room-temperature. 
Several washes with 100ml of distilled water were then performed to “destain” the 
membrane and visualise the proteins. The membrane was placed in a plastic bag and 
scanned.
2.2.4.4. Stripping and reprobing western blots
The membrane was stripped of antibody using stripping buffer by shaking at 50°C 
for 1 hour. The membrane was then washed twice for 1 0  minutes at room-temperature in 
wash buffer. Following the washing steps, the membrane was placed in blocking buffer for 
at least 1 hour at room-temperature and probed as described above. After use, the 
membranes were stored at 4°C in a sealed plastic bag to keep them from drying out and 
allow re-use.
2.2.4.5. Electrophoretic mobility shift assay
2.2.4.5.I. Annealing of the probe
Both the forward and reverse oligonucleotides (Table 2.12) were separately 
resuspended to lOOpM. To anneal the two oligonucleotides 2pl of each oligonucleotide 
was added to lOpl of 5M NaCl and 186pl TE. The sample was mixed and placed at 80°C 
for 1 0  minutes in a heat block. Once the incubation was finished the tube was allowed to 
cool slowly in the block to 23°C. Aliquots were prepared and stored at -20°C. The final 
concentration of the annealed oligonucleotide was lpmol/pl. In this way, double-stranded
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DNA sequences were generated, incorporating the required protein recognition sequence 
and showing 4 nucleotides 5’ overhang.
2.2.4.5.2. Generation and purification of the EMSA probe
To generate the Electrophoretic mobility shift assay (EMSA) probe, lpl of the 
required annealed oligonucleotide (lpmol per probe) was added to 33 pi of H2O, lOpl of 
dCTP 5x buffer (Prime it labelling kit, Stratagene) 5pi of 32P adCTP (50pCi) and lpl of 
Klenow to fill in the overhang. The sample was mixed and incubated at 37°C for 20-30 
minutes. Following the incubation, the probe was purified away from unincorporated 
nucleotides using NICK™ columns (Amersham), which contain Sephadex® G-50. The 
column was equilibrated with 3ml of TE buffer, which was allowed to run through the 
column. The labelled mix was placed on to the column and after a few seconds 400pl of 
TE was added to the column. At this point all the unincorporated nucleotides should be 
eluted. The radiolabelled oligonucleotide was then eluted using a further 400pl of TE and 
collected in a fresh tube. The probe was either used directly or stored at -20°C in a lead 
container until use.
2.2.4.5.3. Preparation of the samples
5 to lOpg of protein extract (the extraction was performed using the high salt 
extraction protocol, section 2.2.4.1) were aliquoted into microfuge tubes. Usually duplicate 
samples were analysed, unless a supershift assay was performed in which case three 
replicate samples were aliquoted. To each sample lpl of polydldC (lpg/pl, Sigma), 25pi 
of GR2 buffer [ 1ml 1M Tris pH 7.5, 3ml 5M NaCl, lOpl 50mM ZnCl2, 0.25ml MgCl2, 
0.025ml 1M DTT, 1.25ml glycerol (final 25%), make up to 25ml with H2Oj and 9pl of 
H20  were added. A tube with no protein extract was also prepared as a free probe control. 
The samples were incubated on ice for 10 minutes. 4pl of labelled probe was added to all 
samples and to the duplicate of each sample between 1 0 0  to 2 0 0 x (lpmol to 2 pmol final) 
of cold competitor (unlabelled double-stranded oligo compared to labelled oligo) was 
added. The samples were incubated on ice for 20 minutes.
If a supershift assay was performed, 4pg of the appropriate antibody was added to 
the third replicate sample, which was incubated at room-temperature for 15 to 20 minutes. 
4pl of labelled probe was then added to the third replicate sample and incubated on ice for 
2 0  minutes.
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2.2.4.5.4. Non-denaturing acrylamide gel preparation
A 6 % non-denaturing acrylamide gel was used to electrophorese the samples using 
the following reagents:
Reagent Volume in ml
5x Tris/glycine buffer 1 0
40% acrylamide 8.3
H20 30
20% (v/v) APS 0.5
TEMED 0.15
Table 2.18: 6% non-denaturing acrylamide gel composition
The gel was left to polymerise for 1 hour and then pre-run for at least 30 minutes in 
the cold room in lx Tris-glycine buffer. The samples were then loaded on to the gel. In the 
first lane, loading dye was usually loaded alone so that the running of the samples (without 
dye) could be monitored. The samples were electrophoresed at 150V for 3 hours or until 
the dye was about 3cm from the bottom. The gel was then transferred on to 2 sheets of 
3MM paper, covered with saran wrap and dried at 80°C for 2 hours. The dried gel was 
exposed to X-AR Kodak film for various exposure times depending on the intensity of the 
signal and the film was developed using an X-Omat developer.
2.2.5. Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) can be used to quantify levels of 
circulating antibodies or cytokines in the serum or cell supernatant. To quantify serum IgM 
a flat-bottom 96 well plate was coated with lOOpl of rat anti-mouse IgM (coating) antibody 
(1/200 dilution to a final concentration of 5p,g/ml) and placed overnight at 37°C. The 
following day, the surplus coating antibody was removed and to each well was added 
200pl of blocking buffer [lxPBS, 0.05% (v/v) Tween 20, 0.5% BSA (w/v)] and placed at 
37°C for 30 minutes. The wells were then washed three times quickly with washing buffer 
[lxPBS, 0.1 % (v/v) Tween 20] and three times for three minutes each with washing buffer. 
All liquid was removed by tapping the plates on to blotting paper before adding 100p,l of 
serum sample to each well (1/800 dilution, for IgM only, in PBS-0.05% Tween 20) and 
incubating at room-temperature for 90 minutes. The unbound serum sample was removed
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and the wells washed and dried as described above. lOOpl of horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgM antibody (1/4000 dilution in PBS-0.05% Tween 
20) was then added to each well and incubated at room-temperature for one hour. The 
wells were washed and dried as described above and then lOOpl per well of 
tetramethylbenzidine (TMB) substrate (Sigma) was added and incubated until a colour 
change was observed in the samples (usually between 5 and 20 minutes). A dark blue 
colour indicated a high level of IgM, whereas a light blue colour indicated a low level. The 
optical density of each sample was then read at 620nm and the concentration of secreted 
IgM determined using a standard curve. To obtain the IgM standard curve, 1/250 dilution 
of lmg/ml mouse IgM antibody was added in the first well. For the following wells, serial 
1/2 dilutions were performed until 1/512000 dilution factor. The assay was performed as 
described for the samples. The same protocol was followed to determine the levels of IgGl 
and IL10, except that for IL10 the serum sample was diluted 1/2 instead of 1/800. An extra 
step was also performed for the detection of IL10. Following the incubation with the 
detection antibody, lOOpl of 1/1000 dilution of streptavidin peroxidase (Diagnostics 
Scotland, catalog number T245, as recommended by the Manufacturer) was added to each 
well and incubated for one hour at room-temperature. The wells were washed and dried as 
described above and then lOOpl per well of TMB substrate was added and incubated until a 
colour change was observed in the samples.
2.2.6. Proteoplex 16 well murine cytokine array kit
A cytokine array kit was supplied by Novagen, catalog number 71454, and the 
reaction performed according to the manufacturer’s instructions. The kit allows for testing 
the levels of 10 different cytokines (ILla, ILip, IL2, IL4, IL6 , IL10, IL12p70, GM-CSF, 
IFNy and TNFa) in 1 0  test samples. Briefly, the pre-coated wells were washed [PBS- 
Tween, provided by the kit] and then lOOpl of 1/3 diluted serum samples and lOOpl of 
each of the five point standard curve samples (which contain different purified cytokines 
and cover a range between 15pg/ml and 800pg/ml) was added to the wells. The samples 
were incubated for one hour at room-temperature with orbital rotation. The wells were then 
washed with PBS-Tween and 80pl of murine detection antibody cocktail was added and 
incubated for one hour at room-temperature with orbital rotation. The wells were washed 
with PBS-Tween and then 1 0 0 pi of PBXL-3 fluorophore detection mix was added to each
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and covered with foil before being incubated for 90 minutes at room-temperature. The 
array apparatus was disassembled, the slide was rinsed and dried by centrifugation at 2 0 0 g 
for 1 minute before being kept 4°C and mailed to the company for analysis. The slide was 
scanned and the data was extracted as pixel density values. The background signal was 
subtracted from both the standard signal and the experimental signal. The mean average of 
the four spots was also determined and used to generate the standard curve and to 
determine the cytokine concentration of each experimental sample. A standard curve was 
generated for each cytokine tested by plotting the signal from each cytokine standard 
against the known cytokine concentration. The signal value of each experimental sample 
along with the different standard curves was used to determine the cytokine concentration 
in the samples. The data was sent as an Excel file and included in a spot data table, a well 
data table and a summary table with the final calculated concentrations for each cytokine 
for all the experimental samples (this is the data presented in table 5.10).
2.2.7. Bacterial techniques
2.2.7.1 . Generating competent DH5 E. coli cells
A single colony of DH5 cells was grown in 5ml of Luria Bertani (LB) medium at 
37°C for approximately 2  hours to an absorbance at 550 nm of 0.3 and then transferred to 
100ml of warmed LB medium. The cells were incubated with shaking at 37°C until they 
reached a maximum OD at 550nm of 0.48. The cells were immediately cooled down on ice 
and pelleted at 4°C, 4000g for 5 minutes. The cell pellet was gently resuspended in 40ml 
of ice-cold filter sterilised transforming buffer I (Tfbl) [30mM potassium acetate, lOOmM 
RbCh, lOmM CaCh, 50mM MnCh, glycerol to 15% v/v and pH adjusted to 5.8 with 0.2M 
glacial acetic acid]. The cells were incubated on ice for 5 minutes and centrifuged at 4°C, 
4000g for 5 minutes. The pellet was resuspended in 4ml ice-cold filter sterilised Tfbll 
[lOmM MOPS, lOmM RbCh, 75mM CaCh, glycerol to 15% v/v and pH adjusted to 6.5 
with KOH]. 200pl of cells were aliquoted in microfuge tubes, snap frozen on dry ice and 
stored at -70°C for up to 3 months.
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2.212. Transformation of competent DH5 Escherichia coli cells with plasmid DNA
An aliquot of competent DH5 Escherichia coli (E. coli) cells was thawed on ice for 
10 minutes. The appropriate amount of DNA (usually lOOng) was added to the cells and 
incubated on ice for 15 minutes. The cells were then heat shocked at 42°C for 90 seconds 
and returned on ice for 2 minutes. 800pl of LB medium was added to the cells and 
incubated for 50 minutes at 37°C, not shaking. The bacteria were plated out on 1.1% agar 
plates supplemented with the appropriate antibiotic (usually ampicillin at 50pg/ml).
2.2.8. Cell culture techniques
2 .2 .8 .1 . Tissue culture and propagation
The cells were cultured in RPMI 1640 supplemented with 10% FCS, 2mM 
glutamine and 1 0 0  units/ml of penicillin/streptomycin in a 37°C and 5% CO2 incubator. 
The cells were grown in 25cm2 or 75cm2 vented flasks. The medium was changed every 2 
to 3 days by diluting the cells 1 /2  with fresh medium. Occasionally the cells were 
centrifuged at 194g for 5 minutes and the pellet resuspended fresh medium.
2.2.8 .2. Trypan blue exclusion detection of viable cells
The cells were diluted (1/2 to 1/10) in 0.4% trypan blue/PBS and incubated for a 
few minutes at room temperature to allow the dye to penetrate dead cells. Trypan blue is a 
polar dye that cannot cross intact cell membranes but crosses the membranes of necrotic 
cells and apoptotic cells. lOpxl of this cell suspension was placed on the haemocytometer 
chamber and the cells were counted under the microscope, where blue stained cells are non 
viable and unstained cells are viable. The number of viable cells counted are expressed as a 
multiple of 1 0 4 cells/ml.
2.2.8.3. DNA transfection of mammalian cells by electroporation
5 to 20pg of either supercoiled or linear DNA was diluted into 50pl of serum free 
medium (SFM) and placed in a 0.4 cm cuvette on ice. lx l 0 7 cells were resuspended in
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250|xl of SFM, mixed with the DNA and incubated on ice for 5 minutes. The cells were 
electroporated at 250V, 960pF (Kilger et al., 1998). After electroporation, the cells were 
incubated at 37°C for 10 minutes. The electroporated cells were added to 10ml of pre­
warmed RPMI supplemented medium and incubated until being harvested.
2.2.8.4. Liquid nitrogen storage of viable cells
For storage in liquid nitrogen, 2xl06 cells were frozen in 1ml of freezing medium 
[90% FBS and 1 0 % DMSO (v/v)] in a cryotube placed in an insulating styrofoam box and 
placed overnight in the -70°C freezer to allow slow cooling. The vials were transferred to 
liquid nitrogen for long-term storage.
2.2.8.5. Revival of frozen stocks
The liquid nitrogen vials were thawed quickly in a 37°C water bath and added to 
6 ml of fresh pre-warmed RPMI supplemented medium. The cells were centrifuged at 194g 
for 5 minutes and the pellet resuspended in 5ml of pre-warmed RPMI supplemented 
medium, transferred to a flask and placed in the incubator.
2.2.9. Animal procedures
All procedures were performed at the biological services animal house under the 
home office regulations and with a home office license.
2.2.9.1. Breeding of transgenic mice
The general housing requirements such as food, water and changing the bedding 
was carried out by the animal house staff. They also set up breeding pairs, monitored litters 
and weaned the pups. Weaning was generally performed at 3 weeks of age and the males 
and females were placed in separate cages.
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2.2.9.2. Numbering of transgenic mice
Each new litter bom from the microinjection procedure was given an alphabetical 
letter as a provisional batch number until a transgenic founder was identified following 
genotyping. Once a new transgenic animal was identified it was given a consecutive line 
number.
Animals were given an ID number at tail biopsy (for genotyping, see section 
2.2.9.4) under halothane anaesthesia. Mice in each line were numbered by ear punching 
with consecutive numbers. The tail biopsy and ear punching of the animals was usually 
carried out by Donald Campbell (of our lab).
2.2.9.3. Animal monitoring
The health of the mice (discomfort, behaviour, coat appearance or lymphoma- 
tumour development) was monitored at least twice-weekly. If an animal appeared to suffer 
it was euthanised by a schedule 1 method.
2.2.9.4. Monitoring the status of the transgenic founders and lines generated
Tail gDNA was extracted as described in section 2.2.2.3 and digested with the 
appropriate restriction enzyme. The digested gDNAs were electrophoresed through an 
agarose gel and this was followed by Southern blotting. The presence of a partial or intact 
EBER1 transgene was also determined by PCR. The PCR reactions were performed with 
300ng of gDNA. For the Epcmyc mice the presence of the transgene was determined by 
PCR.
2.2.9.5. Animal tissue collection
Once the animals for tissue collection were identified they were euthanised by a 
schedule 1 method. The animal was wiped with 70% ethanol and a small incision in the 
dorsal skin was performed. To check for expression profile all organs and different tissues
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were collected. The organs, such as spleen, liver, peripheral lymph nodes, were routinely 
collected and snap frozen in liquid nitrogen before being stored in a -70°C freezer.
22.9.6. Production of transgenic mice
2.2.9.6.1. Strain of superovulated females and superovulation
B6D2.F1 give a large number of embryos, and are usually more resistant to the 
mechanical insults of microinjection. The mice were bought at 4 to 5 weeks and were left 
for at least one week to acclimatise to the animal house and the light-dark cycle. 
Superovulation was performed when the mice were older than 6  weeks.
This procedure was usually performed by animal house staff. As microinjections 
require a large number of zygotes, the females are administered gonadotropins prior to 
mating in order to increase the number of oocytes released. This procedure also minimises 
the number of mice used; for instance 5 superovulated females generally produce about 
150-200 embryos instead of 50-70 if they are not superovulated. Two different hormones 
were used: pregnant mare’s serum gonadotropin (PMS) and human chorionic gonadotropin 
(hCG) (Sigma), dissolved in H2O and filter sterilised. The times of administration of each 
hormone depend on the light-dark cycle of the mouse room. 5 to 10 IU of PMS was 
administered between 1 2  and 2 pm, on day 1 to mimic the oocyte maturation effect of 
endogenous follicule-stimulating hormone (FSH). hCG was administered 45 to 47 hours 
later, day 3 (1  lam to 1pm) at 5IU and was used to mimic the ovulation induction effect of 
luteinizing hormone (LH). It is important to administer hCG prior to the release of 
endogenous LH in order to control the time of ovulation, which usually takes place 10 to 
13 hours after injection of hCG. After the administration of hCG a female was placed in a 
cage with one stud male. The next day (day 4) the female was checked for a plug, which 
signifies that mating has occured. The embryos were then harvested from the plugged 
B6D2.F1 females. Usually between 5 and 10 females were superovulated for each 
microinjection round.
2.2.9.6.2. Harvesting zygotes
This procedure was usually performed by animal house staff. Superovulated 
B6D2.F1 female mice were sacrificed and the ovary and oviduct collected as described in
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Nagy et al., 2003b. The fragment of oviduct and uterus from all the mice was transferred to 
a 5cm petri dish containing PBS. The zygotes are found in the enlarged ampulla 
surrounded by cumulus cells. Each oviduct was transferred separately to a dish containing 
M2 medium and hyaluronidase (5pl of lOmg/ml stock, from Sigma). Using watchmaker’s 
forceps the oviduct was tom near the ampulla to release the embryos and cumulus cells. 
Hyaluronidase digests the cumulus cells releasing the zygotes. After 5 minutes in the 
hyaluronidase solution, the zygotes were transferred to fresh drops of M2 medium to rinse 
them from hyaluronidase solution and debris. The embryos were then transferred to a drop 
of M16 medium in a 5cm dish covered with mineral oil to prevent evaporation (Sigma) and 
placed at 37°C, 5% COz until used for microinjection.
2.2.9.6.3. Pronuclear microinjections of mouse embryos
The harvested embryos with a normal morphology were chosen for microinjections 
and were transferred to a drop of M2 medium, which was covered with mineral oil, in a 
depression slide using an embryo transfer pipette. Usually between 40 and 60 embryos 
were transferred to the slide at a time; the others were kept in the incubator.
Prior to setting up the microinjection microscope, holding and injection needles 
were made. The holding needles were made using a microbumer and a microforge and 
lOpl calibrated pipettes (catalog number P0674) (Nagy et a l , 2003a) and usually kept and 
reused until broken or clogged. The injection needles were made using pipettes from 
Harvard Apparatus (catalog number GC1 OOF-10) and pulled using a mechanical pipette 
puller (Nagy et a l , 2003a) with the following settings: heat 570, pull 150, velocity 100 and 
time 100. These settings were already optimized when I started doing microinjections. 
However, they need to be re-optimised when a new filament is needed. The injection 
needles were usually made on the day of microinjection, or a few days before, to avoid any 
accumulation of dust. The injection needles were changed if the pipette touched a 
nucleolus, the pipette was clogged or the opening of the pipette was too wide. After each 
set of microinjections, needles containing DNA solution were disposed of.
The depression slide containing the embryos to be injected was placed on an 
inverted microscope platform (Nagy et a l , 2003a), which is on an antivibration table. The 
microscope is flanked by 2  micromanipulators: one for the holding needle and one for the 
injection needle. The holding needle was then assembled into the instrument holder of the 
left-hand micromanipulator and filled from the tip with 0.5cm of M2 medium. It was
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inserted in the depression slide so that the curved end lay horizontally on the bottom of the 
depression and entered the drop of medium at an angle of about 45°. At that time, the low 
power, 60x (15x eye piece and 4x objective) of the microscope was used so that all the 
embryos could be seen. The focus and the field of the microscope were then set up. An 
embryo was picked up with the holding needle and the magnification was increased to 
600x (15x eye piece and 40x objective). The focusing ring on the lens and the microscope 
condenser were adjusted until one could clearly distinguish the membrane surrounding the 
pronucleus. These settings were not touched again during a microinjection session, only 
the level of the micromanipulators was used to bring the embryos into the plane of focus. If 
the zygote appeared abnormal at any time during the microinjection procedure or non­
fertilised, it was discarded. The magnification was decreased to 40x and an injection 
needle was placed in the DNA solution loaded from the rear end, at either 2 or 5p.g/ml, 
allowing the DNA solution to enter by capillary action. The injection needle was 
assembled into the instrument holder of the right-hand micromanipulator and inserted in 
the depression slide parallel to the holding needle and at a low angle (5 to 20°). The 
magnification was then increased to 400x. If the pronucleus was not in a good position to 
be injected, the embryo was released from the holding needle and re-loaded. The 
pronucleus to be injected was brought into alignment with the focal plane, using the 
micromanipulator, and the tip of the injection needle was brought in the same focal plane. 
The injection needle was then pushed through the zona pellucida, then the cytoplasm and 
into the pronucleus avoiding the nucleoli as they are very sticky and adhere to the pipette. 
The pipette was then pulled in the center of the pronucleus and pressure was applied to the 
injection needle so that the DNA solution was delivered. If the pronucleus swelled, it was 
successfully injected and the pipette was pulled quickly out of the zygote. If swelling of the 
cytoplasm was observed or movement of the pronucleus, the pronucleus was not 
penetrated and re-injection with the needle was attempted until there was clear swelling of 
the pronucleus. If the pronucleus did not swell, it could mean that the pipette was clogged, 
in which case another needle was filled with DNA and assembled into the 
micromanipulator and the procedure was repeated. The non-swelling of the pronucleus 
could also be due to the fact that the pipette did not puncture the oocyte’s plasma or 
nuclear membranes (which are very elastic), which is apparent when a small liquid 
“bubble” is formed around the tip of the pipette. In that case the focus on both the 
pronucleus and the tip of the injection pipette was changed and the procedure was repeated
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until the pronucleus was visibly seen to swell. The injection chamber was nominally 
divided into 3 parts: non-injected embryos at the bottom of the slide, injected embryos at 
the top right-hand comer and abnormal and non-fertilised embryos at the top left-hand 
comer. Once an embryo was successfully injected, the magnification was taken to low 
power and it was released into its group and a non-injected embryo was picked up for 
injection. When all the zygotes were injected they were transferred to M l6  medium (apart 
from the abnormal ones which were discarded) and placed in the incubator until implanted. 
A new group of non-injected embryos were transferred to the depression slide to be 
injected. The injection procedure was continued until all zygotes collected were injected.
Some of the injected zygotes lyse due to mechanical damage caused by the 
microinjection procedure and will appear translucent and fill their zona pellucida. The lysis 
usually takes place between 5 and 60 minutes after injection. Only the healthy zygotes 
were implanted and can be distinguished by their space between the zona pellucida and the 
plasma membrane. Moreover the cytoplasm appears compact and evenly shaped. Between 
40 and 75% of the embryos should survive the injection procedure. The embryos were 
usually implanted on the day of microinjection; however, when there were not enough 
pseudopregnant females, the embryos were left overnight in the incubator and implanted 
the following day at the 2  cell stage.
2.2.9.6.4. Pseudopregnant recipient and embryo transfer
This procedure was usually performed by animal house staff. ICR strain mice were 
selected as embryo transfer recipients. The day before the microinjections were performed, 
the female ICR mice were set up for mating with vasectomized males. Vasectomies on 
ICR male mice were conducted by animal house staff. Only the plugged females (evidence 
of mating) were used for the implant procedure, as they would be “hormonally” in a state 
of pseudopregnancy. The females were usually 6  weeks to 6  months of age.
The ICR strain was chosen as these mice have a different colour coat (albino), 
compared to the donor strain B6D2 (black, brown) and also because they are relatively out 
bred and fit.
The embryo transfer procedure was usually performed by animal house staff. The 
embryos were either transferred at the one cell stage (approximately 16 hours old) or at a 
two cells stage (approximately 34 hours old). The method used was the oviduct transfer, 
which was first reported on rats by Tarkowski (1959). Whittingham (1968) developed a
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method for the mouse, which provides the basis for this protocol. The method used was 
performed as described in Nagy et al., 2003c. The embryos are transferred to 
pseudopregnant females of like mating timing.
The embryos were transfered using a transfer pipette connected to a mouth-piece. 
In order to reduce the capillary action, the pipette was loaded with air bubbles before 
picking up the embryos. The embryos were loaded between 2 air bubbles and with a 
minimum of medium (M2).
The surgical instruments were sterilised by autoclaving and during procedure rinsed 
in 70% ethanol. The anaesthetic (hypnorm (Janseen Animal Health): hypnovel (Roche) 1:1 
ratio) was used at 0.1ml per g of body weight and injected intraperitoneally (IP). The back 
of the mouse was wiped with 70% ethanol and a small incision in the dorsal skin at the 
level of the last rib was performed with fine scissors either central to access both sides, or 
on one side at a time. An incision was made in the body wall above the ovary. Using blunt 
forceps the ovarian fat pad was picked up and the ovary, oviduct and uterus isolated. The 
mouse was transfered to a stereomicroscope where the oviduct opening (infundibulum) and 
the ampulla could be identified. With watchmakers forceps, the bursa was tom to expose 
the infundibulum. The embryos were transfered into the oviduct, monitored visually by 
following the air-bubbles to the ampulla, which indicates successful transfer. The body 
wall was sewn up with one or two stitches and the dorsal skin was closed with wound 
clips. Embryo transfer to one or both sides was conducted depending on the number of 
embryos. At the end of the procedure the mouse was placed on a warm heated pad until 
recovery.
2.2.9.7. Isolation of primary cells from tissues
Different lymphoid tissues were collected in lxPBS in bijous and placed on ice 
until the isolation was performed. The isolation was performed in a tissue culture hood. 
Once all the tissues were collected, they were transferred to a Petri dish and 3ml of lxPBS 
was added. They were then squeezed between 2 frosted glass microscope slides to release 
the cells. Depending on the size of the tissue more PBS was added to isolate the cells. The 
isolated cells along with the debris were transferred to a 15ml Falcon tube and placed on 
ice. To isolate cells from BM, a 21 1/2 G needle and a 1ml syringe was used. The femur 
was held with tweezers above a 15ml Falcon tube and the needle was placed inside the 
bone. The BM was then flushed withlx PBS. The cells were centrifuged at lOOOrpm
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(194g) for 5 minutes. For red blood cell-free tissues, such as PP, PLNs and MLNs, the cells 
were resuspended in 1 0 ml of lxPBS, left to stand for 1 minute and filtered through a 
MACs filter to remove any traces of debris. However, for tissues such as spleen, liver, 
thymus and BM an erythrocyte exclusion was performed as they contain large numbers of 
red blood cells. After centrifugation, the cells were resuspended in 3ml of NH4CI and 
incubated at room-temperature for 1 0  minutes, which leads to red blood cell lysis. 1 2 ml of 
lxPBS was added and die cells were centrifuged at lOOOrpm (194g) for 5 minutes and 
resuspended in 10ml of lxPBS. The washing step was repeated twice and the cells were 
resuspended in 10ml of lxPBS. They were then filtered on MACs filters to remove any 
traces of debris. The live cells for each tissue were counted using trypan blue exclusion as 
described in section 2.2.8.2. The cells could then be used for in vivo passage, culture or 
FACS.
2.2.9.8 . In vivo passage of tumour cells
This is a procedure which is used to accelerate the development of a tumour 
phenotype. In vivo passages were performed with cells isolated from tumour tissues (see 
section 2.2.9.7). Usually 106 cells in lOOpl of lxPBS were injected into the tail vein of 
each recipient B6D2.F1 animal or negative matched sibling. Female recipients were only 
used with injections of tumour cells collected from females. A male recipient was used 
when tumour cells from either female or male were injected. Males express antigens from 
the Y chromosome recognised as non-self by females whereas X antigens are expressed by 
both males and female.
2.2.9.9. Explantation of tumour cells
The tumour tissue was collected from the mouse and externally cleaned with 
ethanol and then cut into smaller pieces. One piece was placed in sterile lxPBS on ice, one 
was placed in formaldehyde for pathology and the rest was snap frozen in liquid nitrogen 
and stored at -70°C until use.
The cells were isolated from the tumour tissue placed in lxPBS as described in 
section 22 .91 . The cells were centrifuged at 194g for 5 minutes and resuspended in 5ml of 
RPMI supplemented with 20% FCS, 2mM glutamine and 100 units/ml of
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penicillin/streptomycin, fungizone (2ml of 250pg/ml stock solution) and 50pM of 
p-mercaptoethanol. The resuspended cells were transferred to a 25cm2 flask and placed at 
37°C and 5% CO2. The medium was changed the following day. The cells were monitored 
and cultured in complete tissue culture medium until they expanded. They were then 
grown in 10% FBS medium. Aliquots of the cells were frozen down as liquid nitrogen 
stocks as described in section 2.2.8.4.
2.2.10. Fluorescence activated cell sorting
Fluorescence activating cell sorter (FACS) analysis was performed on cells isolated 
from tissues. 106 cells were transferred into a FACSCan tube in a final volume of 500pl 
lxPBS. The cells were then stained with the appropriate antiserum, usually with 
approximately lpg and incubated for at least 45 minutes in the dark at 4°C. Two different 
dyes, which are conjugated to the different antibodies were used (Tables 2.3 and 2.4): 
phycoerythrin (PE) and fluorescein isothiocyanate (FITC). Two washes with lxPBS were 
performed to remove the excess of antibody. The cells were either resuspended in 500pl 
lxPBS and followed by FACS analysis or resuspended in 500p,l lxPBS, 0.1% 
formaldehyde, and placed in the dark at 4°C to fix them overnight. The analysis was then 
performed the following day.
Several staining controls were used including a negative staining control (unstained 
cells) for each cell type, which establishes the background fluorescence of the cells as the 
degree of autofluorescence varies between cell types and the instrument used, and an 
isotype control, which determines non-specific interactions. Single stain controls were also 
used and establish the non-specific staining of the primary or secondary antibodies (FITC 
or PE conjugated), and a few double stain controls (usually CD43FITC/B220PE and 
B220FITC/CD5PE) were also used to calibrate the flow cytometer. The cells were 
analysed using a FACScalibur flow cytometer (Becton Dickinson). Data were collected 
and analysed using CellQuest software (Becton Dickinson). Dead cells and debris were 
excluded from the analysis using the forward and side scatter light distribution gate.
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2.2.11. B and T cell enrichment using Dynabeads
This method enriches B or T cells from mixed populations by antibody affinity 
using either anti-B220 conjugated magnetic beads (Dynal) or anti-Thy 1.2 conjugated 
magnetic beads (Dynal).
When both selections were to be done the T cell selection was performed first. 
Cells were isolated from the appropriate tissue. After counting the cells, an estimation of 
the target cell number was performed in order to determine the number of beads required 
to isolate the cells (number of beads used = 4x number of target cells). Before using the 
beads for the selection, they were thoroughly resuspended and the appropriate amount of 
beads was transferred to a collection tube. The tube was placed on the magnetic device 
(Dynal) and left to stand for 2  minutes. The buffer was removed, the tube was dismantled 
from the magnetic device and the beads were resuspended in 1ml of washing buffer 
[lxPBS, 1% FBS (v/v)]. The wash step was repeated and the beads were resuspended in 
the original volume of washing buffer. Once the beads were washed, the cells were added 
and the tube was incubated for 2 0  minutes at 4°C with gentle rotation. The tube was placed 
on the magnetic device and left to stand for 2 minutes. The supernatant was transferred to a 
new collection tube and was used for the subsequent B cell selection. The cells/beads were 
washed twice in washing buffer and stored at -70°C until used. The B cell selection was 
performed as described for the T cell selection. After incubation, the tube was placed on 
the magnetic device, the supernatant was transferred to a new collection tube and was 
called the “left over” fraction. This tube was centrifuged and the pellet was placed at - 
70°C.
For some assays such as FACS, detachment of the beads was required. This was 
performed by incubating the cells overnight at 37°C in 2ml of supplemented medium. The 
following day the medium was transferred to a collection tube and placed on the magnetic 
device. The supernatant was transferred to a new tube and contained the cells. These could 
then be used for FACS analysis (see section 2.2.1 0 ).
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Chapter 3. Generation of EBER1 transgenic mice
3.1. Introduction
In order to explore the role of EBER1 in vivo, transgenic mice designed to express 
EBER1 in lymphoid cells were generated. This chapter comprises the design of the 
different transgenes, the generation of founder transgenic mice and their establishment to 
transgenic lines.
3.2. Design of the transgenes
One of the critical steps in the generation of transgenic mice is the design of the 
transgene. This is of particular importance for EBER1 as the transcript is abundantly 
expressed in cells and may well be lethal if expressed globally from the viral polymerase 
III (pol III) promoter in the entire organism. Therefore, the immunoglobulin heavy chain 
(IgH) intronic enhancer (Ep) was used in order to direct expression of EBER1 in a spatial 
specific manner to the lymphoid compartment. This enhancer has been previously used in 
the laboratory to direct the expression of pol II transcripts encoding EBNA1 to the B-cell 
compartment (Wilson et al., 1996), LMP1 to the lymphoid compartment (Wilson et al., 
1990) and LMP2A to B cells (Caldwell et al., 1998). However, in the case described here 
the approach was to attempt using Ep (a pol II enhancer) to restrict expression of the pol 
III EBER transcript. The rationale for this novel approach was based on the presence of pol 
II motifs (Spl and ATF sites) within the natural EBER1 promoter suggesting that pol II 
factors can influence the expression of pol III transcripts.
As this is a novel approach and there are no such transgenic models in the 
literature, three different EBER1 constructs were designed. This was done to test if Spl 
and ATF sites are essential or dispensable for efficient expression of EBER1 in vivo in 
addition to Ep and to test if spacing between the elements is critical. The first EBER1 gene 
construct maintains upstream sequences of EBER1 to >322, incorporating the TGTA box (- 
23), ATF (-46), Spl (-60) sites and the putative Myc binding region at -122. The second 
construct is shorter (-78) incorporating only the Spl, ATF sites and the TATA-like box and
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the third construct only maintains the TGTA box of EBER1. The TGTA box was 
maintained in all constructs as it has been shown that this element is important for EBER2 
transcription by RNA pol HI (Howe and Shu, 1993) and therefore may also be critical for 
EBER1 expression. Each of the three constructs includes the transcription unit of EBER1 
from +1 to +167 while the Ep enhancer was linked 5’ to the promoter of each (Figure 3.1).
3.3. Generation of the three different EBER1 constructs
The murine sequence incorporating the Ep enhancer (Figure 3.1, pink box) was 
isolated on a 1594bp H indm  and EcoRI fragment (Baneiji et al., 1983) from lab stock 
plasmid p79. This was inserted into the HindUI-EcoKI site of the multiple cloning site of 
vector pcDNA3.1A. The vector backbone pcDNA3.1A incorporates the CMV promoter 
upstream of the multiple cloning sites and a neomycin resistance gene driven by the SV40 
promoter (Appendix 1). This Ep vector was denoted lab stock p669 and used as “empty” 
vector control in several assays. Plasmid pLEXIII (lab stock number p661) was a kind gift 
from Prof M. Clemens (Laing et al., 2002) and was used as a template for EBER1 
sequences. The forward primers CR1, CR2 and CR3 incorporating a 5’ EcoRI restriction 
site and reverse primer CR4 incorporating a 3’ Xhol restriction site (Figure 3.2) were used 
to amplify the three EBER1 gene fragments from p661. The three PCR products were 
digested with EcoRI and Xhol, isolated and ligated into EcoRJ-Xhol linearised p669 vector. 
Plasmids clones containing the different EBER1 constructs were sequenced and only 
correct clones were used for subsequent analysis. The resulting plasmids containing the 
long, middle and short constructs were denoted p670, p671 and p672 respectively. The 
plasmids were prepared using endotoxin free preparations so as not to trigger an immune 
response in tissue culture assays or cause toxicity as transgenes in vivo, which could 
obscure any effect due to EBER1 expression.
3.4. Assaying expression of the different constructs in tissue culture
Once the different constructs were generated, the efficacy of expression of each 
construct was tested in culture. This is an important step prior to use of the constructs as 
transgenes for microinjection of mouse embryos. If the designed transgene does not 
express in tissue culture assays it would be unwise to go through the lengthy process of
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Figure 3.1: Schematic diagram o f the three different transgenes used for microinjection 
The three different constructs are presented in this figure and called p670 (long construct, 
A),  p671 (middle construct, B) and p672 (short construct, C). The different EBER1 inserts 
were generated using EcoRI and Xhol restriction sites and linked to the Ep via the EcoRI 
site (pink). The EBER promoter is composed o f  pol II/pol III motifs (Spl and ATF - 
yellow) and pol III motifs (TGTA - yellow, and “A” and “B” boxes - orange). The Myc 
binding site is also shown in green on construct A. The transgenes used for microinjection 
were the Xbal (shown in red and bold) restriction fragments. The nucleotide position o f 
each element is shown. The PCR primers used to generate the three fragments are shown 
with blue arrows for construct A (E = EcoRI and X = Xhol). The black arrow indicates the 
transcription orientation.
EBER1 sequence 1: CR1-CR4 primers (501 nt), p670 insert
-323
g a a t t c g t c a g c c t g c a a g g t g g a t g g c g t g t t t t c t g a g g t t a t c c c c g c t a c g t g c a t g
c t g g g t g a t a g a g a c c c t a g a a t g t g t c g a a a t g a c c a a g c g t c c c c g c a g c g g g g c t c c c
a a c a c g g g t t c c c a g a g a g g g t a a a a g a g g g g g c c a t a a a g c c c a g g g t g t a a a a c a c c g a
c c g c g c c a c c a g a t g g c a c a c g t g g g g g a a a t g a g g g t t a g c a t a g g c a a c c c c c g c c t a c
a c a c c a a c t a t a g c a a a c c c c g c c c c g t c a c g g t g a c g t a g t c t g t c t t g a g g a g a t g t a g
a c t t g t a g a c a c t g c a a a a c c t c a g g a c c t a c g c t g c c c t a g a g g t t t t g c t a g g g a g g a g
a c g t g t g t g g c t g t a g c c a c c c g t c c c g g g t a c a a g t c c c g g g t g g t g a g q a c g g t g t c t g
t g g t t g t c t t c c c a g a c t c t g c t t t c t g c c g t c t t c g g t c a a g t a c c a g c t g g t g g t c c g c
atgttttgagctc
EBER1 sequence 2: CR2-CR4 primers (256 nt), p671 insert 
-78
g a a t t c a c t a t a g c a a a c c c c g c c c c g t c a c g g t g a c g t a g t c t g t c t t g a g g a g a t g t a g
a c t t g t a g a c a c t g c a a a a c c t c a g g a c c t a c g c t g c c c t a g a g g t t t t g c t a g q g a q g a g
a c q t g t g t g g c t q t a g c c a c c c q t c c c g g g t a c a a g t c c c g g g t g g t g a g g a c g g t q t c t t
g g t t g t c t t c c c a g a c t c t g c t t t c t g c c g t c t t c g g t c a a g t a c c a g c t g g t g g t c c g c a
tgttttgagctc
EBER1 sequence 3: CR3-CR4 primers (217 nt), p672 insert 
-39
g a a t t c t c t t g a g g a g a t g t a g a c t t g t a g a c a c t g c a a a a c c t c a g g a c c t a c g c t g c c c  
t a g a g g t t t t g c t a g g g a g g a g a c g t g t g t g g c t g t a g c c a c c c g t c c c g g g t a c a a g t c c  
c g g g t g g t g a g g a c g g t g t c t t g g t t g t c t t c c c a g a c t c t g c t t t c t g c c g t c t t c g g t c  
a a g t a c c a g c t g g t g g t c c g c a t g t t t t g a g c t c
Figure 3.2: Sequences o f the different EBER1 inserts
The sequences o f the different EBER1 inserts incorporated into p669 (pcDNA 3.1 
containing the Ep enhancer) using EcoRI (5’ end) and Xhol (3’ end) restriction sites (in 
green and bold) are shown. The EBER1 transcription unit is underlined. The different 
upstream elements (ATF, Spl and TGTA box) are shown in bold and red. The A and B 
boxes are shown in bold and blue.
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generating transgenic mice, especially in this case with the trial pol II/pol III hybrid 
promoters. The different supercoil or linear (Xbal fragments) fragments were transiently 
transfected into 39.415 cells, a murine B cell line derived from an LMP1 transgene positive 
lymphoma (Dabbagh and Wilson, unpublished). A mock (no DNA) transfection and a 
transfection of p669 were performed as negative controls. The supercoiled parental EBER1 
plasmid (p661) was transfected as a positive control for EBER1 expression. 24 hours post- 
transfection, the cells were harvested followed by RNA extraction. An RT reaction was 
performed on total RNA using an EBER1 gene specific reverse primer (CR4). For each 
sample a no RT control was performed in order to check for possible genomic DNA 
(gDNA) contamination in the RNA sample. The RT product was used as template for a 
quantitative PCR using EBER1 primers (CR8 and CR9, Figure 2.1) (Figure 3.3). BJAB 
was used as negative control and Raji and IB4 were used as positive controls. As expected, 
no signal was observed for BJAB as it is a BL cell line negative for EBER1 expression. 
Raji expressed EBER1 at a higher level than IB4. For the supercoil samples, EBER1 
expression level from p670 was similar to that of IB4, p671 and p661, whereas expression 
from p672 was lower (Figure 3.3 A). For the Xbal linear fragments, EBER1 expression 
from p670X is low compared to that of p661, but higher than p671X and p672X (Figure 
3.3 B). It was noticed that expression was higher from the supercoil constructs compared to 
the linear fragments (if the expression level of p661 is used as a reference). This suggests 
that the transfection efficiency could be higher for the supercoil constructs or that the 
presence of the CMV promoter (upstream of the Ep) increases expression levels. However, 
as the samples were not normalised against an internal control, no conclusions can be 
drawn to fully compare the expression level of the different constructs.
This experiment was repeated with only the linear Xbal fragments (as they are the 
same as the transgene) and two RT reactions were performed one with an EBER1 specific 
reverse primer (CR4) and one with an oligodT primer. The RT products of these reactions 
were used as template for a quantitative PCR using either EBER1 primers (CR8 and CR9, 
for the EBER1 RT) or GAPDH primers (G3PDH5’ and G3PDH3’, for the oligodT RT) to 
be used as internal controls. The supercoil EBER1 parental plasmid, p661, was used as 
positive control for EBER1 expression (Figure 3.4). Following normalisation EBER1 
expression from p661 is 9 times higher than that of p670X which is nearly equal to p671X. 
The expression from p672X is the lowest (15 times) compared to p670X and p671X. 
Therefore these results suggest that the Spl and ATF sites in constructs p670 and p671 
(both supercoiled and linear fragments) still contribute to EBER1 expression. It has been
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Figure 3.3: Quantitative PCR for EBER1 expression from the different constructs in 
culture
39.415 cells were transiently transfected with either supercoiled plasmids p661, p670, 
p671, p672 and p669, and linear Xbal fragments p670X (linear Xbal fragment o f  p670), 
p671X, p672X and p669X (vector only sequence). A mock transfection with no DNA was 
also performed as negative control (39.415 sample). 24 hours post-transfection the cells 
were harvested and followed by an RNA extraction. BJAB (EBV negative human BL cell 
line) was used as negative control and Raji (EBV positive 50 copies human BL cell line) 
and IB4 (EBV positive human cell line) were used as positive controls for EBER1 
expression. Total RNA was subjected to DNAse I treatment followed by an acid phenol 
extraction. The RT reaction was performed with an EBER1 specific primer (CR4, for the 
EBER1 Q-RT-PCR) and 5pg o f total RNA. An RT plus and minus reaction was performed 
for each sample. The Q-RT-PCR reaction was performed with 1 /4th o f the RT reaction 
using CR8 and CR9 primers Panel A shows the results from the supercoil plasmid 
transfections and panel B shows the results from the linear Xbal fragment transfections.
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Figure 3.4: Normalised data o f EBER1 expression from the linear Xbal fragments 
39.415 cells were transiently transfected with p661, p670X (linear Xbal fragment o f p670), 
p671X, p672X and p669X (vector only sequence). A mock transfection with no DNA was 
also performed as negative control (39.415 sample). 24 hours post-transfection the cells 
were harvested and followed by an RNA extraction. Total RNA was subjected to DNAse I 
treatment followed by an acid phenol extraction. The RT reaction was performed with an 
EBER1 specific primer (CR4, for the EBER1 Q-RT-PCR) or an oligodT primer (for the 
GAPDH Q-RT-PCR) and 5fig o f total RNA. An RT plus and minus reaction was 
performed for each sample. The Q-RT-PCR was performed with 1 /4th o f the RT reaction 
using either CR8 and CR9 primers (for EBER1) or the G3PDH5’and G3PDH 3,primers 
(for GAPDH). The results for the QPCR with the EBER1 primers are shown and the 
normalised data is tabulated below. The fold differences are also presented.
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shown for both EBER1 and EBER2 using deletion mutants in transfection assays, that the 
deletion of the two upstream pol II elements, Spl and ATF, greatly reduces transcription of 
the EBERs (Wensing et al., 2001, Howe and Shu, 1989). This assay also demonstrates that 
all three linear constructs express EBER1 in culture following transient transfections.
A northern blot was performed on the RNA of the cells transiently transfected with 
both supercoil and Xbal linear fragments. The blot was probed with radiolabelled EBER1 
sequence and subsequently with rpL32 to control for loading (Figure 3.5). EBER1 
expression from Raji and IB4 was observed and no expression was detected for BJAB 
(Figure 3.5 A). For the three human B-cell lines no expression of rpL32 internal control 
was detected, which was expected as it is a mouse specific gene (Figure 3.5 B). EBER1 
expression was observed following transfection of the three linear fragments at low level 
and at a relatively even intensity between the three constructs as observed with the 
normalised data (Figures 3.5 A and C). This result is different from the quantitative PCR 
data as EBER1 from p672X was expressed at a lower level compared to p671X and 
p670X. EBER1 expression was also detected from the supercoiled plasmids and at a 
relatively higher level (Figures 3,5 A and C). In this assay p661 expressed EBER1 at a 
lower level compared to p670 and p671 supercoiled plasmids (Figure 3.5 C). As observed 
with the quantitative PCR assay, the expression from the supercoiled constructs was higher 
than that of the linear fragments. The higher expression of supercoil versus linear fragment 
could be due to higher transfection efficiency of supercoiled DNA compared to linear 
DNA, or due to the fact that in the supercoil construct a CMV promoter is present 
upstream of the Ep (see appendix) and could therefore increase the rate of transcription. It 
could also be a combination of both as p661 (the parental EBER1 plasmid), which does not 
have a CMV promoter or the Ep enhancer, was transfected as a supercoiled fragment and 
the expression of EBER1 from that plasmid is lower than that of p670, p671 and p672. It 
was also noted on figure 3.5 that the size of EBER1 from the supercoiled fragments was 
higher than that of Raji and IB4. This could be due to the presence of transcripts with a 
polyA tail as the constructs contain two additional pol II elements (a CMV promoter and 
the Ep enhancer) compared to EBER1 in Raji. However, pol II or pol HI transcription 
specificity was not analysed for these samples.
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Figure 3.5: Northern blot for EBER1 expression of the different constructs in culture 
A transient transfection of Xbal linear constructs (669Xba\, 610Xba\, 61\Xba\ and 612Xba\) 
or supercoil plasmids (669 (Ep only plasmid), 661 (parental EBER1 plasmid), 670, 671 and 
672) was performed into 39.415 cells. A mock (no DNA) transfection control was also 
performed. The cells were harvested 72 hours post-transfection, which was followed by an 
RNA extraction. 12pg of total RNA sample derived from the transiently transfected cells was 
electrophoresed through a 1.4% agarose-formaldehyde gel and electroblotted. The membrane 
was first hybridised overnight at 60°C with an EBER1 probe. Cold washes were followed by a 
30 minutes hot wash at 60°C (panel A). The membrane was then stripped and re-probed 
overnight at 65°C with rpL32, a mouse specific probe (internal loading control). Cold washes 
were followed by a 30 minutes hot wash at 65°C (panel B). Raji and IB4 were used as positive 
human B-cell line controls along with a negative human B cell line control BJAB. For both 
blots, the membrane was exposed to a phosphorimager intensifying screen for the required 
amount of time, before being scanned. In panel C a table with the signal intensities of each 
sample from the EBER1 and rpL32 probes is presented as determined by the phosphorimager 
software. The background value was subtracted to the “determined value” of each sample. The 
relative expression (EBERl/rpL32) for each sample is also presented. For p672 supercoil no 
RNA was loaded on the gel (panel B). It was subsequently shown that supercoil p672 does 
express in culture.
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specific
C
Sample name rpL32 value EBER1 value Normalised value
39.145 no DNA 7042
669 Xbal 10690
670 Xbal 8318 974 0.1
671 Xbal 9599 1344 0.14
672 Xbal 10110 898 0.09
661 7574 3053 0.4
669 8311
670 7156 7775 1.04
671 9069 7529 0.83
672 Not measured
Raji Not measured 170800
IB4 Not measured 4096
BJAB Not measured 114
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3.5. Microinjection into mouse embryos
As the three constructs all expressed in tissue culture assays, they were prepared for 
microinjection of zygotes. For the generation of transgenic mice, B6D2.F2 zygotes were 
harvested and selected on the basis of having 2 visible pronuclei. Any non-fertilised or 
abnormal looking embryos were discarded prior to microinjection. The three transgenes 
were microinjected in turns into the zygotes as shown in figure 3.6. Successfully injected 
embryos were then implanted into pseudopregnant ICR recipient mice.
3.6. Generation of transgenic mice
3.6.1. Screening of the pups
Between 19 and 21 days following implant of the microinjected embryos, pups 
were bom. These pups were tail-tipped at 3-4 weeks of age so that their genotype could be 
determined. gDNA was extracted from digested tails and then an aliquot subjected to 
digestion with EcoKl. The digested gDNA was electrophoresed through a 1% agarose gel, 
Southern blotted and hybridised with an appropriate radiolabelled EBER1 sequence probe. 
A summary of the pups bom following injection of the three constructs and of the number 
of transgenic positive founders is presented in table 3.1. The status of the transgene was 
also assessed by PCR to evaluate if the transgene was either an intact or a partial copy. 
Different PCR reactions were performed with either IgHF-CR20 (for p670 constructs), 
IgHF-CR16 (for all constructs) or CR3-CR4 (for all constructs) pairs of primers and gDNA 
as template (Figure 3.7). For each line two different PCRs were performed. The first one 
was to check for the presence of the Ep and part of the EBER1 promoter and the second 
one was to check for the presence of the EBER1 gene. Figure 3.8 shows a representative 
example of the IgHF-CR16 PCR. A DNA fragment of the expected size was observed in 
sample 136.30 but not in sample 129.2. When the EBER1 part of the transgene was 
analysed a DNA fragment of the expected size was observed for both samples (Figure 3.9) 
indicating that the transgene was an intact copy for animal 136.30 but a partial copy for 
animal 129.2. Figure 3.10 shows a representative example of the IgHF-CR20 PCR for a 
sample with a p671 construct. A DNA fragment of the expected size was observed in
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Figure 3 .6: Pronuclear microinjection o f mouse embryo
B6D2.F2 embryos were harvested and microinjection was performed into either o f the 
pronuclei o f the embryo with the transgene sequences. If  the injection was successful, the 
pronucleus membrane was seen to increase in size without rupture o f the embryo, as shown 
in the bottom picture.
Construct Number of pups bom Number of founders
p670 Xbal 68 6
p671 Xbal 58 3
p672 Xbal 104 10
Table 3.1: Summary of the number of pups and founders born from the different 
microinjections performed
IgHF 
----- ►
CR3 
----- ►
Ep Spl ATF — TATA EBER1
CR16 CR20 CR4
IgHF-CR16: 482bp 
4--------------- ►
IgHF-CR20: 546bp for p671 
----------------------------------------------------------------
507bp for p672
. _____C^_-CR4:_233bp
Figure 3.7: Schematic diagram of the different PCR primers used to determine if the 
transgene was an intact or a partial copy in the different lines generated 
The different primers used are shown with an arrow along with their orientation, location 
on the construct and their name. A bi-directional arrow shows the expected size of the PCR 
product for each primer pair.
127 131 129 136
31 32 12 13 1 2 30 31 670 H20
 <  EBER1
 <------- primer dimers
Figure 3.8: PCR o f line 136 gDNA with IgHF and CR16 primers
A PCR was performed using IgHF and CR16 primers and 300ng o f gDNA. Two controls 
were performed for the reaction: a no DNA control (H20 )  and a positive plasmid DNA 
control (670). The PCR products were electrophoresed through a 1.5% agarose gel. The 
expected size product for the PCR is 482bp. Arrows indicate the EBER1 DNA fragment 
and the primer dimers. The sizes o f a DNA ladder are shown in kb on the left hand side. 
The transgenic status o f the animals was first determined by Southern blotting. For line 
127 samples 31 and 32 are transgenic positive, samples 131.12 and 13 are transgenic 
positive, sample 129.1 is negative and 129.2 is transgenic positive. For line 136, sample 30 
is transgenic positive and sample 31 is transgenic negative. Note that with this primer pair 
only transgenic positive samples with a p670 construct (lines 129 and 136) will show a 
DNA fragment by PCR.
127 131 129 136
31 32 12 13 1 2 30 31 670 H20
1OOObp —
500bp —
298bp _
220bp —
Figure 3.9: PCR on gDNA from lines o f each construct using CR3 and CR4 primers 
A PCR was performed using CR3 and CR4 primers and 300ng o f gDNA. Two controls 
were performed for the reaction: a no DNA control (H20 )  and a positive plasmid DNA 
control (670). The PCR products were electrophoresed through a 1.5% agarose gel. The 
expected size product for the PCR is 233bp. Arrows indicate the EBER1 DNA fragment 
and the primer dimers. The sizes o f a DNA ladder are shown in bp on the left hand side. 
The transgenic status o f the animals was first determined by Southern blotting. For line 
127 samples 31 and 32 are transgenic positive, samples 131.12 and 13 are transgenic 
positive, sample 129.1 is negative and 129.2 is transgenic positive. For line 136, sample 30 
is transgenic positive and sample 31 is transgenic negative.
L .m .......1
  EBER1
m  primer dimers
144
1 2 3 4 5 670
1.6kb
lkb
500bp EBER1
primer dimers
Figure 3.10: PCR o f line 144 gDNA with IgHF and CR20 primers
A PCR was performed using IgHF and CR20 primers and 300ng o f gDNA. A positive 
plasmid DNA control (670) was also performed for the reaction. The PCR products were 
electrophoresed through a 1% agarose gel. The expected size product for the PCR is 
546bp. Arrows indicate the EBER1 DNA fragment and the primer dimers. The sizes o f a 
DNA ladder are shown in kb on the left hand side. The transgenic status o f the animals was 
first determined by Southern blotting and sample 144.2 was shown to be transgenic 
positive and is the founder o f line 144 and the other offspring are negative siblings.
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sample 144.2, indicating that this part of the transgene was intact. A similar example is 
also presented for lines with a p672 construct (figure 3.11) and samples 131.7, 133.8, 134.9 
and 135.11 all showed a DNA fragment of the expected size. For line 131 the transgene 
was an intact copy as the EBER1 part also showed a DNA fragment of the correct size 
(figure 3.9). A summary of the intact or partial copy of the transgene is presented for each 
founder in tables 3.2, 3.3 and 3.4.
3.6.2. Establishment of lines from the founders
The next step in the generation of transgenic mice is to establish lines from the 
founders. For this purpose, the different founders were bred to C57B1/6 strain stock mice. 
The genotype of all offspring born was determined by Southern blotting. From the six 
founders generated for construct p670 three lines were established (lines 136, 141 and 142, 
table 3.2). From the three founders generated for construct p671 two lines were established 
(lines 127 and 145, table 3.3) and from the ten founders generated for construct p672 eight 
lines were established (lines 131, 132, 133, 134, 135, 137, 138 and 143, table 3.4). 
However, six founders did not give rise to a new line (126.1, 128.1, 129.2, 130.1, 140.2 
and 144.2). For five of these founders (126.1, 128.1, 129.2, 130.1, 140.2) no transgenic 
positive offspring were bom indicating that they might be mosaic. A mosaic arises when 
the transgene integrates after fusion of the two pronuclei. Therefore some cells in the 
animal will be transgenic whereas some others will not. For founder 144 no offspring were 
bom despite several pairings, indicating that it was sterile. All the founders along with a 
matched negative sibling were kept and monitored regularly and tissues were collected 
when the mouse showed signs of ill health or at the end of the 2-year study period.
3.6.3. Inheritance patterns of the different lines established
3.6.3.1. Integration
For line 127, it was noticed that only the female offspring of the male founder were 
transgene positive. This lead to the hypothesis that the transgene might be X-linked. To test 
this hypothesis, two positive females were crossed with C57B1/6 negative males and as 
would be expected for either autosomal or X-linkage both male and female positive
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1.6kb
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0.5kb EBER1
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Figure 3.11: PCR on gDNA o f lines o f construct p672 using IgHF and CR20 primers 
A PCR was performed using IgHF and CR20 primers and 300ng o f gDNA. Two controls 
were performed for the reaction: a no DNA control (H20 )  and a positive plasmid DNA 
control (670). The PCR products were electrophoresed through a 1% agarose gel. The 
expected size product for the PCR is 507bp. Arrows indicate the EBER1 DNA fragment 
and the primer dimers. The sizes o f a DNA ladder are shown in kb on the left hand side. 
The transgenic status o f the animals was first determined by Southern blotting. Sample 
131.7 is transgenic positive, sample 133.8 is transgenic positive, sample 134.9 is transgenic 
positive and 134.10 is negative. Finally sample 135.11 is transgenic positive.
Line/founder
number
M/F
founder
Partial or intact 
transgene
Founder or line
126 M Partial Founder
129 F Partial Founder
136 M Intact Line
140 M Intact Founder
141 M Intact Line
142 M Intact Line
3.2: Summary of the partial or intact transgene, line estab ished and copy num
the different p670 founders
Line
number
M/F
founder
Partial or intact 
transgene
Founder or line
127 M Intact Line
144 M Intact Founder
145 M Intact Line
Table 3.3: Summary of the partial or intact transgene, line established and copy number for 
the different p671 founders
Line
number
M/F
founder
Partial or intact 
transgene
Founder or line
128 F Partial Founder
130 M Partial Founder
131 F Intact Line
132 M Intact Line
133 F Intact Line
134 F Intact Line
135 F Intact Line
137 M Intact Line
138 F Intact Line
143 F Intact Line
3.4: Summary of the partial or intact transgene, line estab ished and copy num
the different p672 founders
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offspring were bom. Two positive males from this cross were then bred with C57B1/6 
negative females and only the female offspring from both crosses were positive for the 
EBER1 transgene confirming that the transgene in this line is integrated into the X- 
chromosome (Figure 3.12). The other lines show autosomal inheritance patterns.
3.6.3.2. Transgene copy number
The transgene copy number of each line was estimated once the lines were 
established as the founder can be a mosaic. Two approaches were used for this purpose. 
For the first one, a partial digest of gDNA from two offspring of each line was performed 
using an enzyme which only cuts the transgene once, in this case EcoRI, and followed by a 
Southern blot (Figures 3.13 and 3.14). For line 143, only one offspring was present when 
the assay was performed. The number of transgene length multimers (for example 900 bp, 
1800bp, 2700bp etc...) will reflect the copy number in a head to tail tandem configuration 
(excluding the junction fragments) (Figure 3.13). Thus, the number of bands observed in 
each track plus one reflects the total copy number. With this method the estimated copy 
number from each line was determined. The number of copies is variable from one line to 
the other, ranging from 1 to 11 with the majority of the lines having 8 or 9 copies (145, 
131, 134, 142 and 127) (Table 3.5). With this method the line with the highest estimated 
copy number is line 132 and the one with the lowest is line 141. For the second approach, a 
slot blot was performed with undigested gDNA from two offspring for each line (except 
for line 143 where only one offspring was present) and known quantities of plasmid 
control (Xbal fragment of plasmid 672). The intensity of each sample was determined 
using a phosphorimager (Figure 3.15 and table 3.5). With this approach a relative copy 
number for each line can be determined with respect to the quantity of DNA in plasmid 
controls. For instance, with a transgene of approximately 900bp and a haploid genome of 
3xl09bp, a single copy transgene per haploid genome equals 3x1 O'7. Therefore, 5pg of 
gDNA will have 1.67pg of transgene. Hence 1 copy of a 900bp transgene equals 1.67pg of 
DNA. The copy number of plasmid control used for this assay and the copy number of the 
different samples are shown in tables 3.6 and 3.5 respectively. In this assay the upper limit 
of copy number is greatly increased compared to the first assay (with a maximum of 208). 
However, the lines with the highest and lowest copy numbers are the same with both 
approaches. Lines 136, 141, 133 and 137 have a similar copy number with the two
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Figure 3.12: Southern blot of generation 3 pups of line 127
Two generation two transgenic positive males (line 127) were bred witb C57B1/6 females. 
5pg of gDNA from the offspring were digested with EcoRl overnight. The digested 
products were electrophoresed through a 1% agarose gel and Southern blotted with a 
radiolabelled EBER1 probe overnight at 60°C. A final hot wash was performed at 60°C. 
Animal numbers are indicated along with their male or female status for the offspring. 
Animal 127.38 was used as negative control and animal 127.37 was used as positive 
control. The expected size of the transgene was 0.9kb.
A
3 copies
6 copies
 ► Transgene
M ► 1 copy of the transgene
----------  Surrounding sequences
B
Wt 3 6 Full
Figure 3.13: Schematic diagram of the estimated copy number following a partial digest 
with a single cutter
Panel A represents a schematic diagram of two different lines, one with 3 copies of the 
transgene, the second one with 6. The restriction enzyme used is represented by a vertical 
line and cuts only once in the transgene. Therefore, following partial digestion of gDNA 
and Southern blotting, the line with 3 copies of the transgene will have two bands visible 
on the autoradiograph, whereas the line with 6 copies will have five bands on the 
autoradiograph, as represented on panel B. The total copy number in a line is determined 
as the number of bands observed +1. A full digest of the line with 6 copies of the transgene 
is also presented on panel B (full).
Figure 3.14: Southern blot of the different 670, 671 and 672 lines generated 
5|ig of gDNA from two different samples of each 670, 671 (panel A) and 672 (panel B) lines 
generated was partially digested with EcoKl for 1 hour at 37°C. Then the enzyme was 
inactivated by incubating the samples at 70°C for 10 minutes. The partially digested gDNAs 
were electrophoresed through a 1% agarose gel and Southern blotted with a radiolabelled 
EBER1 probe overnight at 60°C. A final hot wash was performed at 65°C. The line number 
and animal numbers are indicated. Animal 127.28 was used as negative control for 670 and 
671 lines and animal 131.9 was used as a negative control for 672 lines. The molecular weight 
markers are shown according to their size on the left hand side.
670 671
bp
4072 —  
3054 —  
2036 —
1636 — 
1018 —
517 —
143 138 137 135 134 133 132 131
7 26 27 19 17 25 23 27 21 20 19 42 41 14 12 9
bp
4072 —
3054 —
2036 —
1636 —
1018 —
517 —
136 141 142 127 145
16 29 19 20 20 21 28 27 29 9 12
672
Table 3.5: Relative and estimated copy number of the different EBER1 lines generated 
The intensity value is presented as the intensity observed minus the background value as 
determined using the phosphorimager software. The average intensity is presented as the 
average of two samples. The relative quantitative copy number shows the copy number 
determined following the slot blot approach. The minimum copy number indicates the copy 
number determined using the partial digest method. The final estimate copy numbers are the 
values determined using the relative copy number, except for lines 141, 127 and 143 where the 
values determined using the minimum copy number were chosen. The sign * indicates lines 
with similar relative and estimated copy numbers.
Line
number
Animal
number
Intensity
value
Average
intensity
Relative 
quantitative 
copy number
Minimum
copy
number
Final
estimate
136* 16 - 117.6 2.1 2 2
29 235.2
141 * 19 68.1 34.05 0.6 1 1
20 -
142 20 2747.4 2876.1 51.2 9 51
21 3004.8
127 27 150.7 355.9 6.3 9 9
29 561.5
145 9 1283.6 1418 25.2 8 25
12 1552.4
131 12 865.4 830.4 14.8 8 15
14 795.4
132 41 9353.4 11699.5 208.2 11 208
42 14045.5
133 * 19 375.2 233.6 4.2 4 4
20 92
134 21 1666.4 1074.2 19.1 8 19
27 481.9
135 25 645.4 652.4 11.6 7 12
23 659.4
137* 17 380.6 389.1 6.9 5 7
19 397.6
138 27 2291.4 2351.4 41.8 10 42
26 2411.4
143 7 369.9 369.9 6.6 2 2
A B
~ nr
I II III
2pg lOpg 50pg
127.28 (-ve) 131.9 (-ve)
136.16 136.29 141.19
141.20 142.20 142.21
127.27 127.29 145.9
145.12
131.12 131.14 132.41
132.42 133.19 133.20
134.21 134.27 135.23
135.25 137.17 137.19
138.27 138.26 143.7
Figure 3.15: Slot blot o f the different lines generated
Panel A shows a slot blot o f 5pg o f gDNA from each sample which hybridise with EBER1. 
The samples in the top line of the slot blot were from different quantities of linear plasmid 
DNA. The samples were loaded onto a pre-soaked membrane. The slot blot membrane was 
hybridised overnight at 60°C with an EBER1 specific probe. Cold washes were followed by a 
30 minutes hot wash at 65°C. Panel B shows the ID of the samples in the order they appear on 
the slot blot. For each line two samples were used except for line 143. Two wild-type mice 
were also used as negative controls (127.28 and 131.9) in lanes I and II.
Plasmid amount Copy number Phosphorimager intensity Intensity 1 copy
20pg 11.9 699.1 58.7
lOOpg 59.9 2918 48.7
500pg 299.4 18330 61.2
Table 3.6: Phosphorimager intensities o f the plasmid controls
The intensity o f each control is presented as the intensity observed minus the background 
value. From this table, the average intensity o f one copy is 56.2.
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approaches and are the lowest. For the other lines the copy number is different when the 
two methods are compared; however, it follows the same trend. For instance, a line with a 
high copy number with one approach also has a high copy number with the other approach. 
For example, line 145 was determined to have 25 copies when using the relative copy 
number method and 8 with the estimated copy number method, whereas line 135 was 
determined to have 12 copies when using the relative copy number method and 7 with the 
estimated copy number method. Lines 132, 142, 145, 138 and 134 have a high (veiy high 
for lines 132 and 142) relative copy number compared to the estimated copy number. One 
has to bear in mind that the first approach does not provide an accurate copy number 
because the highest bands are hard to distinguish as they all run together; therefore a line 
which was estimated to have approximately 9 copies of the transgene with this method 
could have more than this. Moreover, this method relies on a partial digestion. It is possible 
that under the conditions used a line with 100 copies only gives a maximum of 9 
transgenes uncut in a row (thus giving the value of 10). Therefore it is likely that this 
partial approach depending on the conditions has an upper limit that vastly underestimates 
the copy number. Due to time constraint this aspect was not explored further. In the case of 
line 134, the intensity values obtained from the two samples are very different, suggesting 
that one of the samples was either over or underloaded compared to the other one which 
would lead to an inaccurate copy number. It is possible that sample 21 was overloaded 
compared to sample 27. For instance, when the value of sample 27 is used the copy 
number equals 8.6 which is very close to that obtained with the other approach (8 copies). 
For line 143, the presence of a second sample could bring the copy number values from 
both approaches closer together. Line 127 is the only line where the estimated copy 
number is higher than that of the relative copy number. In this case, with 8 actual bands, 
the copy number cannot be 6, suggesting that the estimate approach shows a definite 
minimum but under estimates the maximum. As observed for line 134, the intensity values 
of the two samples used are very different If the value of sample 29 only is used to 
calculate the copy number of the transgene for this line it would equal 9.9, which is similar 
to that observed from the other approach. A summary of the final copy number estimate is 
also presented in table 3.5. For lines 136, 141, 133 and 137 the values of both methods 
were used to determine the final copy number estimate. For line 127, the final estimate is 9 
as determined using the partial digestion method. In the case of lines 142, 145, 131, 132, 
134 and 138 the copy number determined using the slot blot approach was chosen as the 
final estimate as it is more likely that these lines have more copies than the ones
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determined using the partial digestion method, which could under estimate copy number. 
However in the case of line 132 208 copies might not be a very reliable estimate. For 
instance, if the minimum value determined using the partial digest method is 10 fold out 
compared to that of the relative quantitative value, the final copy number should have been 
110. The intensity values of both samples are different and it could be that one sample was 
overloaded compared to the other. If the value of sample 41 only is used to calculate the 
copy number of the transgene for this line it would be equal to 166.5, which is closer to 
110 than 208. For line 143 a difference in copy number was also observed between the two 
methods. Therefore for the final estimate the minimum value was chosen as it was shown 
this approach shows a definite minimum (see line 127 copy number). However more 
conclusions could be drawn with a second sample.
3.7. Line 127 homozygous breeding
As described in section 3.6.3.1 the transgene of line 127 is X-linked, whereas it is 
autosomal for all the other lines. Due to the phenomena of X inactivation in females 
(Heard, 2004) a different transgene amount is likely to be expressed in the tissues of 
heterozygous females of this line and most likely never with a maximum transgene 
expression. Males have only one X chromosome and therefore EBER1 is expressed at the 
same level in these animals. In order to determine if a phenotype could arise faster with 
maximum expression in females, homozygous line 127 was established. A positive male 
was crossed with a positive female. The genotype of the offspring was characterised by 
Southern blot using an EpEBERl probe (Figure 3.16). The endogenous Ep band was used 
as internal loading control and allows the comparison between animals if this band is equal 
in intensity. From the Southern blot both the endogenous and transgenic Ep bands can be 
observed. Two females, numbers 109 and 111 were identified as possible homozygous. 
The intensity of the Ep endogenous band in these two animals is similar to that of male 
106 whereas the intensity of the EBER1 band is stronger for 109 and 111 compared to 106. 
The genotype of female 108 was undetermined due to partial digestion of the DNA. To 
confirm that female 109 was homozygous, it was bred with a negative C57B1/6 male. All 
the offspring (eight in total) from this cross were transgenic positive (both males and 
females) leading to the conclusion that this female was homozygous (had this female been 
heterozygous, 50% of the offspring would be expected to be wild-type). Therefore female
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Figure 3.16: Line 127 homozygous breeding
Line 127 positive females and males were bred together in order to generate homozygous 
females. gDNA of the offspring tails was extracted and 5pg was digested with EcoK\. The 
digested gDNAs were electrophoresed through a 1% TAE gel and Southern blotted. The 
membrane was hybridised overnight at 60°C with an Ep-EBERl radiolabelled probe. Cold 
washes were followed by a hot wash at 60°C. The numbers shown are the animal numbers. 
Number 37 was used as positive control and number 38 was used as negative control for the 
blot. The transgenic and endogenous bands o f Ep are indicated as well as the EBER1 specific 
monomer band. Note that partial digestion leads to an EBER1 ladder of transgene multimers 
(indicated with bars).
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109 was bred with a positive male in order to fully establish the homozygous line. The 
animals from this line were not genotyped further as they should all be positive. The 
homozygous females were monitored for any sign of phenotype.
3*8. Summary
The aim of this chapter was to generate transgenic mice expressing EBER1. As pol 
III transcripts are highly expressed in cells, we decided to direct the expression of the 
transgene to the B cell compartment of the animal using the immunoglobulin heavy chain 
intronic enhancer. Three different EBER1 constructs were generated to explore which 
factor binding sites would be essential to achieve tissue specific transgene expression.
Expression in culture from the three different constructs was confirmed and 
pronuclear microinjections were performed into mouse embryos. In total 19 founders were 
generated, 6 for p670, 3 for p671 and 10 for p672. To date this is the first report of a 
transgenic model in which the transgene combines both tissue specific pol II and pol HI 
elements. 13 lines have been successfully established. The intact or partial copy of the 
transgene was analysed for the different founders and lines. In line 127 the transgene was 
also shown to have integrated on the X chromosome, whereas the other lines showed 
autosomal inheritance patterns. In line 127 homozygous breeding was also established. For 
all the established lines the transgene copy number was determined using two different 
approaches and mice of line 132 were shown to have the highest copy number, whereas 
mice of line 141 have the lowest. It was also observed that the copy number is variable 
between the lines.
The next step of this study is to test the expression status of each line established 
and to verify if it is directed to the lymphoid compartment.
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Chapter 4. Expression of EBER1 in the different lines
generated
4.1. Introduction
The generation of EBER1 transgenic mice was described in the previous chapter. 
Nineteen founders were generated and thirteen lines were established from these. The aim 
of the work presented in this chapter was to study the expression pattern of the EBER1 
transgene in the different lines. This is an important step for the phenotype study. For 
instance, if a phenotype occurs in one (or more than one) of the lines it needs to be 
correlated with the transgene expression.
The Ep enhancer was cloned upstream of EBER1 in order to direct expression to 
the lymphoid compartment. Therefore the expression analysis has mainly been focused on 
the lymphoid tissues for each line. As the EBERs are pol III transcripts the expression 
analysis was only performed at the RNA level.
4.2. Mice with 670 transgene: lines 136 and 142
The transgene for these lines incorporates all the defined upstream elements of the 
EBER1 promoter. RNA was extracted from tissues collected from positive offspring 
usually between two to four months of age and from a transgene negative control (line 127 
control, section 4.3). For small tissues, such as Peyer’s patches, peripheral lymph nodes, 
mesenteric lymph nodes and bone marrow, tissues from two animals from the same line 
were pooled. Total RNA was DNase I treated followed by an acid phenol extraction to 
minimise DNA contamination of the samples. The RNA was reverse transcribed (RT) 
using an EBER1 specific 3s primer (CR4, Figure 2.1) followed by PCR using a nested 3’ 
reverse primer (CR9) and a 5’ forward primer (CR8) (Figure 2.1). A minus RT reaction 
was performed as control to check for possible gDNA contamination. Two PCR controls 
were performed: a positive control using an EBER1 plasmid as template and a negative 
water control. The RT-PCR products were electrophoresed through an agarose gel
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followed by a Southern blot as the expression was usually too low for the products to be 
visualised under UV light. The Southern blot was probed with an EBER1 probe. The 
expression has been tested in the two 670 lines, line 136 and line 142 (Figures 4.1,4.2 and 
summary table 4.1). Line 141 had only produced two offspring and therefore expression 
analysis has not been performed on this line. Both lines express EBER1 in the lymphoid 
tissues and in both cases the highest expressing tissue is the thymus. While this assay is not 
precisely quantitative (explored later in section 4.6) relative expression levels between 
tissues can be estimated. For line 136 expression was strongest in thymus followed by 
peripheral lymph nodes, mesenteric lymph nodes, bone marrow and Peyer’s patches. 
EBER1 expression level was relatively low in the spleen and liver (Table 4.1). For line 142 
expression was strongest in the thymus followed by bone marrow, spleen and liver. 
EBER1 expression level in this line was lowest in peripheral lymph nodes, mesenteric 
lymph nodes and Peyer’s patches (Table 4.1). For line 136 the expression of EBER1 has 
also been checked in several non-lymphoid tissues (Figure 4.2 and table 4.1). Expression 
was detected in most of the tissues tested at a relatively even level except for ovaries, 
kidney and trachea where the expression level of EBER1 is slightly higher.
The expression analysis was also performed on a transgenic negative sibling to 
ensure that the expression was specific to the transgene itself and not a result of a non­
specific binding of the primers to a different gene. The analysis was performed on line 127 
negative siblings and the results are shown in figure 4.3. No signal was detected in any of 
the lymphoid tissues, suggesting that the signal detected in the plus RT samples of lines 
136 and 142 is specific to EBER1.
4.3. Mice with 671 transgene: lines 127 and 145
The transgene for this construct contains the Ep enhancer as well as the three 
upstream elements of the EBER1 promoter: Spl, ATF and TATA like box. The expression 
analysis was performed for both 671 lines (127 and 145) and the results are presented in 
figures 4.3, 4.4 and summary table 4.2. For line 127 the expression analysis was also 
performed on tissues from transgenic negative siblings, and in all the cases no signal or 
background signal was detected (Figure 4.3). Mice of both lines express the transgene in 
all the lymphoid tissues; however the pattern of expression is slightly different. For line
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Figure 4.1: Expression analysis in the different lymphoid tissues o f 670 transgenic lines 
The lymphoid tissues from lines 136 and 142 were collected from transgenic positive 
animals. RNA extraction was performed, followed by DNAse I treatment, acid phenol 
extraction and RT-PCR. The RT reaction was performed with an EBER1 specific primer 
(CR4) and 5pg o f total RNA. For each sample a minus RT (-) control was performed. The 
PCR was performed with 1 /4th o f the RT reaction using CR8 and CR9 primers. A no DNA 
control (H20 )  and a positive plasmid DNA control (PCR control) were also performed for 
the PCR as indicated. The RT-PCR products were electrophoresed through a 1% agarose 
gel followed by Southern blotting and probing using an EBER1 probe. The expected 
product size is 144 bp. Line 136 is presented in the top panel and line 142 in the bottom 
panel. The sizes o f a DNA ladder are shown in bp on the left hand side.
BM: bone marrow, PP: Peyer’s patches, PLN: peripheral lymph nodes, MLN: mesenteric 
lymph nodes.
stomach lung heart S. int testis ovaries uterus kid oesp trachea PCR 
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Figure 4.2: EBER1 expression in different tissues o f line 136
The different tissues were collected from positive transgenic animals o f line 136. RNA 
extraction was performed, followed by DNAse I treatment, acid phenol extraction and RT- 
PCR. The RT reaction was performed with an EBER1 specific primer (CR4) and 5pg o f 
total RNA. For each sample a minus RT control (-) was performed. The PCR was 
performed with 1 /4th o f the RT reaction using CR8 and CR9 primers. Controls were also 
performed for the PCR, a no DNA control (FfO) and a positive plasmid DNA control 
(PCR control). The RT-PCR products were electrophoresed through a 1% agarose gel 
followed by Southern blotting and probing with an EBER1 probe. The expected product 
size is 144 bp. The sizes o f a DNA ladder are shown in bp on the left hand side. Note a 
slight DNA contamination is suggested by the signal in the -RT tracks o f the small 
intestine. S.int: small intestine, kid: kidney, oesp: oesophagus.
Tissues collected 136 142
PLNs ++ +
MLNs ++ +
BM ++ ++
Spleen + ++
Liver + ++
Thymus +++ +++
Peyer’s patches ++ +
Ovaries ++ Not tested
Testis - Not tested
Uterus + Not tested
Kidneys + Not tested
Small intestine + Not tested
Stomach + Not tested
Heart - Not tested
Lungs + Not tested
Trachea + Not tested
Oesophagus + Not tested
Table 4.1: Summary of the expression in the different lines of construct 670 
+++: highly expressed (relative to other lines)
++: medium expression level 
+: low expression level
Line 127
Liver Spleen BM PLN MLN Thymus PP
PCR
control
506 —
396 —
220 — +ve
Line 145
Liver Spleen Thymus MLN PLN PP BM 
+ - + - + - + control
bp
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Figure 4.3: Expression analysis in the different lymphoid tissues o f 671 transgenic lines 
The lymphoid tissues from lines 127 negative and positive siblings were collected and for 
line 145 the lymphoid tissues were collected from transgenic positive animals. RNA 
extraction was performed on the collected tissues, followed by DNAse I treatment, acid 
phenol extraction and RT-PCR. The RT reaction was performed with an EBER1 specific 
primer (CR4) and 5pg o f total RNA. For each sample a minus RT control (-) was 
performed. The PCR was performed with 1 /4th o f the RT reaction using CR8 and CR9 
primers. Controls were also performed for the PCR, a no DNA control (FLO) and a 
positive plasmid DNA control (PCR control). The RT-PCR products were electrophoresed 
through a 1% agarose gel followed by Southern blotting and probing with an EBER1 
probe. The expected product size is 144 bp. Line 127 is presented in the top panel with 
negative (-ve) and positive (+ve) siblings and line 145 in the bottom panel. The sizes o f a 
DNA ladder are shown in bp on the left hand side. BM: bone marrow, PP: Peyer’s patches, 
PLN: peripheral lymph nodes, MLN: mesenteric lymph nodes.
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Figure 4.4: EBER1 expression detected in the brain o f line 127 transgenic positive mice 
Tissues were collected from both positive (+ve) and negative (-ve) line 127 siblings. RNA 
extraction was performed, followed by DNAse I treatment, acid phenol extraction and RT- 
PCR. The RT reaction was performed with an EBER1 specific primer (CR4) and 5pg o f 
total RNA. For each sample a minus RT control (-) was performed. The PCR was 
performed with 1 /4th o f the RT reaction using CR8 and CR9 primers. Controls were also 
performed for the PCR, a no DNA control (H2O) and a positive plasmid DNA control 
(PCR control). The RT-PCR products were electrophoresed through a 1% agarose gel 
followed by Southern blotting and probing with an EBER1 probe. The expected product 
size is 144 bp. The sizes o f  a DNA ladder are shown in bp on the left hand side. Note a 
slight DNA contamination is suggested by the signal in the -RT tracks and in the +RT 
tracks o f the -ve tissues. NPR: nasopharyngeal region, SG: salivary gland.
Tissues collected 127 145
PLNs ++ +++
MLNs + ++
BM ++ +
Spleen + ++
Liver - -
Thymus ++ ++
Peyer’s patches + + - H - +
Muscle - Not tested
Ovaries - Not tested
Testis - Not tested
Uterus - Not tested
Kidneys - Not tested
Small intestine - Not tested
Stomach - Not tested
Heart - Not tested
Lungs - Not tested
Trachea - Not tested
Oesophagus - Not tested
Tongue - Not tested
NP region - Not tested
Dorsal skin - Not tested
Ears - Not tested
Brain + Not tested
Salivary glands - Not tested
Table 4.2: Summary of the expression in the different lines of construct 671 
++++: particularly high expression level 
+++: highly expressed (relative to other lines)
++: medium expression level 
+: low expression level
Chapter 4. Results
127 EBER1 expression is highest in Peyer’s patches, followed by peripheral lymph nodes, 
bone marrow and thymus. The lowest expressing lymphoid tissues for this line are 
mesenteric lymph nodes and spleen. No expression was detected in the liver and in the 
other tissues tested except for the brain (Figure 4.4 and table 4.2). It is not unusual to 
observe expression in the brain from a variety of tissue specific promoters/enhancers. 
However in our case as both Spl and ATF are present on 671 it could be that the Ep, is not 
selective enough to prevent non-lymphoid expression for this particular construct. High 
expression was detected in the peripheral lymph nodes of line 145 and moderate 
expression was observed in mesenteric lymph nodes, spleen and thymus. EBER1 
expression was low in bone marrow and Peyer’s patches and no expression was detected in 
the liver (Figure 4.3 and table 4.2).
4.4. Mice with 672 transgene: lines 131,132,133,134,135,137 and 138
This transgene contains the Ep, enhancer and the TATA-like box of the EBER1 
promoter as well as the EBER1 gene but Spl and ATF sites are deleted. Line 143 had only 
produced one offspring at the time of writing and therefore expression analysis has not 
been performed. The results for the expression of the different lines from construct 672 are 
presented in figures 4.5, 4.6, 4.7, 4.8 and summary table 4.3. All the different lines tested 
express EBER1 in lymphoid tissues with different patterns except line 133 where no 
expression was detected (Figure 4.5). For line 133, DNA contamination was observed in 
the water control and in several samples tested despite repeated DNasel treatement. 
Despite this problem, there was no evidence of expression as the RT+ samples did not 
reveal a stronger band than in the RT- samples. Therefore analysis of this line was not 
pursued further and the line was discontinued. However, the founder as well as the three 
transgenic positive offspring were kept and monitored for any phenotype.
For the other lines, lines 131 and 132 show expression in all the lymphoid tissues; 
however the intensity of the signal is stronger for line 131 compared to line 132 (Figure 
4.6). For line 131 the highest expressing tissues are peripheral lymph nodes and mesenteric 
lymph nodes, followed by bone marrow, spleen, thymus and Peyer’s patches. The lowest 
expression was observed in the liver (Figure 4.6 and table 4.3). For line 132, the highest 
expressing tissue was the thymus and low expression was observed in all the other 
lymphoid tissues (peripheral lymph nodes, mesenteric lymph nodes, bone marrow, spleen,
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Figure 4.5: Expression analysis in line 133
The lymphoid tissues from line 133 were collected from transgenic positive animals. RNA 
extraction was performed, followed by DNAse I treatment, acid phenol extraction and RT- 
PCR. The RT reaction was performed with an EBER1 specific primer (CR4) and 5pg o f 
total RNA. For each sample a minus RT control (-) was performed. The PCR was 
performed with l/4 lh o f the RT reaction using CR8 and CR9 primers. An RT-PCR was also 
performed with Raji RNA and used as positive control for the detection o f EBER1. A no 
DNA control (FLO) was performed for the PCR. The RT-PCR products were 
electrophoresed through a 1% agarose gel followed by Southern blotting and probing with 
an EBER1 probe. The expected product size is 144 bp. The sizes o f a DNA ladder are 
shown in bp on the left hand side. Note a DNA contamination is suggested by the signal in 
the -RT tracks and in the H20  control. PP: Peyer’s patches, PLN: peripheral lymph nodes, 
MLN: mesenteric lymph nodes and BM: bone marrow.
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Figure 4.6: Expression analysis in the different lymphoid tissues o f 672 transgenic lines 
The lymphoid tissues from lines 131, 137, 132, 134, 135 and 138 were collected from positive 
transgenic animals. RNA extraction was performed, followed by DNAse I treatment, acid 
phenol extraction and RT-PCR. The RT reaction was performed with an EBER1 specific 
primer (CR4) and 5pg o f total RNA. For each sample a minus RT control (-) was performed. 
The PCR was performed with 1 /4th o f the RT reaction using CR8 and CR9 primers. Controls 
were also performed for the PCR, a no DNA control (FLO) and a positive plasmid DNA 
control (PCR control). The RT-PCR products were electrophoresed through a 1% agarose gel 
followed by Southern blotting and probe with an EBER1 probe. For lines 135 and 138 only 
the expressing tissues are shown. The expected product size is 144 bp. The sizes of a DNA 
ladder are shown in bp on the left hand side. Note a slight DNA contamination is suggested by 
the signal in the -RT tracks o f line 132 PP and BM, line 134 spleen and line 138 thymus. PP: 
Peyer’s patches, PLN: peripheral lymph nodes, MLN: mesenteric lymph nodes and BM: bone 
marrow.
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Figure 4.7: EBER1 expression in different tissues of line 131
The different tissues were collected from positive transgenic animals. RNA extraction was 
performed, followed by DNAse I treatment, acid phenol extraction and RT-PCR. The RT 
reaction was performed with an EBER1 specific primer (CR4) and 5pg of total RNA. For each 
sample a minus RT control (-) was performed. The PCR was performed with 1 /4th o f the RT 
reaction using CR8 and CR9 primers. Controls were also performed for the PCR, a no DNA 
control (H20 )  and a positive plasmid DNA control (PCR control). The RT-PCR products were 
electrophoresed through a 1% agarose gel followed by Southern blotting and probing with an 
EBER1 probe. The expected product size is 144 bp. The sizes o f a DNA ladder are shown in 
bp on the left hand side. Note a slight DNA contamination is suggested by the signal in the - 
RT tracks of the lung and small intestine. Small int: small intestine, Oesp: oesophagus.
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Figure 4.8: EBER1 expression in different tissues of line 137
The different tissues were collected from positive transgenic animals. RNA extraction was 
performed, followed by DNAse 1 treatment, acid phenol extraction and RT-PCR. The RT 
reaction was performed with an EBER1 specific primer (CR4) and 5fig o f total RNA. For each
reaction and CR8 and CR9 primers. Controls were also performed for the PCR, a no DNA 
control (FEO) and a positive plasmid DNA control (PCR control). The RT-PCR products were 
electrophoresed through a 1% agarose gel followed by Southern blotting and probing with an 
EBER1 probe. The expected product size is 144 bp. The sizes o f a DNA ladder are shown in 
bp on the left hand side. Note a DNA contamination is suggested by the signal in the -RT 
tracks of kidney, lung, small intestine and testis. Small int: small intestine.
sample a minus RT control (-) was performed. The PCR was performed with 1 /4th o f the RT
Tissues
collected
131 132 133 134 135 137 138
PLNs +++ + - - - + +++
MLNs +++ + - + - + -
BM ++ + - - - + -
Spleen ++ + - +++ - + -
Liver + + - - - - -
Thymus ++ ++ - + ++ +++ ++
Peyer’s patches ++ + - - - + -
Muscle + nt nt nt nt nt nt
Ovaries ++ nt nt nt nt + nt
Testis nt nt nt nt nt ++ nt
Uterus ++ nt nt nt nt ++ nt
Kidneys + nt nt nt nt + nt
Small intestine + nt nt nt nt + nt
Stomach ++ nt nt nt nt + nt
Heart + nt nt nt nt + nt
Lungs - nt nt nt nt - nt
Trachea ++ nt nt nt nt nt nt
Oesophagus ++ nt nt nt nt nt nt
Table 4.3: Summary of the expression in the different lines of construct 672 
nt: not tested
+++: highly expressed (relative to other lines)
++: medium expression level 
+: low expression level
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liver and Peyer’s patches) (Figure 4.6 and table 4.3). Several non-lymphoid tissues were 
also analysed for EBER1 expression in line 131 (Figure 4.7 and summary table 4.3). 
Expression was detected in most of the tissues tested, except for lung, at a relatively even 
level.
For lines 134, 137 and 138, expression of EBER1 was observed in one of few 
lymphoid tissues but not others. For line 134 expression was almost exclusive to the 
spleen, while for lines 135 and 137 it was predominant in thymus and for line 138 in both 
thymus and peripheral lymph nodes (Figure 4.6 and table 4.3). For line 137, the expression 
has also been tested for different non-lymphoid tissues (Figure 4.8 and summary table 4.3). 
Similarly to line 131, line 137 expresses EBER1 in several non-lymphoid tissues such as 
testis, uterus, ovaries, heart, small intestine, kidney and stomach but at a very low level. 
The expression of EBER1 in lines 132, 134, 135 and 138 appears to be lower than that of 
lines 131 and 137. Therefore these two lines have been selected for further investigation. In 
the meantime, the other lines have been discontinued by freezing embryos where possible 
or terminating the lines. All the founders for the lines and their positive offspring were 
monitored for any signs of phenotype.
4.5. B and T cell expression
4.5.1. Line 127
In line 127 EBER1 is expressed in the thymus (mainly composed of T cells) as well 
as the spleen (both B and T cells) and other lymphoid tissues of B and T cell composition. 
Therefore the expression in this line was studied in more detail to determine if it is directed 
to the B cells, the T cells or both. For this purpose, spleen and Peyer’s patches were 
collected from 3 transgenic positive animals and each tissue type pooled. The lymphocytes 
were isolated and subjected to positive T cell selection using Thy 1.2 dynabeads. The flow 
through was subjected to positive B cell selection using B220 dynabeads. For the 
splenocytes only, an aliquot of each fraction collected was used for FACS analysis with 
B220FITC/CD3PE antibody stain to determine the proportion of B and T cells in each 
fraction (figure 4.9 A). After T cell selection 91% of the cells were T cells and 1.3% were 
B cells and after B cell selection 4% of the cells were B cells and 17% of the cells were T 
cells. Not many B cells were observed following B cell selection because most of the cells
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Figure 4.9: Expression in the B and T cells of Peyer’s patches in line 127 animals 
Cells were extracted from Spleen and PP collected from 3 transgenic positive siblings. A 
fraction o f cells were pelleted prior to the B and T cell selection and was collected “before”. T 
cells were then separated using T hyl.2 dynabeads (the fraction was called T cells) and the 
flow through was subjected to B cell selection with B220 dynabeads (the fraction was called B 
cells). Panel A shows the FACS analysis for the splenocytes. An aliquot was collected from 
each fraction and subjected to B220 FITC (FLl channel) and CD3 PE (FL2 channel) staining. 
The percentage of each cell population is also presented. Panel B shows the expression 
analysis for the PP. RNA was extracted from the different fractions, DNAse I treated followed 
by acid phenol extraction. An RT-PCR was performed using EBERl primers. A -RT control 
was included for each sample. The RT-PCR products were electrophoresed through a l%  
agarose gel followed by Southern blotting using an EBERl probe.
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were dead (observation from the forward and side scatter). This could be due to the fact 
that the cells were left overnight in an incubator to separate them from the beads, and most 
of the remaining cells died. The thymus was also collected from these animals but not 
subjected to B and T cell selection as it predominantly consists of T cells. As the B and T 
cells were enriched in these fractions, RNA was extracted from the cells and the expression 
of EBERl was then determined. The results are presented for the Peyer’s patches in figure 
4.9 B. EBERl expression was detected in both the B and the T cell enriched fractions of 
Peyer’s patches to similar degree without bias towards one enriched fraction or another. 
The expression in the spleen is not presented as the gDNA contamination in the minus RT 
was too extensive to be able to draw any conclusions. These results suggest that in line 127 
mice the transgene is expressed in both the B and T cells in the lymphoid tissues.
4.5.2. Other lines
The B and T cells were not separated from different tissues from the other EBERl 
lines. However, if a transgene is expressed in several lymphoid tissues including the spleen 
and the thymus it is possible that expression of this transgene is directed to both the B and 
T cells. If the transgene is predominantly expressed in the thymus, it is most likely that the 
expression is directed to the T cells, while expression in spleen but not thymus would be 
suggestive of B-cell expression. Therefore it was hypothesised that EBERl is expressed in 
both the B and T cells in lines 131, 132 and 145.
For line 134 the expression of EBERl is very high in the spleen and very low in 
the thymus and mesenteric lymph nodes suggesting that the transgene might be expressed 
only in B cells in this line.
For lines 135, 137 and 138 the expression of EBERl is mainly detected in the 
thymus suggesting that the transgene might be expressed only in the T cells. For lines 136 
and 142 the expression in spleen is low and high in thymus suggesting that EBERl might 
only be expressed in T cells.
4.6. Quantification between lines 127,131,136,137 and 142
The different lines generated express EBERl at a low level as an RT-PCR followed 
by a Southern blot has been usually needed to be able to detect the product. A comparison
94
Chapter 4. Results
of the levels of expression in Peyer’s patches and thymus from different lines was 
undertaken to determine which of these lines expresses the transgene at the highest level. 
These tissues were chosen for this study because EBERl expression was most readily 
detected in these tissues in most of the lines and Peyer’s patches was the highest 
expressing tissue for line 127. For this purpose, a Q-RT-PCR was performed using cDNA 
from Peyer’s patches and thymus from mice of lines 127 (671 construct), 131 and 137 (672 
construct) using both EBERl and GAPDH specific primers (Figure 4.10 A and B). For 
both thymus and Peyer’s patches mice of line 127 express EBERl at a higher level than 
line 131 followed by line 137.
A similar study was performed to compare mice of line 127 with lines 136 and 142 
(670 construct) (Figure 4.10 C and D). In this case EBERl expression in the Peyer’s 
patches of mice of line 127 was higher than line 142 and 136. However EBERl expression 
in the thymus of mice of line 142 was higher than line 127, followed by line 136. In this 
figure (panels C and D) AK2003 was included to compare the relative level of expression 
of the transgene in these three lines to that of an EBV positive BL cell line. The level of 
EBERl expression in the thymus of mice of line 142 (Figure 4.10 D) is 100 fold lower 
than that of AK2003 even when the template for the cell line was used at 1/50th dilution. 
Therefore the level of expression of the transgene is lower than that of an EBV positive BL 
cell line. In summary, mice of line 127 express EBERl at a high level in Peyer’s patches, 
followed by lines 131 and 142, then 137. The Peyer’s patches of mice of line 136 express 
EBERl at the lowest level. For the thymus, EBERl expression is the highest in mice of 
line 142, closely followed by line 127, then line 131, line 137 and finally line 136.
4.7. Is the transgene in the different lines transcribed by RNA 
polymerase II?
It was demonstrated by in vitro transcription with the absence and presence of a- 
amanitin that the EBERs are transcribed by RNA polymerase III (pol III) (Rosa et al, 
1981, Howe and Shu, 1989) despite the presence of pol II elements in the promoters: Spl, 
ATF and a TATA- like box (Howe and Shu, 1989). In the different transgenic mice 
described here, an additional pol II element has been included, the Ep enhancer, which 
could influence the control of transcription by pol II and pol HI. In order to test if EBERl
95
D1/50 AK2003
142
127
136
AK31
9 x 
733 x
Figure 4.10: Comparison of the levels o f expression of EBERl in mice of lines 127, 131, 137, 
136 and 142 in both thymus and Peyer’s patches
RNA was extracted from PP and thymus of transgenic positive animals. Total RNA was 
subjected to DNAse I treatment followed by an acid phenol extraction. The RT reaction was 
performed with an EBERl specific primer (CR4, for the EBERl Q-RT-PCR) or an oligodT 
primer (for the GAPDH Q-RT-PCR) and 5pg o f total RNA. An RT plus and minus reaction 
was performed for each sample. The Q-RT-PCR was performed with 1 /4th o f the RT reaction 
using either CR8 and CR9 primers (for EBERl) or the G3PDH5’and G3PDH3’primers (for 
GAPDH). AK31 was used as negative control and AK2003 (panels C and D) was used as 
positive control for EBERl Q-RT-PCR. The results for the QPCR with the EBERl primers 
are shown and the normalised data is tabulated below. The fold differences are also presented. 
Panel A shows the comparison in Peyer’s patches (PP) o f lines 127, 131 and 137, whereas 
panel B shows the comparison in the thymus (T). Panels C and D show the comparison 
between lines 127, 136 and 142 in Peyer’s patches (PP, panel C) and in the thymus (T, panel 
D).
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in this transgenic system is transcribed by pol II or by pol III, two sets of reverse 
transcriptase reactions were performed, one using an EBERl specific reverse primer and 
the second one using an oligodT primer, which recognises mRNA sequences due to the 
presence of the poly A tail. Then on the RT products several PCR reactions were 
performed using different sets of primer pairs (Figure 4.11). GAPDH specific primers were 
used as a control for a pol II gene, therefore no amplification should be expected when 
these primers are used with a template from the EBERl specific RT. Similarly, tRNA 
specific primers were used as a control for a pol HI gene and no amplification should be 
expected when these primers are used with a template from the oligodT RT. The test PCR 
was performed using EBERl specific internal primers CR8 and CR9 (Figure 2.1). The 
GAPDH PCRs showed amplification from the different samples using the oligodT RT 
primer (Figure 4.12). The fragment intensity from the different samples was similar, except 
for line 127 which was more intense. However, for this sample a DNA contamination of 
the RNA sample is likely as observed by the product in the no RT track, which could 
account for the increased signal in the +RT track. A product was also faintly observed 
using the EBERl specific primer for the RT reaction. No signal should have been detected 
from this PCR; a possible explanation for this is a miss-priming of the EBERl specific 
primer CR4, which could have hybridised to similar sequences in several RNAs and 
allowed amplification of GAPDH. For the tRNA PCR, no signal was detected in any of the 
tracks except for the PCR control, suggesting that the PCR was working and that the 
oligodT primer is specific to pol II transcripts (Figure 4.13). The EBERl PCR showed a 
signal from the different samples when the EBERl specific primer was used for the RT 
reaction, as previously observed in sections 4.2, 4.3 and 4.4 (Figure 4.14 A), indicating that 
primer CR4 does primarily recognise the EBERl sequence. However this PCR does not 
distinguish if the transcript is of pol II or pol ID origin. A very faint signal was detected in 
the EBERl PCR products following an oligodT RT reaction (Figure 4.14 B). As the signal 
is only detected after long exposure of the Southern blot gel to the film, it could be due to a 
miss-priming from the oligodT primer as it was previously observed with GAPDH PCR 
and EBERl specific RT primer. These results strongly suggest that in the transgenic mice 
tested in this assay, EBERl is not transcribed by RNA Pol II.
A run on assay with untreated AK2003 nuclei or treated AK2003 nuclei with a- 
amanitin was attempted to further determine if EBERl is transcribed by RNA pol II or pol 
HI. However, the results were not conclusive and this assay should be repeated.
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RNA from the highest expressing tissue of lines 127,131, 137, 136 and 134 
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Figure 4.11: Experimental design of pol n/pol ID analysis using RT-PCR 
Total RNAs from the highest expressing tissue of lines 127, 131, 137, 136 and 134 were 
either used for a reverse transcriptase reaction using oligodT primer or using an EBERl 
gene specific reverse primer. The RT products were then used for different PCRs as 
indicated in the figure.
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127 131 136 137 134
+ - +  - +  - C H  + - +  -
1018bp 
5 17bp 
298bp
Figure 4.13: OligodT reverse transcriptase followed by PCR using tRNA primers 
Total RNA (5pg) from Peyer’s patches of line 127, peripheral lymph nodes o f line 131, 
thymus o f lines 136 and 137 and spleen o f line 134 was subjected to an RT reaction using an 
oligodT primer. For each sample a minus RT control (-) was performed. A PCR was 
performed with l/4th o f the RT reaction using tRNA primers. Controls were also performed for 
the PCR, a no DNA control (FI) and a positive plasmid tRNA control (C) showing a DNA 
fragment of the expected size o f 217bp. The RT-PCR products were electrophoresed through a 
1% agarose gel. The tRNA plasmid was a kind gift from Prof R.J. White, Gomez-Roman et 
al., 2003.
A 127 131 136 137 134
PCR
+ - + + - + - + -  H2O control
EBERl 
specific RT
B
127 131 136 137
+ - + + - +
134
PCR 
H2O control
506----
396----
220----
154----
OligodT RT
Figure 4.14: Reverse transcriptase either using an EBERl specific primer or an oligodT primer 
followed by a PCR using EBERl primers
Total RNA (5jng) from Peyer’s patches of line 127, peripheral lymph nodes o f line 131, 
thymus o f lines 136 and 137 and spleen o f line 134 was subjected to an RT reaction using an 
EBERl specific primer (CR4) (panel A) or an oligodT primer (panel B). For each sample a 
minus RT control (-) was performed. A PCR was performed with 1 /4th o f the RT reaction 
using CR8 and CR9 primers. Controls were also performed for the PCR, a no DNA control 
(FCO) and a positive plasmid DNA control showing a DNA fragment o f the expected size 
(144bp). The RT-PCR products were electrophoresed through a 1% agarose gel followed by a 
Southern blot using an EBERl probe. For panel A the blot was exposed to film overnight 
whereas for panel B it was exposed for 3 days prior to being developed. Note a slight 
contamination is suggested by the signals in the -RT tracks o f 134 in panel A and in 127, 136 
and 134 in panel B.
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4.8. The EBERl gene has an upstream start
4.8.1. A minor species of EBERl is observed in Raji cell extracts
Two reports have previously described the presence of a minor, slower migrating 
EBERl species following SI nuclease mapping of the 5’ start. This minor EBERl product 
was estimated to represent 1% of the major species. A similar species was not observed for 
EBER2 (Jat and Arrand, 1982, Arrand and Rymo, 1982). This suggested the minor use of 
an upstream start site for EBERl transcription. In order to confirm if an upstream start site 
of EBERl is used in Raji cells, an RT-PCR approach was undertaken. An EBERl specific 
RT was performed using primer CR4 followed by two different sets of PCRs using 
different primer pairs, one being CR8 and CR9 and the second using CR25 and CR9 where 
CR25 anneals upstream of the recognised start of EBERl (Figure 4.15 A). The PCR 
performed using CR8 and CR9 showed an amplification from Raji RNA but not from 
BJAB RNA as expected (Figure 4.15 B). The PCR performed using CR25 and CR9 
primers also showed a signal for Raji, of a lower intensity compared to the previous one 
(Figure 4.15 C). This indicates that there is a second upstream start for the EBERl gene, 
which confirms the previous observations from Arrand and colleagues.
4.8.2. The minor species of EBERl is observed in lines 127 Peyer’s patches 
and line 131 peripheral lymph nodes
In Chapter 3 northern blotting was used to assess the expression in culture of the 
different transgenes generated. On this blot, the EBERl signal appears very smeary which 
either reflects poor resolution or could suggest the presence of different sizes of EBERl 
transcripts. In order to test if a minor upstream start species of EBERl is also expressed in 
the transgenic lines as it is in Raji cells, an RT-PCR using CR25 and CR9 primers was 
performed (Figure 4.16). A signal from line 127 Peyer’s patches and line 131 peripheral 
lymph nodes was observed at lower intensity compared to using the internal CR8/CR9 
primers (compare to figure 4.14 A). No signal was detected from the other samples tested 
following one day exposure, although there is a hint in 137. This result suggests that in the
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— ► — ► <  < 
CR25CR8 CR9 CR4
B Raji BJAB PCR 
H2O control
bp
396
220
154 CR8-CR9
C Raji BJAB
bp
396
220
154
+ +
PCR 
H20  control
CR25-CR9
Figure 4.15: Reverse transcriptase using an EBERl specific primer followed by PCR using 
different EBERl primer pairs
Panel A shows the relative position o f the different primers used in this assay (not to scale). 
Total RNA (5pg) from Raji and BJAB cells was subjected to an RT reaction using an EBERl 
specific primer (CR4). For each sample a minus RT control (-) was performed. Two PCR were 
performed with l/4lh o f the RT reaction using either CR8 and CR9 primers (panel B) or CR25 
and CR9 primers (panel C). Controls were also performed for the PCR, a no DNA control 
(H2O) and a positive plasmid DNA control. The RT-PCR products were electrophoresed 
through a 1% agarose gel and followed by Southern blotting using an EBERl probe. The 
expected size products are 144bp and 163bp for CR8/CR9 and CR25/CR9 amplifications 
respectively.
127 131 136 137 134
_____________    PCR
+ - + - + - + _ +  - H2O control
EBER1 
specific RT
Figure 4.16: EBER1 specific reverse transcriptase followed by PCR primers CR25 and CR9 
Total RNA (5fig) from Peyer’s patches o f line 127, peripheral lymph nodes o f line 131, 
thymus o f lines 136 and 137 and spleen o f line 134 was subjected to an RT reaction using an 
EBER1 specific primer. For each sample a minus RT control (-) was performed. A PCR was 
performed with 1 /4th o f the RT reaction using CR25 and CR9 primers. Controls were also 
performed for the PCR, a no DNA control (H20 )  and a positive plasmid DNA control showing 
a DNA fragment o f the expected size (163bp). The RT-PCR products were electrophoresed 
through a 1% agarose gel and followed by Southern blotting using an EBER1 probe. The 
autoradiographs o f the southern blots are presented in this figure. The blot was exposed to 
film overnight before being developed.
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transgenic EBER1 mice, at least from lines 127 and 131, an upstream start site is used to a 
minor extent.
4.9. Summary
19 EBER1 transgenic positive founders were generated and 13 lines have been 
established from these. The expression analysis was performed on the lymphoid tissues of 
all the lines and on other tissues for lines 127,131,136 and 137. For construct 670, mice of 
lines 136 and 142 express EBER1 in the lymphoid tissues. The expression profile has not 
yet been determined for line 141. For construct 671, mice of the two lines express EBER1 
in the lymphoid tissues. For line 127 the expression was also detected in the brain but not 
in any of the other tissues tested. The expression was also shown to be directed to both the 
B and T cells. For construct 672, mice of all the lines express EBER1 in the lymphoid 
tissues with different patterns of expression except line 133 where no expression was 
detected. Both lines 131 and 137 also express the transgene in non-lymphoid tissues, which 
could suggest that the transgene has integrated near a cellular gene which could influence 
the expression pattern or that the transgene was not sufficiently lymphoid specific. This 
was not investigated further. The expression profile has not yet been determined for line 
143.
The expression level has been compared between different lines in both the thymus 
and Peyer’s patches. In summary, mice of line 142 have the highest expression of EBER1 
in the thymus, followed by line 127, whereas in the Peyer’s patches, mice of line 127 have 
the highest expression of EBER1 followed by line 131. It was also noted that the 
expression in the transgenic tissues is much lower than that of an established EBV positive 
BL cell line in culture.
An RT-PCR approach was used to determine if in the transgenic positive mice 
EBER1 is an RNA pol II or RNA pol III transcript. The results showed that the EBER1 
transcripts in the different tissues tested do not have a poly A tail as no product was 
detected when a PCR using EBER1 primers was performed following an oligodT RT. This 
suggests that EBER1, in the tissues tested, is an RNA pol HI transcript.
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The presence of a second upstream start for EBER1 was confirmed in Raji cell 
extracts and in tissues of different EBER1 transgenic positive lines using an RT-PCR 
approach.
For the next chapters the phenotypes of lines 136, 142 (construct 670), lines 127, 
145 (construct 671) and lines 131, 137 (construct 672) will be further analysed.
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Chapter 5. Phenotype analysis of the different expressing
lines
5.1. Introduction
In the previous chapter the generation of transgenic mice expressing EBER1 was 
described. For each of the three constructs two lines have been selected (lines 136, 140 for 
construct 670, lines 127 and 145 for construct 671 and lines 131 and 137 for construct 672) 
and studied in more detail. This chapter describes the phenotype of the different lines 
selected. Data is also presented on the expression of c-Myc and Id2 in different EBER1 
positive tissues. The effect of expression ofEBERl on the proportions of the B and T cells 
as well as on cytokine secretion is presented. Finally, the activity of PKR and other IFN 
related genes in response to dsRNA treatment of the mice is described. As line 127 was the 
first line where EBER1 expression was detected its analysis was taken further than the 
other lines.
5.2. Tumour phenotype of the different EBER1 lines
5.2.1. Phenotype of the lines
The main aim of this project was to determine if the expression ofEBERl in vivo 
could lead to the development of a phenotype, particularly malignancy. Where possible a 
cohort of 10-16 mice (of both positive and negative siblings) was set aside for a phenotype 
watch (Table 5.1) and each group was monitored weekly for any external signs of 
phenotype. To date, 9 out of 17 animals (53%) have developed lymphoma in line 127 aged 
between 14 and 22 months old and for the wild-type 2 animals out of 16 have developed 
lymphoma (12.5%) (one at 18 months and one at 24 months) (Table 5.1). The phenotype 
observed in the transgenic positive animals was expansion of the spleen (10-15x the 
normal size), expansion of the thymus (3-5x the normal size, not shown in the figure), 
enlarged mesenteric lymph nodes (to a pea size) and sometimes a slight expansion of
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136 127 145 131 137
Tg status + + - + + + -
Number of 
mice
11 17 16 13 10 12 11
Number of 
tumour
0 9 2 0 1 0 0
Table 5.1: Phenotype watch of the different lines selected
For lines 136, 127, 145, 131 and 137, a cohort of animals was monitored in a phenotype 
watch. The number of animals used is presented as well as their transgenic status (Tg 
status), + being a transgenic positive animal and - a transgenic negative. The number of 
animals with tumours to date is indicated.
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peripheral lymph nodes and Peyer’s patches (Figure 5.1). Some of the lymphoid tissues 
were sent for pathological analysis.
A Kaplan Meier graph is shown in figure 5.2, which displays incidence of 
lymphoma in these animals. 53% of the transgenic positive animals (EBER1) developed 
lymphoma with an average age of onset of 18 months. The P value between the two curves 
is 0.0258, indicating that the difference between the onset of lymphoma in the transgenic 
positive mice and wild-type is statistically significant. 12.5% of the wild-type animals 
developed lymphoma (with expansion of mesenteric lymph nodes, peripheral lymph nodes 
as well as the spleen for the 18 months old animal and expansion of mesenteric lymph 
nodes and spleen for the 24 months old animal) which can happen in old C57B1/6 mice but 
is observed at low frequency in our colony.
It was also observed whilst dissecting animals for various assays that 20 out of 39 
mice between 3 and 11 months old showed signs of expansion of lymphoid tissues (spleen, 
thymus, peripheral lymph nodes, mesenteric lymph nodes or Peyer’s patches) (Tables 5.2 
and 5.3) and none of the negative mice of matched age analysed showed a phenotype. This 
was not observed in younger transgenic animals between 2 and 6 months old, suggesting 
that the phenotype in this line arises later than 6 months. Therefore our results from line 
127 older animals suggest that EBER1 acts as an oncogene. However to be able to 
conclude that this is exclusively due to the action of EBER1 and not any cellular gene 
disruption in this line, similar supporting data from other lines are required.
For the other lines, most of the animals are younger than mice of line 127 as the 
founders were generated afterwards and they are still under study. Line 127 was the first 
line generated and characterised to express EBER1. However, one transgenic positive 
animal from line 131 developed a lymphoma at 13.5 months of age and had a similar 
phenotype compared to line 127 (Figure 5.3 and tables 5.4 and 5.5). It can be noted that the 
expansion of the spleen was smaller than that observed for line 127 but the animal was also 
younger. This animal also had an infection and tissues were sent for pathology analysis. In 
younger mice of line 131 no signs of lymphoid expansion were observed when compared 
to age matched negative siblings. For line 136, it was observed that 6 out of 10, 2 to 10 
months old animals showed signs of lymphoid expansion (Tables 5.4 and 5.5). For line 137 
it was observed that 11 out of 14, 4.5 to 8 months old animals showed signs of expansion
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Liver
Spleen
WT Ep-EBERl
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Spleen
>
WT Ep-EBERl
LNs
Cervical
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WT Ep-EBERl
Figure 5.1: Tumour phenotype in line 127
Panel A shows the tumour phenotype observed in a transgenic positive 18 months old 
animal compared to an aged matched negative sibling (WT). A cervical lymph node (LN), 
the spleen and the liver are shown by an arrow. Panel B shows the dissected spleen and the 
different lymph nodes (LNs) alongside their negative aged matched control (WT). The 
infiltration from the white pulp can be noticed in the transgenic spleen. Note that the 
transgenic mesenteric lymph node was a portion o f a large interconnected series o f nodes.
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Figure 5.2: Kaplan Meier plot o f lymphoma incidence in line 127 animals 
This curve shows the percentage o f  lymphoma free against age (days). The red curve 
represents the transgenic positive animals o f line 127 (EBER1) and the blue curve the 
negative siblings (WT). The graph was generated and the data analysed for statistical 
significance with a log rank test using Graphpad Prism 4 software. The study end point 
was 2 years.
Animal number Tg status Age in 
months
Phenotype observed
127.111 +
(homozygous)
9 T lx, PLNs 3x, MLNs 5x, 1PP 
was very large lOx others OK
127.123 + 11 np
127.69, 70, 71, 83, 84 
and 85
3 np
127.92, 93 and 94 - 3.5 np
127.9, 10, 39 and 40 - 4 np
127.120 and 121 - 7 np
127.113 and 114 - 8 np
127.104 and 105 - 9 np
Table 5.2: Phenotype in younger line 127 animals
In this table the animal ID, transgenic status (Tg status), age and the phenotype observed are 
presented, np indicates that no phenotype was observed. MLNs: mesenteric lymph nodes, 
PLNs: peripheral lymph nodes, CLNs: cervical lymph nodes, PP: Peyer’s patches, SILNs: 
superficial inguinal lymph nodes, LN: lymph node, ALN: axillary lymph nodes, T: thymus.
Age months
0/614/19>  6 -  11 <
0/72/14> 3 - 6  <
4/6 0/6<3
PX <0.001
Table 5.3: Summary of the lymphoid pathology in younger mice of line 127 
This table presents the number of animals which have developed signs of lymphoid expansion 
on the total number of animals for different age categories for mice of line 127. Both the 
transgenic positive (+) and negative (-) siblings are shown. For full details for the negatives 
see summary table 7.1. The data was analysed for statistical significance using a Chi squared 
(X2) test and is presented as P %.
Animal number Tg status Age in 
months
Phenotype observed
127.73 + 3 ALN 3x
127.75 and 76 + 3 np
127.86 + 3 CLN 2x
127.87 and 88 + 3 PLNs 2x, MLNs 2x
127.95 3.5 Thymus 2x
127.96, 97, 106 and 110 + 3.5 np
127.108 + 3.5 MLNs 2x, PLNs 2x
127.11. 12,41,42, 103 
and 107
+ 4 np
127.101 and 102 + 5 np
127.119 and 122 + 7 np
127.134 + 7 PLNs 2x and PP2x 
LN around spine 3x
127.135 + 7 PLNs 2x and PP2x
127.136 + 7 Spleen 2x
127.137 + 7 Spleen 2x, thymus 2x and PP 
2x
127.139 and 141 + 7.5 np
127.140 + 7.5 Thymus 2x, PP 2x
127.142 + 7.5 Thymus 2x
127.143 + 7.5 Thymus 2x, PP 2x
127.144 + 7.5 Spleen 2x
127.115 + 8 Spleen 2x, thymus lx
127.116 + 8 Spleen 2x
127.117 + 8 Spleen 6x,
127.128 + 8 1/2 np
127.129 + 8 1/2 Spleen lx, thymus 2x
Spleen
131.18 131.20
Ep-EBERl Wt control
Figure 5.3: Tumour phenotype in line 131
This figure shows the expanded spleen o f a transgenic positive 13.5 months old animal 
(line 131) alongside its aged matched negative sibling (Wt) control.
\ T g  
Age m o n tn s " \^
131 + 131 - 136 145
> 10-14  < 1/1 0/1
V Os 1 o IA 4/8 2/3
> 3 - 6  < 0/1
<3 0/5 0/5 2/2 2/2
P Fisher’s exact 0.18 <0.001 0.00007
Table 5.5: Summary of the lymphoid pathology in younger mice of lines 131, 136 and 145 
This table presents the number of animals which have developed signs of lymphoid expansion 
on the total number of animals for different age categories for mice of lines 131, 136 and 145. 
Both the transgenic positive (131 +) and negative (131 -) siblings are shown for line 131. For 
full details for the negatives see summary table 7.1. The data was analysed for statistical 
significance either using a Chi squared (x2) test or a Fisher’s exact test and is presented as P x2 
or P Fisher’s exact respectively.
Animal number Tg status Age in 
months
Phenotype observed
131.12, 15, 22, 23 
and 25
+ 3 np
131.11, 16, 54, 26 
and 27
3 np
131.18 + 13.5 Tumour: Spleen 4x, MLNs 5x
131.20 - 13.5 np
136. 29 + 2 MLNs 2x, PLNs 4x
136.30 + 2 MLNs 2x
136.47 and 48 + 9 np
136.51 + 9 Thymus 2x
136.38 + 10 Spleen 1/2 size, PP 3-4x
136.42 + 10 Thymus 2x
136.43 + 10 Thymus 2x, PP 2-3x
136.39 and 40 + 10 np
145.9 + 2 SILNs more than 1 LN each side, 
ALNs and CLNs 2x, MLNs 2x, PP 3x
145.13 + 2 SILNs more than 1 LN each side, 
ALNs and CLNs 2x, MLNs 4x, PP3x
145.45 + 4 np
145.29 and 31 + 8 2 SILNs each side, thymus 2x, PP 3x
145.30 + 8 np
Table 5.4: Pathology of mice of lines 131, 136 and 145
In this table the animal ID, transgenic status (Tg status), age and the phenotype observed 
are presented. The line number is indicated first followed by the animal number, np 
indicates that no phenotype was observed. MLNs: mesenteric lymph nodes, PLNs: 
peripheral lymph nodes, CLNs: cervical lymph nodes, PP: Peyer’s patches, SILNs: 
superficial inguinal lymph nodes, LN: lymph node, ALN: axillary lymph nodes.
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of lymphoid tissues, mainly peripheral lymph nodes, mesenteric lymph nodes and thymus 
(Tables 5.6 and 5.7). The three without phenotype were young animals (4, 4 and 5 
months). None of the age matched negative siblings analysed showed a phenotype. And 
finally 4 out of 6 line 145 animals (2 to 8 months old) showed an unusual phenotype as 
well as signs of lymphoid expansion (Tables 5.4 and 5.5). This phenotype has not been 
seen in other lines, where the superficial inguinal lymph nodes are not markedly expanded, 
but instead of one at each site, several small individual nodes were detected.
5.2.2. The tumours arising in line 127 are of B cell origin
In order to determine if the tumours arising in line 127 were of B cell or T cell 
origin, tumour sample gDNA was examined for clonal IgH and T cell receptor (TCR) 
rearrangements. The IgH rearrangement was analysed by Southern blot using tissues from 
two animals that developed tumours (Figure 5.4). A wild-type sample was used as negative 
control to identify the endogenous band and two transgenic EpN-myc tumour tissues were 
used as positive controls for IgH rearrangement (Dildrop et aL, 1989). IgH rearrangements 
were observed from two different EBER1 mice with tumours (two tissue samples each) 
due to the presence of extra bands when compared to the negative control. Moreover the 
rearrangements were clonal within an animal, the same bands being detected in both 
tissues analysed. No TCR rearrangements were observed for either of the EBER1 tumour 
samples (Data not shown). These results indicate that the tumours arising in line 127 
animals are of B cell origin. Moreover, FACS analysis performed on a third EBER1 
tumour sample (127.51) with B220FITC and CD3PE staining showed an extensive B cell 
population (B220 positive) compared to the T cell population (CD3 positive) (Figure 5.5).
5.2.3. EBER1 expression in the tumour tissues of line 127
In order to assess if EBER1 expression is altered in the tumour samples an RT-PCR 
was performed on RNA extracted from two tumour samples and followed by a Southern 
blot (Figure 5.6 A). A control experiment was performed with different pre-tumour line 
127 tissues (Figure 5.6 B). For both the spleen and the mesenteric lymph node sample, no 
difference in EBER1 expression levels were observed between the pre-tumour and tumour 
stage, indicating that EBER1 expression does not increase in the tumours. However, this
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Age mom
>  6 -  10 < 6/6 0/6
5/8> 3 - 6  < 0/6
<0.001
Table 5.7: Summary of the lymphoid pathology in younger mice of line 137 
This table presents the number of animals which have developed signs of lymphoid expansion 
on the total number of animals for different age categories for mice of line 137. Both the 
transgenic positive (+) and negative (-) siblings are shown for line 137. For full details for the 
negatives see summary table 7.1. The data was analysed for statistical significance using a Chi 
squared (x2) test and is presented as P x2-
Animal number Tg status Age in 
months
Phenotype observed
137.24 + 4.5 PLNs 3x, MLNs 2x
137.28 + 4.5 PLNs 3x, MLNs 3x, thymus 3x
137.69 + 4.5 MLNs 2x, CLNs 2x
137.70 and 72 + 4.5 np
137.52 + 5 np
137.57 + 5 MLNs 2x
137.58 + 5 Thymus 2x
137.71 + 6.5 Thymus 2x, spleen 1.5x
137.55 + 7 Thymus 1.5x, spleen 2x
137. 43 + 8 Thymus 2x
137.46 + 8 Thymus 2x
137.50 + 8 Thymus 2x, spleen 1.5x
137.51 + 8 Thymus 2x
137.63, 66, 67 and 68 - 4.5 np
137.56 and 59 - 5 np
137.53 and 54 - 7 np
137.44, 45, 48 and 49 - 8 np
Table 5.6: Pathology of mice of line 137
In this table the animal ID, transgenic status (Tg status), age and the phenotype observed 
are presented. The line number is indicated first followed by the animal number, np 
indicates that no phenotype was observed. MLNs: mesenteric lymph nodes, PLNs: 
peripheral lymph nodes, CLNs: cervical lymph nodes, PP: Peyer’s patches.
EBER1 EBER1 
N-myc 49  37
Wt S MLN S MLN S MLN
Endogenous 
 ►
6.5kb
Figure 5.4: IgH rearrangements in line 127 tumour samples
gDNA was extracted from different tissues (spleen: S, and mesenteric lymph node: MLN) and 
5jug was digested with EcoRl. The digested gDNAs were electrophoresed through a 0.8% 
TAE gel and Southern blotted. The membrane was hybridised overnight with an IgH 
radiolabelled probe at 65°C. The washes were performed the following day with a high 
stringency wash at 65°C and the membrane was exposed to film. A wild-type (Wt) sample was 
used as negative control. Two N-myc tumour tissues were used as positive controls for IgH 
rearrangement. The endogenous band is indicated by an arrow on the left hand side and the 
rearranged bands are shown by arrows on the right hand side.
Rearrangements
Figure 5.5: The splenocytes from line 127 tumours are of B-cell origin 
The spleen was collected from a line 127 mouse with a tumour. Primary cells were isolated 
and 106 cells were stained with B220FITC and CD3PE. The percentage of the cells in each 
quadrant is indicated. A B cell population with this stain should be in the lower right 
quadrant, whereas a T cell population should be in the upper left quadrant.
Spleen MLNs
+ - + H2O control
Liver Spleen BM PLNs MLNs Thymus PP
PCR
control
Figure 5.6: EBER1 expression in line 127 tumour samples
The spleen and mesenteric lymph nodes (MLNs) from a line 127 tumour animal were 
collected. RNA extraction was performed followed by DNAse I treatment, acid phenol 
extraction and RT-PCR. The RT reaction was performed with an EBER1 specific primer 
(CR4) and 5p.g of total RNA. For each sample a minus RT control was performed. The PCR 
was performed with l/4th of the RT reaction and CR8 and CR9 primers. A no DNA control 
(H2O) and a positive plasmid DNA control were also performed for the PCR. The RT-PCR 
products were electrophoresed through a 1% agarose gel followed by Southern blotting and 
probing using an EBER1 probe (panel A). A gDNA contamination can be observed in the 
Spleen and MLN samples. A similar experiment was performed with different pre-tumour 
tissues of line 127 (panel B). BM: bone marrow, PLNs: peripheral lymph nodes, MLNs: 
mesenteric lymph nodes, PP: Peyer’s patches.
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PCR and blot approach is not strictly quantitative. Nevertheless the higher expression in 
the Peyer’s patches (as seen by quantitative PCR) can be discerned by this method and it is 
therefore semi-quantitative.
5.2.4. Preliminary protein analysis of line 127 tumour samples
5.2.4.1. c-Myc expression analysis of line 127 tumour samples
In order to assess what secondary events may have occurred in the development of 
line 127 tumours, the expression of various proteins was examined by western blot The 
first protein analysed was c-Myc, due to its involvement in BL (Lindstrom and Wiman, 
2002). A western blot was performed with 5 different samples from EpEBERl mice and 
controls from a wild-type C57B1/6 mouse, an Epcmyc mouse tumour (line 97, Adams et 
aL, 1985) and an EpEBNAl mouse tumour (line 26, Wilson et ah, 1996) and probed with 
an anti c-Myc antibody (Figure 5.7). Two bands at approximately 66kDa (the expected size 
for c-Myc) were observed in all the samples. In order to correctly identify the c-Myc band 
the western was stripped and re-probed using a blocking peptide for this primary antibody. 
No signal was detected from this blot indicating that the blocking peptide is not an 
effective means to identify c-Myc in this case. However, the two bands indicated by an 
arrow are both stronger in the two line 97 samples (as is a band at approximately 130kDa) 
which are overexpressing c-Myc and were used as positive controls to identify c-Myc, 
suggesting that either or both could be c-Myc products. Therefore, if  the two bands are c- 
Myc, no increase in c-Myc was detected in the different EBER1 samples (pre-tumours or 
tumours) compared to wild-type. The signal appears of a similar intensity to that of the 
wild-type control. This is supported by the normalisation data, as the value obtained is 
similar in the wild-type (wt), the young line 127 mouse (N), the pre-tumour (P) and the
127.49 tumour samples (49T) (Table 5.8), whereas the value obtained from the c-Myc 
positive controls (line 97) is clearly higher. However, it should be noted that the signal 
obtained from the p tubulin blot may be distorted as this blot was stripped several times 
before being re-probed with an antibody to p tubulin. This could lead to a non-uniform 
decrease in protein levels and therefore this blot might not be very accurate as a loading 
control. Moreover, the software comparing pixel number of images is not likely to reflect a 
true linear quantitation of the protein sample and therefore just represents a rough guide of
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Wt N P 49T 49T 37T 37T 97S 97CLN 26 12726
Norm
data
0.27 0.15 0.22 0.23 0.73 20.5
*
2.45 5.09 0.85 2.99
Norm 
data to Wt
1 0.56 0.81 0.85 2.7 76 9.1 18.9 3.1 11.1
Table 5.8: Norma isation of the c-Myc western ?lot
The intensity of the bands on the c-Myc western blot and the ptubulin western blot were 
determined using the ID image analysis software. The intensity values of the c-Myc bands 1 
and 2 were added and then divided by the ptubulin intensity value to give the normalised data 
(Norm data). The normalised values were then divided by 0.27 to relate to a wild-type value of 
1 (Norm data to Wt) to be able to compare the samples to the wild-type. The order of the 
samples is the same as on the western. It should be noted that the value with the * sign appears 
too high for the signal observed on the blot, which may be due to some track distortion for this 
sample.
Figure 5.7: c-Myc western blot of line 127 tumour samples
Proteins from tissues of different animals were extracted using the high salt nuclear extraction 
method. lOOjig protein extracts were separated by a 7.5% SDS-PAGE and the gel was western 
blotted. The membrane was probed with a rabbit anti-c-Myc antibody followed by a goat anti­
rabbit IgG-HRP secondary antibody and visualised using ECL+ (panel A). Several controls 
were used, a wild-type (Wt) spleen control, two c-Myc tumour tissues (S: spleen, CLN: 
cervical lymph nodes) (97), an EBNA1 spleen tumour tissue (26), an EBNA1/EBER1 bi- 
transgenic spleen tumour tissue (26127). For the EBER1 line 127 samples, a spleen from a 
young animal was used (N), a spleen where signs of lymphoid expansion were observed (P) 
and four tumour tissues (spleen and mesenteric lymph nodes) (T) from two animals (127.37 
and 127.49) were used. c-Myc is 67kDa and the most likely c-Myc bands are indicated by two 
arrows. The membrane was stripped and reprobed with a rabbit anti-ptubulin antibody and a 
goat anti-rabbit IgG-HRP secondary antibody and visualised using ECL+ (panel B). It should 
be noted that no c-Myc protein was observed for the second track of animal 127.37; however 
this sample was shown to be degraded. The molecular weights according to the marker lane 
(in kDa) are shown.
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comparative levels. A slight difference in intensity (3.5 fold) was also observed between 
the EBNA1 tumour sample (26) and the EBNA1/EBER1 bi-transgenic tumour sample (26
my
This western blot was stripped several times and re-probed with the following 
antibodies: anti-p53, since p53 is frequently mutated in BL (Farrell et al., 1991), anti- 
phospho Rb and anti-total Rb. The results were not very conclusive as for both p53 and 
pRB several bands were detected at around the expected size. However, for all the different 
bands the pattern was similar showing no obvious differences in p53 or pRB levels in both 
EBER1 pre-tumour and tumour stages.
5.2.4.2. c-Myc DNA binding activity of line 127 tumour samples
The DNA binding activity of Myc was addressed by EMSA using a myc binding 
site oligo for Myc/Max (Figures 5.8 and 5.9). The positive control used for both EMSAs 
was from a line 97 tumour tissue protein extract. The specific c-Myc band was competed 
out from each sample using 200x competitor unlabelled oligo. A non-specific band, which 
was not competed out, was observed in all the tracks. The attempted supershift with a c- 
Myc antibody showed no shift, suggesting that it either did not work or the band observed 
is not c-Myc. The same protein extracts were used for an Spl EMSA, which reveals the 
quality of the extracts and also allows monitoring of the loading of the samples, as Spl is a 
ubiquitously expressed protein (Figure 5.10). The wild-type, 127.37 and 127.49 samples 
appear degraded compared to sample 97 where the three Spl expected bands are observed. 
The Spl EMSA was performed after multiple freezing and thawing of the samples and this 
could lead to protein degradation. Due to time limitations, this assay was not repeated. 
Unfortunately this limits the interpretation of the c-Myc binding reactions as comparative 
quality and quantity of the samples loaded is not certain. However, it should be noted that 
tumours 127.37 and 127.49 show a different banding profile. Two additional bands (B and 
C in figure 5.9) were observed for sample 127.49, suggesting that in this tumour additional 
protein complexes binding to this oligo have been activated. Moreover, although the 
subsequent Spl analysis of the extracts after freeze/thaw was not informative, the binding 
of a non-specific band (see * in figures 5.8 and 5.9) suggests that the extracts are of 
relatively equal loading. If  so, binding to the Myc oligo in both EBER1 tumours (37 and
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Wt 127.37 97
+ + + competitor
c-Myc antibody
^------- A
*
Figure 5.8: EMSA showing the DNA binding activity o f Myc in extracts from line 127.37 
tumour and a line 97 tumour
Protein was extracted from different samples using the high salt nuclear extraction buffer. 
10pg o f protein extract was used for each sample. Line 97 (c-Myc) extract was used as 
positive control and a wild-type splenic extract was used as negative control (Wt). The EBER1 
sample was extracted from animal number 37. Three reactions were prepared for each sample: 
one without and one with 200x unlabelled competitor and a third one with 4pg o f c-Myc 
antibody (as indicated). Labelled myc oligo was added to each sample and incubated for 20 
minutes on ice before loading the samples on to a 6% polyacrylamide gel. A labelled oligo 
without extract was also used as control (P). The gel was electrophoresed for 3 hours before 
being dried and exposed to film for the required amount of time. The arrow indicates the 
specific binding band o f c-Myc and the * shows a non-specific band.
Wt 127.49 97
+ + + competitor
+ + + c-Myc antibody
ft* » AB
C
Figure 5.9: EMSA showing the DNA binding activity of Myc in extracts from line 127.49 
tumour and a line 97 tumour
Protein was extracted from different samples using the high salt nuclear extraction buffer. 
10p,g o f protein extract was used for each sample. Line 97 (c-Myc) extract was used as 
positive control and a wild-type splenic extract was used as negative control (Wt). The EBER1 
sample was extracted from animal number 49. Three reactions were prepared for each sample: 
one without and one with 200x unlabelled competitor and a third one with 4p,g o f c-Myc 
antibody (as indicated). Labelled myc oligo was added to each sample and incubated for 20 
minutes on ice before loading the samples on to a 6% polyacrylamide gel. A labelled oligo 
without extract was also used as control (P). The gel was electrophoresed for 3 hours before 
being dried and exposed to film for the required amount o f time. The arrow A indicates the 
specific binding band o f c-Myc and the B and C arrows indicate specific bands for animal 49. 
The * sign shows a non-specific band.
p127.49 Wt 97 127.37
+ + + + competitor
Figure 5.10: EMSA showing the DNA binding activity of Spl in extracts from tumour 
samples of mice o f lines 127 and 97
Protein was extracted from different samples using the high salt nuclear extraction buffer. 
lOpg of protein extract was used for each sample. Two EBER1 tumour extracts (127.49 and 
37), a line 97 (c-Myc) extract and a wild-type extract (Wt) were used. Two reactions were 
prepared for each sample: one without and one with 200x unlabelled competitor. Labelled Spl 
oligo was added to each sample and incubated for 20  minutes on ice before loading the 
samples on to a 6 % polyacrylamide gel. A labelled oligo without extract was also used as 
control (P). The gel was electrophoresed for 3 hours before being dried and exposed to film 
for the required amount o f time. The arrows indicate the specific binding bands of Sp 1.
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49) is stronger than the wild-type sample and almost equivalent to the 97 sample, despite 
overexpression of c-Myc not being apparent by western.
In order to explore this further a Southern blot designed to identify possible 
rearrangements at the c-Myc locus was performed. This experiment was designed to assess 
if any rearrangements in close proximity to the c-Myc locus had occurred in the EBER1 
tumours. No rearrangements were observed in the different EBER1 samples tested.
5.2.4.3. Id2 expression analysis of line 127 tumour samples
The protein level of Id2, a downstream transcriptional activation target of c-Myc 
(Lasorella et al., 2000), was analysed in the EBER1 tumour samples by western blot 
(Figure 5.11). The samples were the same as the ones used for the c-Myc western blot. 
This blot was probed with an anti-Id2 antibody and a band at approximately 17kDa was 
observed in the pre-tumour track, the 127.37 tumour samples, the c-Myc and the c- 
Myc/EBERl bi-transgenic tumour samples. A faint Id2 band was observed in one of the
127.49 tumour samples. These results suggest that Id2 could be upregulated in the 127.37 
EBER1 tumour sample where the banding pattern in the Myc EMSA was similar to that of 
the c-Myc positive control. Interestingly the sample (127.49) that either shows faint or no 
Id2 expression is the one that had a different c-Myc binding pattern in the Myc EMSA. It is 
also interesting to note that the pre-tumour sample showed upregulation of Id2 whereas the 
sample from a younger line 127 animal did not, nor was expression detected in wild-type. 
Therefore upregulation of Id2 may occur in turnourigenesis in the EBER1 mice.
5.3. FACS analysis of the different lymphoid tissues in lines 127 and 131
In order to determine if EBER1 expression affects B and T cell proportions in the 
different lymphoid tissues, the tissues were analysed by FACS. The lymphoid tissues 
(spleen, thymus, peripheral lymph nodes, mesenteric lymph nodes, Peyer’s patches and 
bone marrow) from young mice of the lines 127 and 131 were collected from both positive 
and negative siblings and cells isolated. For each line three positive and three negative 3 
months old mice were used and separately pooled. FACS analysis was performed with 
B220FITC and either CD3PE or Thyl.2PE. B220 (or CD45R) is a B cell marker which is
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Figure 5.11: Id2 western blot of line 127 tumour samples
Proteins from tissues of different animals were extracted using the high salt nuclear extraction 
method. I OOptg o f proteins were separated by 12.5% SDS-PAGE and the gel was western 
blotted. The membrane was probed with a rabbit anti-ld2 antibody followed by a goat anti­
rabbit IgG-HRP secondary antibody and visualised using ECL+. Several controls were used, a 
wild-type (Wt) spleen control, two c-Myc tumour tissues from the same mouse (S: spleen and 
CLN: cervical lymph nodes) (97) and a c-Myc/EBERl bi-transgenic tumour tissue (cervical 
lymph nodes) (97127). For the EBERI samples, a spleen from a young animal was used (N), a 
spleen where signs of lymphoid expansion were observed (P) and four tumour tissues (spleen 
and mesenteric lymph nodes) from two animals (127.37 and 127.49) (T) were used. The 
molecular weights according to the marker lane (in kDa) are shown. Id2 is 15kDa and the 
most likely Id2 band is indicated by an arrow.
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expressed from the pro-B cells stage to mature B cells. Thy 1.2 (or CD90), is a T cell 
marker mainly present on immature T cells, whereas CD3 is a T cell marker detected on 
mature T cells. No differences were observed between mice of the two transgenic positive 
lines and their negative siblings for the different tissues tested- Figure 5-12 shows a 
representative example of the results obtained, with the spleen of mice of line 127 stained 
with B220FITC and CD3PE and the bone marrow with B220FITC and Thyl-2PE- 
Therefore the transgene does not appear to affect the proportion of the B and T cells in 
young mice of lines 127 and 131-
In order to determine if EBER1 expression affects the differential status of the B 
and T cells in the different lymphoid tissues (spleen, thymus, peripheral lymph nodes, 
mesenteric lymph nodes, Peyer’s patches and bone marrow) FACS analysis was 
performed- The different stains used for the FACS analysis are presented in table 5-9- For 
this experiment, no differences were observed for line 131 transgenic positive animals 
compared to negative siblings for any of the lymphoid tissues and strains tested, suggesting 
that for this line the status of the B and T cells (with respect to the stains used) is not 
modified by the presence of the transgene- For line 127 no differences were observed for 
the different stains with all the lymphoid tissues tested except for one tissue and one stain. 
An increase of the CDS1*1811, B220neg/low cell population was observed in the Peyer’s Patches 
of transgenic positive animals compared to the negative animals (figure 5.13 A). This 
population could be a B1 population as B1 cells are characterised by CDS111811, B220negor Iow 
and are also bigger and more granular than normal B cells, which was also observed using 
the FSC-H and SSC-H channels (figure 5.13 B). As was shown in Chapter 4, Peyer’s 
patches is the highest expressing tissue in this line. This could explain the fact that this is 
the only affected tissue-
5.4. ELISA analysis of lines 127,131 and 137 sera
In order to assess if the presence of EBER1 in the lines interferes with the secretion 
level of different cytokines or antibodies, serum samples were collected whenever 
possible-
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Figure 5.12: B and T cell proportions of line 127 animals
The spleen and bone marrow were collected from 3 positive and 3 negative siblings and 
separately pooled. Primary cells were isolated and 106 cells were stained with B220FITC 
and Thyl.2PE for the bone marrow cells (panel A) or with B220FITC and CD3PE for the 
splenocytes (panel B). For both panels, the results for the negative siblings (Wt) are shown 
on the left whereas the results for the transgenic positive animals (Tg) are presented on the 
right. The percentage of the cells in each quadrant is indicated.
Antibody name Stage In combination with References
B220 (FITC or 
PE)
Pro-B to mature B 
and activated B
All the stains below Coffman ef al., 1982 
Hathcock e ta l, 1992
CD3 (FITC or PE) Mature T cells B220, CD5, CD8 and 
CD4
Miescher et al., 1989
CD5 (FITC or PE) Subtype Bl, Mature 
B
B220, CD3, CD23 and 
CD43
Luo e ta l, 1992
CD43 (FITC) Immature B 
also onBl subtype
B220 and CD5 Gulley eta l., 1988 
Wells et al., 1994
CD23 (FITC) Mature and 
activated B 
not on B 1 subtype
B220 and CD5 Rao etal., 1987 
Waldschmidt et al., 
1988
Waldschmidt et al., 
1992
slgs (FITC) 
combination of 
IgA, IgM and IgG
Mature B B220
CD2 (FITC) Pre-B to mature B 
and T
B220, CD3 Yagitaef a/., 1989
Thy 1.2 (PE) Immature T B220 Ledbetter et a l, 1979 
Ledbetter etal., 1980
CD4 (FITC or PE) Mature T helper CD3 and CD8 Dialynas etal., 1983
CD8 (FITC) Mature T killer CD3 and CD4 Ledbetter et al., 1980
Table 5.9: The different FACS antibodies used to determine the status of the B and T cells
in animals from lines 127 and 131
This table presents the different FACS antibodies used along with their B or T cell 
expression pattern. The antibody used for co-staining is also given (in combination with).
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Figure 5.13: CD5FITC and B220PE stain of Peyer’s patches from both positive and 
negative siblings of line 127
Peyer’s patches were collected from 3 positive and 3 negative siblings and separately 
pooled. Primary cells were isolated and 106 cells were stained with CD5FITC and B220PE. 
Panel A shows the FL1 and FL2 channels, which is the repartition of the cells according to 
the stain. Panel B represents the forward and side scatter, which shows the size (forward 
scatter, FSC-H) and the granularity (side scatter SSC-H) of the cells. For both panels, the 
results for the negative siblings (Wt) are shown on the left whereas the results for the 
transgenic positive animals (Tg) are presented on the right.
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5.4.1. Anti-IgM ELISA with serum from lines 127 and 131
The soluble form of IgM is secreted by mature activated B cells; therefore in order 
to determine if EBER1 modifies the activated status of the B cells or the secretion of 
soluble IgM, an ELISA was performed using an anti-IgM antibody on the serum of both 
positive and negative siblings from mice of lines 127 and 131 (Figure 5.14). For line 127 
no differences were observed for the production of secreted IgM (P value = 0.91, two 
sample T test, Minitab software), suggesting that the presence of the transgene does not 
affect the secretion of this soluble antibody (Figure 5.14 A). For line 131, a lower average 
was observed for the transgenic positive sample compared to the wild-type sample; 
however this reduction is not statistically significant (P value = 0.41, two sample T test, 
Minitab software) (Figure 5.14 B). Moreover, it should be noted that for this line, only 5 
serum samples have been used in each group. These data indicate that transgenic EBER1 
expression does not affect IgM secretion. A similar assay was performed to monitor levels 
of soluble IgGl; however no results were obtained even for the standard curve. Due to time 
limitations this assay was not repeated.
5.4.2. Proteoplex murine cytokine array with serum from lines 127, 131 and 
137
It has been reported that in BL cells the presence of EBER1 leads to an increase in 
IL10 expression and secretion (Kitagawa et aL, 2000). To determine if  an increase in IL10 
serum level is induced in EpEBERl mice, an ELISA was performed using an anti-ILlO 
antibody on serum samples from mice of lines 127 and 131. However, several ELISA trials 
have been performed without success even using recombinant IL10 for the standard curve, 
suggesting that the antibody may not be sufficiently effective. Therefore the “Proteoplex” 
16 well murine cytokine array kit from Novagen was used. It is a chip array, which allows 
comparison of the level of 10 murine cytokines including IL la , IL10, IL2, IL4, IL6, IL10, 
IL12, GMCSF, IFNy and TNFa. The chip is composed of 16 wells and each well is spotted 
with four spots with the different antibodies and four spots of positive and negative 
controls (which are supplied with the kit). Eight alignment spots are also present and are 
used for the spot-finding software. The experiment was performed using 5 wells for a
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Figure 5.14: Results o f the IgM ELISA for lines 127 and 131
Serum samples (diluted 1/800) from mice o f lines 127 and 131 (positive and negative 
controls) were subjected to an ELISA  using an anti-IgM  antibody. Each sam ple was 
analysed in duplicate. Panel A shows the results for line 127 with 19 transgenic positive 
samples and 8 negative samples analysed and panel B shows the results for line 131 with 5 
samples for both the transgenic positive and negative siblings. For both graphs the Y axis 
represents the cytokine concentration in pg/ml as determined using an IgM standard curve. 
The error bars show the standard error o f the mean. The analysis was perform ed using 
Minitab and Cricket graph software, n represents the number o f samples.
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standard curve in order to obtain an estimate of the cytokine concentration for each serum 
sample. One well was left blank to measure the background signal for each cytokine. The 
remaining wells were used for the different serum samples, which were diluted 4 fold. A 
detection antibody cocktail was then added to each well and was followed by a fluorophore 
detection reagent (both supplied with the kit). The slide was rinsed and dried before being 
sent for scanning to Novagen. The experiment was performed once and in total 2 samples 
from line 127 young animals, 2 samples from line 131, 2 samples from line 137, 2 wild- 
type controls and 2 samples from line 127 tumour animals were used for the array (Table 
5.10). The results show that no cytokines were dectected for the negative controls used, 
except for a low level of TNFa in sample 131.27. Similarly none of the cytokines present 
on the chip were detected in the serum of the transgenic positive samples of mice of line 
131. However for mice of both lines 127 and 137, several cytokines were detectable in the 
sera tested. For line 127, IL4, IL6, IL10, IL12 and IFNy levels were detected in both pre- 
tumour samples tested. It should be noted that the concentration of cytokines determined 
are very different between the two samples ranging from 5 to 10 fold difference. Moreover 
two additional cytokines were detected (IL la  and GMCSF) for sample 127.137 and not 
127.136. Furthermore in the two 127 tumour serum samples two cytokines were detected, 
IL10 and the stress-induced cytokine TNFa. For each sample an additional cytokine was 
also detected, IL la  for sample 127.31 and DL6 for sample 127.37. For line 137, two 
cytokines were detected in both samples tested, IL6 and IFNy and the concentrations 
detected were relatively similar. In sample 137.58, IL12 and TNFa were also detected. As 
only two samples were used from each line tested, this assay should be repeated with more 
samples in order to be able to draw any conclusions. Also, since for mice of line 131 
(transgenic positive and negative) young animals were used, it is possible that more 
cytokines are secreted when the animals are older.
5.5. In vivo experiments using mice of lines 127 and 137
5.5.1. Does EBER1 block PKR action in vivo?
PKR is implicated in the IFN response following a viral infection and is activated 
by dsRNA (Goodboum et al., 2000). EBER1 was shown to block the IFN response in 
cultured cells by binding PKR and inhibiting its autophosphorylation (Nanbo et aL, 2002).
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Line 131 131 131 131 127 127 137 137 127 127
ID 26 27 22 23 136 137 58 69 31 37
Age
months
3 3 3 3 7 7 5 4 19 17
Tg status - - + + + + + + + +
Lymphoma - - - - - - - - + +
IL la 14.9
ILip 22.6
IL2
IL4 124.6 899.6
IL6 55.5 351.3 44.9 19 49.3
IL10 55.6 283 187.2 304
IL12 20.7 205.5 145.3
GMCSF 14
IFNy 259.8 948.7 44.8 35.3
TNFa 13.8 23 86 46.7
Table 5.10: Cytokine chip array summary table
The concentration of cytokine (in pg/ml) in the serum is presented in the table. No 
concentration value indicates that the data point was below the limit of detection. The 
animal number (ID), the age in months as well as the transgenic status (Tg status) is 
presented. Two of the serum samples were from mice that succumbed to lymphoma (as 
indicated).
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Polyinosinic-polycytidylic acid (pIC) is a chemical which mimics dsRNA and is therefore 
often used in assays to induce an IFN response. In order to test if  EBER1 can functionally 
block an IFN response in vivo, 200pg of pIC was injected in the tail vein of both positive 
and negative siblings of line 127 and line 137 (7 to 9 months old mice). Both positive and 
negative mice in the control groups were injected also with PBS as control. Each group 
was composed of three mice. For each animal, spleen, thymus and Peyer’s patches were 
collected 18 hours post-injection; other tissues were collected if an abnormal phenotype 
was observed. Serum was collected one week before the injection and at the time of tissue 
collection. Proteins were extracted from spleen of both pIC and PBS injected mice of line 
127 and the expression of several proteins involved in the IFN response was assessed by 
western blot. The first protein examined was PKR (line 127 spleen samples), due to its 
involvement in the primary phase of the IFN response. In response to dsRNA PKR 
becomes phosphorylated. Therefore both the level of total PKR and phospho-PKR was 
assessed by western blot (Figure 5.15). BJAB cells stimulated with IFNa for 24 hours 
were used as positive control for the induction of an IFN response. A strong band at 66kDa 
(the predicted size for PKR) was observed for BJAB on both the anti-phospho PKR blot 
(Figure 5.15 A) and also on the anti-total PKR blot (Figure 5.15 B). From the figure both 
the level of total PKR and activated PKR appear similar in mice treated with PBS or pIC 
for both the wild-type and the transgenic mice. The intensity of each band was normalised 
against the intensity of P-tubulin (Table 5.11). For the wild-type mice a slight increase in 
the average of both total PKR and phosphorylated PKR was observed following pIC 
treatment For the transgenic positive mice, the level of total PKR remained the same and a 
very slight increase in the average phosphorylated PKR occurred following pIC treatment, 
which could be considered as negligible. For both the wild-type and the transgenic positive 
this assay needs to be repeated with an increased number of samples to determine if the 
results obtained are consistent and to be able to draw conclusions from them. Problems 
were previously encountered in the laboratory when using these antibodies with known 
controls; no signal was detected which suggested the use of these two antibodies was not 
very reproductible. Therefore, the western blot was stripped and reprobed with both anti- 
phospho eIF2a and anti-total e IF 2 a  antibodies(Figure 5.16), which is a downstream 
target of PKR. eIF2a becomes phosphorylated upon PKR activation. A 40kDa band was 
expected for eIF2a and a single band at approximately 35-40kDa was observed using the 
anti-phospho eIF2a antibody (Figure 5.16 A) whereas several bands were observed using
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Figure 5.15: PKR expression and activation following pIC treatment in line 127 spleen 
Protein from spleens o f PBS or pIC injected transgene-positive (tg) or negative (wt) animals 
was extracted using the high salt nuclear extraction method. lOOpg o f protein per track was 
separated by 7.5% SDS-PAGE and the gel was western blotted. The membrane was probed 
with a rabbit anti-phospho PKR (panel A) antibody, followed by a goat anti-rabbit IgG-HRP 
secondary antibody and visualised using ECL+. The blot was then stripped and reprobed with 
a rabbit anti-total PKR (panel B) antibody and then with a rabbit anti-(3tubulin (panel C) 
antibody. For both antibodies a goat anti-rabbit IgG-HRP secondary antibody was used and 
visualised using ECL+. The molecular weights (in kDa) according to the marker lane are 
shown. Both PKR and phospho PKR are 6 6 kDa.
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Figure 5.16: elF2a expression and activation following pIC treatment in line 127 spleen 
Protein from spleens o f PBS or pIC injected positive (tg) or negative (wt) animals was 
extracted using the high salt nuclear extraction method. lOOpg of protein per track was 
separated by 7.5% SDS-PAGE and the gel was western blotted. The membrane was probed 
with a rabbit anti-phospho eIF2a (panel A) antibody, followed by a goat anti-rabbit IgG-HRP 
secondary antibody and visualised using ECL+. The blot was then stripped and reprobed with 
a rabbit anti-total eIF2a (panel B) antibody and then with a rabbit anti-ptubulin (panel C) 
antibody. For both antibodies a goat anti-rabbit IgG-HRP secondary antibody was used and 
visualised using ECL+. The molecular weights (in kDa) according to the marker lane are 
shown. Both eIF2a and phospho elF2a are 40kDa.
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the anti- total eIF2a antibody (Figure 5.16 B). When the two blots were superimposed, 
phospho eIF2a migrated slightly more slowly than total eIF2a. The intensities of both total 
eIF2a and phospho eIF2a were determined and normalised against the intensity of 13- 
tubulin (Table 5.12). An apparent increase in the level of phospho eIF2a was observed 
following pIC injection in the wild-type mice. However the amount of total eIF2a 
remained the same with and without pIC. Similarly for the transgenic positive mice an 
increase in phospho eIF2a level was noticed upon pIC injection, whereas a slight decrease 
in total eIF2a level was observed Therefore eIF2a appears to be phosphorylated in both 
wild-type and transgenic positive mice following pIC injection. These results indicate that 
in the spleen of line 127 mice eIF2a was modified in both positive and negative pIC 
injected mice and therefore EBER1 does not appear to block this activation.
Statl is a protein which becomes activated following an IFN response and 
translocated in a complex into the nucleus to activate several genes (section 1.5.3), 
Therefore, the previous western blot was stripped and reprobed with an anti-total Statl 
antibody, and an anti-phospho Statl antibody (Figure 5.17). Two bands were observed for 
Statl and represent the two isoforms, Statla and Statlp. For both the total Statl and the 
phospho Statl blots an increase was observed following pIC injection in both wild-type 
and transgenic positive mice. The intensity of the band from both isoforms was determined 
and normalised against the intensity of p-tubulin (Table 5.13). For the wild-type mice, a 
clear increase in both total Statla and pwas observed as well as an increase in activated 
Statip following pIC injection. A very slight activation was observed for Statl a  when 
using the anti-phospho Statl tyr701 antibody whereas no increase was observed with the 
anti-phospho Statl ser 727 antibody. For the transgenic positive mice upon pIC injection, 
again a clear increase in both total Statla and pwas observed as well as an increase in 
both activated Statla and p. These results first indicate that Statl induction and activation 
can be detected in the spleen samples following intravenous pIC injection and secondly 
suggest that EBER1 does not block Statl induction or activation. Thus no impact upon 
these branches of the IFN pathway by EBER1 was noted in the spleen of transgenic 
positive mice of line 127.
Another substrate of PKR is the specific inhibitor of NFkB, IkB. When PKR 
becomes phosphorylated it phosphorylates IkB by a mechanism involving NFkB inducing
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Figure 5.17: Statl expression and activation following pIC treatment in the spleen of line 127 
mice
Protein from spleens o f PBS or pIC injected positive (tg) or negative (wt) animals was 
extracted using the high salt nuclear extraction buffer. lOOpg o f protein per track was 
separated by 7.5% SDS-PAGE and the gel was western blotted. The membrane was probed 
with a rabbit anti-phospho Statl ser 727 (panel A) antibody, followed by a goat anti-rabbit 
IgG-HRP secondary antibody and visualised using ECL+. The blot was then stripped and 
reprobed with a rabbit anti-phospho Statl tyr 701 (panel B) antibody, followed by a goat anti­
rabbit IgG-HRP secondary antibody. The blot was stripped and reprobed with a rabbit anti­
total Statl (panel C) antibody and then with a rabbit anti-(3tubulin (panel D) antibody. For both 
antibodies a goat anti-rabbit IgG-HRP secondary antibody was used and visualised using 
ECL+. The molecular weights (in kDa) according to the marker lane are shown. There are 2 
isoforms of Statl a  and (3 and their sizes are 97 and 84kDa. Anti-phospho Statl ser 727 
antibody only recognises the S ta tla  isoform whereas the anti-phospho Statl tyr 701 and the 
anti-total Statl antibodies recognise both isoforms.
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kinase (NIK) and IkB kinase (IKK) (Zamanian-Daryoush et al., 2000) which releases 
NFkB from IkB, leading to an increase in NFkB translocation to the nucleus and DNA 
binding. In order to examine this, an EMSA was performed using the spleen protein 
extracts and an NFkB nucleotide recognition oligo (Figure 5.18). The positive control used 
was an epithelial extract from a transgenic positive mouse line expressing LMP1 (line 117) 
which was previously shown to have an NFkB DNA binding activity (Charalambous, 2005 
thesis). Two specific binding bands were observed for NFkB and were competed out when 
the 200x competitor was added. When comparing the intensities of the two specific bands, 
no differences were noticed between PBS and pIC injected animals in either the positive or 
the negative siblings. An Spl EMSA was performed using the same extracts to check the 
quality of the samples and the loading (Figure 5.19). Sample 117 may be of lower quantity 
or quality as no shift was observed using this extract All the extracts appeared equally 
loaded on the first gel and of equal quality (Figure 5.19 A), whereas for the second gel the 
pIC/wt and the pIC/tg samples appeared underloaded. However, these extracts were used 
after multiple freeze-thaw cycles and therefore the samples could have been partially 
degraded by this process. This assay should be repeated to be able to draw any conclusions 
on the DNA binding activity of NFkB with these extracts. These preliminary results show 
no apparent increase in NFkB DNA binding activit, although with samples in gel B, if  the 
Spl is lower, there may be an increase in NFkB. These results show that no increase in 
NFkB DNA binding activity upon pIC treatment was observed. Despite lack of induction 
by pIC an increase of phospho eIF2a and Statl was observed with pIC injection. This 
indicates that the pIC reached the spleen collected- However, eIF2a and Statl were also 
activated in transgenic positive mice upon pIC injection suggesting that EBER1 in this 
assay did not block the induction of this arm of the IFN response. This could be due to the 
low expression of EBER1 in the spleen in these mice.
Therefore as both mice of lines 127 and 137 express EBER1 at a higher level in the 
thymus, proteins were then extracted from this tissue of both pIC and PBS injected mice 
and the expression of total Statl and phosphorylated Statl was analysed at the time of 
writing (Figures 5.20 and 5.21). For line 127, if  the non-specific band indicated is used to 
reflect the sample loading, an increase was observed in total Statl in the wild-type samples 
following pIC treatment, as well as for Statla activation. For the transgenic positive 
animals, there was no increase in either Statl expression (both isoforms) or activation
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Figure 5.18: EMSA showing binding activity o f NFkB in extracts from pIC or PBS treated 
positive or negative line 127 mice
Proteins were extracted from spleens o f PBS or pIC injected positive (tg) or negative (wt) 
animals using the high salt nuclear extraction buffer. lOpg o f protein extract was used for each 
sample. A hyperplastic epithelial tissue extract was used as positive control (117). Two 
reactions were prepared for each sample: one without and one with 2 0 0 x unlabelled 
competitor. Labelled NFkB oligo was added to each sample and incubated for 20 minutes on 
ice before loading the samples on to a 6% polyacrylamide gel. A labelled oligo without extract 
was also used as control (P). The gel was electrophoresed for 3 hours before being dried and 
exposed to film for the required amount o f time. Panels A and B are gels with different 
samples except for the 117 control. The double arrows indicate the specific binding bands. The 
* indicates a non-specific band.
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Figure 5.19: EMSA showing binding activity o f Spl in extracts from pIC or PBS treated 
positive or negative line 127 mice
Proteins were extracted from spleens o f PBS or pIC injected positive (tg) or negative (wt) 
animals using the high salt nuclear extraction buffer. lOpg o f protein extract was used for each 
sample. A hyperplastic epithelial tissue extract was used as positive control (117). Two 
reactions were prepared for each sample: one without and one with 2 0 0 x unlabelled 
competitor (Comp). Labelled Spl oligo was added to each sample and incubated for 20 
minutes on ice before loading the samples on to a 6 % polyacrylamide gel. A labelled oligo 
without extract was also used as control (P). The gel was electrophoresed for 3 hours before 
being dried and exposed to film for the required amount o f time. Panels A and B are gels with 
different samples except for the 117 control. The samples on panel A are the same as the 
samples on panel A from figure 5.18 and the samples from panel B are the same as the 
samples on panel B from figure 5.18. The double arrows indicate the specific binding bands.
Figure 5.20: Statl expression and activation following piC treatment in the thymus o f line 127 
mice
Protein from thymuses of PBS or piC injected positive (tg) or negative (wt) animals was 
extracted using the high salt nuclear extraction buffer. lOOjig o f protein per track was 
separated by 7.5% SDS-PAGE and the gel was western blotted. Extract pIC/wt from the 
spleen of mice of line 127 was used as a positive control. The membrane was probed with a 
rabbit anti-phospho Statl Ser 727 (panel A) antibody, followed by a goat anti-rabbit IgG-HRP 
secondary antibody and visualised using ECL+. The blot was stripped and reprobed with a 
rabbit anti-total Statl (panel B) antibody followed by a goat anti-rabbit IgG-HRP secondary 
antibody and visualised using ECL+ The molecular weights (in kDa) according to the marker 
lane are shown. There are 2 isoforms of statl a  and p and their sizes are 97 and 84kDa. Anti- 
phospho Statl Ser 727 antibody only recognises the S ta tla  isoform whereas the anti-total 
Statl antibody recognises both isoforms. The * sign indicates a non-specific band which could 
reflect the loading of the samples.
pIC/wt
PBS/w t pIC /w t PBS/tg pIC/tg 127
97
Figure 5.21: Statl expression and activation following piC treatment in the thymus o f line 137 
mice
Protein from thymuses of PBS or piC injected positive (tg) or negative (wt) animals was 
extracted using the high salt nuclear extraction buffer. lOOpg o f protein per track was 
separated by 7.5% SDS-PAGE and the gel was western blotted. Extract pIC/wt from the 
spleen o f mice o f line 127 was used as a positive control. The membrane was probed with a 
rabbit anti-phospho Statl Ser 727 (panel A) antibody, followed by a goat anti-rabbit IgG-HRP 
secondary antibody and visualised using ECL+. The blot was stripped and reprobed with a 
rabbit anti-total statl (panel B) antibody followed by a goat anti-rabbit IgG-HRP secondary 
antibody and visualised using ECL+ The molecular weights (in kDa) according to the marker 
lane are shown. There are 2 isoforms of Statl a  and p and their sizes are 97 and 84kDa. Anti- 
phospho Statl Ser 727 antibody only recognises the S ta tla  isoform whereas the anti-total 
Statl antibody recognises both isoforms. The * sign indicates a non-specific band which could 
reflect the loading of the samples.
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following piC injection, again if the non-specific band is used as loading control (the third 
pIC/tg sample appears overloaded compared to the first one). This blot should be re­
probed with anti-P-tubulin to check the loading more accurately and tested for anti- 
phospho Statl (tyr 701). For line 137, a similar pattern was observed. An increase in total 
Statl (both isoforms) and in Statla activation following piC treatment was observed in 
wild-type mice, suggesting that the piC reached the thymus. For the transgenic positive 
samples, no increase in expression of Statl or activation of Statla was observed. However 
these samples appear to be underloaded, as judged by the non-specific band, and therefore 
it is important to confirm this finding. If confirmed these results would suggest that in the 
thymus of mice of lines 127 and 137 treated with piC, EBER1 blocks the induction of 
Statl expression and its activation (of at least the a  isoform), which might reflect the 
higher level of EBER1 expression in the thymus compared to the spleen.
5.5.2. Treatment of lines 127 and 137 splenocyte and thymocyte explants with 
piC and IFNa
In order to stimulate the cells directly with piC and IFNa, an explant of splenocytes 
and thymocytes was performed. It was hypothesised that this assay might show a more 
pronounced IFN response by treating the cells directly and possibly reveal any EBER1 
effect Spleen and thymus were chosen as they are larger tissues and therefore have more 
cells than lymph nodes or Peyer’s patches. In addition the thymus was expressing EBER1 
at a comparatively high level in lines 127 and 137. Spleen and thymus were collected from 
six transgenic positive mice of each line, 127 (7-10 months of age) and 137 (4 months of 
age) and from six wild-type controls. The phenotypes of these mice were described in 
tables 5.2 and 5.3. Other tissues were collected if a phenotype was observed. This was 
followed by primary cell isolation. In figure 5.22 a schematic diagram of the experiment is 
presented. Each group of six animals was divided into three independent subgroups as two 
tissues were pooled together in each subgroup to provide sufficient cells for the assay. The 
cells were then counted and from each subgroup lx l 07 cells were plated into each of three 
wells of a 24 well plate in 1ml of medium. Each well was subjected to a different 
treatment. To the first of the three wells PBS was added and used as a negative control, 
200pg of piC was added to the second well and 1000U of IFNa was added to the third 
well. The cells were incubated for 18 hours at 37°C before being harvested. At the time of
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Figure 5.22: Schematic diagram of the design of the splenocytes and thymocytes explant of 
lines 127 and 137
Only 1 set of six animals is represented and the animals are numbered 1 to 6. Two animals 
from each set were pooled together leaving three independent groups. For each group cells 
were plated on a 24 well plate and PBS (control), pIC or IFNa was added. The cells were 
placed at 37°C and 5% CO2. The cells were harvested after 18 hours. This assay was 
performed with splenocytes and thymocytes.
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writing the extractions had not been performed and therefore no results can be presented on 
this part.
5.6. Summary
In this chapter the phenotype of the different lines and particularly of line 127 was 
presented. Several mice of line 127 developed a lymphoma phenotype and early signs of 
lymphoid expansion were also observed in younger mice of this line. One animal from line 
131 also developed a lymphoma. Several mice of lines 136,137 and 145 have shown early 
signs of lymphoid expansion and pathology.
Analysis of several tumour tissues from mice of line 127 has revealed that the 
tumours were of B cell origin. No increase in EBER1 expression was detected in the 
EBER1 tumours. No increase or loss of c-Myc, p53 or Rb expression was observed in the 
tumour samples. No rearrangements of the c-Myc locus were observed in the line 127 
tumours. However, this will not reveal if a translocation or trisomy has occurred. The Myc 
DNA binding activity was also analysed by EMSA in two tumour samples and appeared 
stronger. Furthermore, two additional bands were observed in one of the tumour sample 
(number 49) tested. This suggested that in this tumour sample other protein complexes 
have been activated and bind the Myc oligo. In addition, tumour 127.49 did not show an 
upregulation of Id2 whereas the tumour sample 127.37 did. The mechanism of tumour 
formation in line 127 is unknown.
For both lines 131 and 127, no differences were observed in the B and T cell 
proportions between transgenic and wild-type mice. For line 131, no differences were 
observed in the status of the B and T cells. A similar result was seen for line 127, except 
for an increased CD5+ cell population, possibly a B l population, in the Peyer’s patches of 
transgenic positive mice. No differences were observed in the serum of lines 127 or 131 for 
IgM secretion. None of the cytokines tested in the Proteoplex chip array were upregulated 
in the serum of line 131. For lines 127 and 137 several cytokines were present at higher 
levels including IL4, IL6, IL10, IL12 and IFNy. Whether this represents a consistent 
induction is yet to be confirmed.
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In vivo experiments to monitor the response to dsRNA were performed in lines 127 
and 137 with pIC injection. In the spleen from line 127 mice eIF2a and Statl and possibly 
PKR were activated following pIC injection, whereas NFkB binding activity was 
unchanged. This suggests that EBERT in this tissue does not block this part of the IFN 
response following pIC treatment. However for Statl an observation was made using the 
thymus of mice of lines 127 and 137. An upregulation of total Statl and activation was 
observed in wild-type animals following treatment with pIC, whereas no increase in Statl 
expression or activation was observed in the transgenic positive samples. Therefore in the 
thymus of these mice, EBER1 may be blocking Statl expression/induction and activation 
following pIC treatment, by as yet unknown mechanism and yet to be confirmed.
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Chapter 6. Cooperation study between EBER1 and
EBNA1 or Myc
6.1. Introduction
Burkitt’s lymphoma (BL) is one of the malignancies associated with EBV 
(Magrath, 1990, for review). In BL, EBNA1 and the EBERs are the only latent genes to be 
consistently expressed. BL is also characterised by a c-m yc  translocation to an 
immunoglobulin locus (usually IgH) leading to de-regulated expression of c-Myc in the B 
cells. In order to examine if EBER1 cooperates with either Myc or EBNA1 in 
lymphomagenesis, crosses were undertaken between EpEBERl and Ep-EBNAl, EjaN- 
myc or Epc-myc mice. If cooperation occurs, the phenotype may arise faster or be altered 
in some way in the bi-transgenic mice. The generation of the different bi-transgenic mice 
and the bi-transgenic data are presented in this chapter.
6.2. Does EBER1 cooperate with EBNA1 In lymphomagenesis?
A cross-breeding programme was started by breeding mice of EpEBERl line 127 
with mice of EpEBNAl line 26 (Wilson et al., 1996). The genetic status of the offspring 
was determined by Southern blotting, probing with both EBNA1 and EBER1 at the same 
time as they show a distinguishable pattern (representative examples shown in figure 6.1). 
From this blot, mice numbered 26127.3, 6, 8, 9 and 10 were negative, mice numbered
26127.4, 7 and 13 were EBNA1 positive, mouse number 26127.12 was EBER1 positive 
and mice numbered 26127.5 and 11 were bi-transgenic. A summary of the number of 
animals used in this study and their genetic status is presented in table 6.1. The animals 
were monitored weekly for any sign of phenotype. Once the appearance of lymphoma 
(mainly observed by an enlargement of the abdomen for the EBNA1 animals) was 
detected, the mice were euthanised and tissues were collected. The observed phenotype 
was the same in both the EBNA1 mice and the bi-transgenic EBER1/EBNA1 mice and 
was described previously (Wilson et al., 1996). A Kaplan Meier plot to explore a possible 
cooperation between EBER1 and EBNA1 is shown in figure 6.2. In the time frame of this 
study only one EBER1.127 mouse developed a lymphoma at 310 days, whereas none of
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Figure 6.1: Southern blot from EBNA1 (line 26) and EBER1 (line 127) cross-breeding 
programme
Line 127 transgenic positive mice were crossed with line 26 transgenic positive mice. The 
offspring were genotyped as described in the materials and methods section. 5pg o f gDNA 
was digested with EcoRI and the products electrophoresed through a 0.8% agarose gel and 
Southern blotted. The Southern blot was hybridised with both EBER1 and EBNA1 
radiolabelled probes at 60°C in Church buffer. A final hot wash was performed at 60°C. 
The numbers shown above the tracks are the animal numbers either from line 127 or from 
the 26x127 cross. Number 127.37 was used as positive control and number 127.38 was 
used as negative control for EBER1. Numbers 26127.1 and 26127.2 were used as negative 
and positive controls for EBNA1 respectively. The EBNA1 and EBER1 bands are 
indicated with arrows. Note that the strong signal in lane 26127.1 is not EBER1 as this 
mouse is negative for EBER1, but is a blot artifact.
Transgene Number o f animals
EBNA1 9
EBER1 6
EBNA1 and EBER1 8
Negative 7
Table 6.1: Summary o f the 26127 cross-breed
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Figure 6.2: Kaplan Meier survival curve of line 26127 mice
The graph shows the proportion of mice succumbing to lymphoma (Y axis) over time (X 
axis). The graph was generated and the data analysed for statistical significance with a log 
rank test using Graphpad Prism 4 software.
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the negative control mice developed lymphoma. While the EBNA1.26 mice and the bi- 
transgenic.26127 mice developed lymphoma at a similar rate initially, all bi-transgenic 
mice had succumbed to lymphoma by the age of 270 days, while a tail of EBNA1.26 
showed a longer survival period up to 452 days. The median age is similar between the 
EBNA1.26 and the bi-transgenic.26127 animals with 236 days and 225 days respectively. 
The P value between the bi-transgenic.26127 and the EBNA1.26 curves is 0.2627, which 
demonstrates that the difference between the two curves is not statistically significant. 
These results suggest that EBER1 and EBNA1 do not cooperate in lymphomagenesis in 
vivo in our transgenic system. However, the absence of a tail in the curve of the bi- 
transgenic mice compared to that of the EBNA1.26 mice may suggest an additive effect 
between the effects of the two genes. The tail might also suggest that if a larger study was 
conducted a difference could be revealed between EBNA1.26 mice and bi- 
transgenic.26127 mice.
6.3. Does EBER1 cooperate with N-myc in lymphomagenesis?
6.3.1. Generation of EpEBERl and E^N-myc bi-transgenic mice
At the start of this study the Epc-myc mice were no longer available in the 
laboratory and had to be imported from the Jackson laboratoiy. However, the EpN-myc 
animals were present in the laboratory colony and it is published that N-myc can replace 
most of c-Myc’s functions (Malynn e ta l , 2000). Moreover, when N-myc is overexpressed 
in B cells in transgenic mice, the phenotype is similar to that of Ep,c-myc animals with the 
only difference being the delayed tumour onset (Dildrop etal., 1989, Adams etal., 1985). 
Therefore a cross-breeding study was undertaken between EpEBERl lines 127 and 137 
and EpN-myc line 96 (Dildrop et al., 1989) mice. It should be noted that for this study the 
parental mice were from different strains, the EBER1 mice were in a C57B1/6 background 
(as described in Chapter 3) whereas the N-myc mice were in a Balb/c background. 
However, all the offspring issuing from the crosses were identical in their genetic 
background as they were all FI of C57B1/6 and Balb/c strains and therefore the offspring 
could be directly compared to each other. The genetic status of the offspring from these 
crosses was determined by Southern blotting (a representative example is shown in figure 
6.3). From this blot, mice numbered 96127.3, 4, 6, 10 and 15 were N-myc positive, mice
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Figure 6.3: Southern blot from N-myc (line 96) and EBER1 (line 127) cross-breeding 
programme
Line 127 transgenic positive mice were crossed with line 96 transgenic positive mice. The 
offspring were genotyped and 5pg of gDNA was digested either with £coRI (for EBER1) or 
with BamYW (for N-myc). The digestion products were electrophoresed through a 0.8% 
agarose gel for the BamYW products or through a 1% agarose gel for the EcoR\ products and 
Southern blotted. The Southern blot was hybridised with either EBER1 radiolabelled probe at 
60°C or N-myc radiolabelled probe at 65°C in Church buffer. A final hot wash was performed 
at 60°C (for EBER1) or at 65°C (for N-myc). Panel A shows the EBER1 blot and panel B 
shows the N-myc blot. The numbers shown above the tracks are the animal numbers either 
from lines 127 and 96 or the 96x127 cross. Number 127.37 was used as positive control and 
number 127.38 was used as negative control for EBER1. Numbers 96.487 and 96.488 were 
used as positive and negative controls for N-myc respectively. The endogenous N-myc, 
transgenic N-myc and EBER1 bands are indicated with arrows.
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numbered 96127.5, 7, 11 and 14 were EBER1 positive and mice numbered 96127.8, 9, 12 
and 13 were bi-transgenic. No 96127 negative mice were identified from this blot. A 
representative example of the genetic status of the 96137 offspring is also shown in figure
6.4. From this blot, mice numbered 96137.16, 18, 19 and 20 were N-myc positive, mouse 
number 96137.21 was EBER1 positive, mice numbered 96137.17 and 22 were bi- 
transgenic and mouse number 96137.23 was negative. A summary of the number of 
animals used in the 96127 and the 96137 studies and their status is presented in tables 6.2 
and 6.3.
6.3.2. Phenotype and survival of the bi-transgenic EBERl/N-myc mice
The animals were monitored weekly for any sign of phenotype. Once the 
appearance of lymphoma (mainly observed by an enlargement of the peripheral lymph 
nodes in the N-myc animals) was detected, the mice were euthanised and tissues were 
collected. Tissues were also placed in formalin for subsequent histo-pathological analysis. 
Figure 6.5 shows a comparison between a wild-type mouse, an EBER1 127 positive mouse 
and an EBER1/N-myc bi-transgenic mouse, when the latter two developed lymphoma at 
19 and 12 months of age respectively. For the bi-transgenic animal a clear enlargement of 
all the lymph nodes was observed as well as an expansion of the spleen, whereas for the 
EBER1 animal the spleen was enlarged and infiltrated and only the mesenteric lymph 
nodes were very enlarged (as described in Chapter 5). In the EBER1 mouse it was also 
noticed that the thymus was enlarged (not shown). For both animals (127 and 96127) the 
Peyer’s patches were double the size of a wild-type Peyer’s patch. These results indicate 
that the phenotype of the bi-transgenic mice resembles that of the EpN-myc mice which 
was described by Dildrop et al (1989) and observed in the N-myc mice in this study. From 
this study it was also noticed that the EpN-myc mice have a biphasic phenotype. The first 
phenotype is characterised by a thymoma (and previously noted for line 96 by Mark Drotar 
in the laboratory, unpublished observation) and the animals succumb at an early age 
whereas for the second type the animals succumb to expanded lymph nodes when older 
than 8 months of age, which is characteristic of the myc phenotype in B cells (shown in 
figure 6.5).
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Figure 6.4: Southern blot from N-myc (line 96) and EBER1 (line 137) cross-breeding 
programme
Line 137 transgenic positive mice were crossed with line 96 transgenic positive mice. The 
offspring were genotyped and 5pg o f gDNA was digested either with EcoRI (for EBER1) 
or with BamYW (for N-myc). The digestion products were electrophoresed through a 0.8% 
agarose gel for the BamYW products or through a 1% agarose gel for the EcoRI products 
and Southern blotted. The Southern blot was hybridised with either EBER1 radiolabelled 
probe at 60°C or N-myc radiolabelled probe at 65°C in Church buffer. A final hot wash 
was performed at 60°C (for EBER1) or at 65°C (for N-myc). Panel A shows the EBER1 
blot and panel B shows the N-myc blot. The numbers shown above the tracks are the 
animal numbers either from lines 137 or 96137 and 96x127 crosses. Number 137.34 was 
used as negative control and number 137.35 was used as positive control for EBER1. 
Numbers 96127.29 and 96127.30 were used as negative and positive controls for N-myc 
respectively. The endogenous N-myc, transgenic N-myc and EBER1 bands are indicated 
with arrows.
Transgene Number
N-myc 12
EBER1 5
N-myc and EBER1 12
Negative 14
Table 6.2: Summary of the 96127 cross-breed
Transgene Number
N-myc 4
EBER1 5
N-myc and EBER1 6
Negative 8
Remain to be tested 11
Table 6.3: Summary of the 96137 cross-breed
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Figure 6.5: Phenotype of line 96127 bi-transgenic mice
Panel A shows a dissected wild-type mouse (12 months), an EBER1 positive mouse with a 
tumour (line 127, 19 months) and an EBER1 /N-myc bi-transgenic mouse with a tumour (line 
96127, 12 months). The spleen and a cervical lymph node in each are indicated with arrows. 
Panel B shows the different lymph nodes removed from these mice and panel C focuses on the 
spleens of these animals.
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Kaplan Meier plots to explore the possible cooperation between EBER1 and N-myc 
are shown in figure 6.6. The study is still ongoing as not all the bi-transgenic (3 mice 
remaining) and N-myc (4 mice remaining) mice had succumbed to lymphoma at the time 
of writing. In the time frame of this study no EBER1 mice developed lymphoma; nor did 
any negative control. The first Kaplan Meier plot shows the lymphoma incidence of all the 
N-myc and bi-transgenic mice in the study (Figure 6.6A). 8/12 N-myc mice developed 
lymphoma between 104 and 406 days with a median age of 441.5 days. The bi-transgenic 
mice developed lymphoma faster than the N-myc mice, as is shown by their median age of 
214 days compared to 441.5 days. Despite the apparent difference between the two curves, 
the P value is 0.1514, which is not statistically significant. However in this plot 2/12 N- 
myc mice succumbed to a thymoma at an early age (104 and 135 days). As this phenotype 
is different from that of the B-cell lymphoma a second Kaplan Meier plot was generated 
excluding these two mice from the percentages of B-cell lymphoma (Figure 6.6 B). In this 
plot the P value is 0.0481, showing a significant difference between the two curves. This 
suggests that EBER1 and N-myc may cooperate in B-cell lymphomagenesis. However, in 
order to support this approach, the two thymomas should be checked for T cell receptor 
rearrangement. Depending on the outcome of this analysis, the two animals will be 
included or removed from the plot. A T cell lymphoma was described by Dildrop et a l , 
(1989) in one mouse; however they do not state if it originated from a mouse with a 
thymoma or from a mouse with expanded lymph nodes, except for the fact that both 
kidneys were invaded by tumour cells.
For line 96137 the study is still ongoing as line 137 was established later. 2/12 N- 
myc animals succumbed to lymphoma at 83 and 250 days and 2/6 bi-transgenic animals 
succumbed to lymphoma at 194 and 210 days as represented by the Kaplan Meier plot 
(Figure 6.7 A). The P value between the two curves is 0.428, which is not statistically 
significant and the oldest mice for both N-myc and bi-transgenic are now 335 days old. 
However, a young N-myc mouse (83 days) had a thymoma and a second Kaplan Meier 
plot was generated excluding this animal (Figure 6.7 B) with a P value of 0.1815. So far 
none of the other animals in the study have developed disease.
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Figure 6 .6 : Kaplan Meier survival curves o f line 96127 mice
The graphs show the proportion o f mice succumbing to lymphoma (Y axis) over time (X axis). 
The graphs were generated and the data analysed for statistical significance with a log rank 
test using Graphpad Prism 4 software. Panel A shows the survival curve o f all the offspring 
resulting from the 96x127 cross, whereas panel B shows the survival curve of the offspring 
from the same cross, omitting for the two N-myc transgenic positive mice which developed a 
thymoma at an early age.
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Figure 6.7: Kaplan Meier survival curves o f line 96 137 mice
The graph shows the proportion o f mice succumbing to lymphoma (Y axis) over time (X axis). 
The graph was generated and the data analysed for statistical significance with a log rank test 
using Graphpad Prism 4 software. Panel A shows the survival curve of all the offspring 
resulting from the 96x137 cross (except for the mice that are not genotyped), whereas panel B 
shows the survival curve o f the offspring from the same cross discounting the young N-myc 
transgenic positive mouse which developed a thymoma at an early age
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6.3.3. Characterisation of the EBERl/N-myc bi-transgenic tumour tissues
6.3.3.1. Immunoglobulin gene rearrangement analysis
The tumour tissues were analysed for both immunoglobulin heavy chain (IgH) and 
T cell receptor (TCR) rearrangements to determine if the tumours were of B cell or T cell 
origin. Tumours arising in N-myc positive animals are reported to be of B cell origin, 
showing an IgH rearrangement (Dildrop et al., 1989) (C57B1/6 strain). gDNAs were 
extracted from different tumour tissues (liver, spleen, thymus, cervical lymph nodes and 
mesenteric lymph nodes) of two bi-transgenic 96127 mice, number 9 and 13. Two 
Southern blots were performed and one was probed with an IgH (Jh region) probe and the 
other with a TCR (Jpl, constant region 1 fragment) probe. No TCR rearrangement was 
observed in any of the tissues tested for the two mice (data not shown). However, IgH 
rearrangements were observed in all the tissues tested (Figure 6.8). In both animals 9 and 
13 the endogenous band was observed as well as additional bands. For animal 13 the 
additional band is smaller than the endogenous band (4.5kb) whereas for animal 9 the 
bands are larger (at 8 and 9kb) indicating that different rearrangements occurred in the two 
animals. However, within an animal these rearrangements are the same showing that the 
tumours are of clonal origin. For the thymus of animal 13 an extra band was also noticed 
(3.5kb) suggesting that tumour cells in this tissue had undergone an additional 
rearrangement of the second immunoglobulin heavy chain locus. Further analysis of 
tumour tissues from different bi-transgenic and N-myc mice also indicated that these 
tumours were of B cell origin. FACS analysis also supported this result showing an 
increase in B220+, CD3' cells in the tissue compared to wild-type (Figure 6.9).
6.3.3.2. EBER1 and N-myc expression analysis
In order to explore if the apparent cooperation in B cell lymphomagenesis between 
line 127 and 96 was simply due to one transgene affecting the expression level of the other, 
expression analysis of both EBER1 and N-myc was undertaken. For EBER1 expression, 
RNA was extracted from the tumour tissues of single positive (line 127) and bi-transgenic 
(line 96127) mice and was followed by an RT-PCR using EBER1 specific primers. No
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Figure 6 .8 : IgH rearrangements in line 96127 bi-transgenic mice
gDNA was extracted from tumour bearing tissues collected from line 96127 bi-transgenic 
mice. 5jig of gDNA digested with £coRI was electrophoresed through a 0.8% agarose gel and 
Southern blotted. The blot was hybridised with an IgH probe at 65°C in Church buffer. A final 
hot wash was performed at 65°C. Tail gDNA from animal 127.38 was used as negative control 
for IgH rearrangements. gDNAs from 2696.16 were used as positive control for IgH 
rearrangements. The endogenous (E) band is shown with an arrow on the left hand-side 
whereas the rearranged (R) bands are shown with arrows on the right hand-side. As the 
EBER1 transgene is fused to Eji an EjaEBERl band is also observed at 0.9kb and is indicated 
by an arrow. The tissues analysed were: CLN: cervical lymph nodes, S: spleen, MLN: 
mesenteric lymph nodes, T: thymus and L: liver.
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Figure 6.9: The tumour cells from a 96127 bi-transgenic mouse are mainly B cells 
The spleen and thymus were collected from a 96127 bi-transgenic mouse with a tumour. 
Primary cells were isolated and 106 cells were stained with B220FITC and CD3PE. The 
percentage of the cells in each quadrant is indicated.
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difference in EBER1 expression was observed between the different bi-transgenic tissues 
tested and two EBER1 tumour tissues (Figure 6.10). However, it should be noted that 
although relative expression levels can be seen by this technique, it is not an accurately 
quantitative method.
N-myc expression was examined by western analysis (Figures 6.11 A and 6.12). 
The study was performed on three bi-transgenic 96127 mice (Figures 6.11 and 6.12), two 
N-myc mice (Figure 6.12), an EBER1 mouse with a tumour and a wild-type control 
(Figure 6.12). A band of approximately the correct size for N-myc (67kDa) was clearly 
detected in the bi-transgenic samples along with several other bands (Figures 6.11 and 
6.12). In order to confirm if this band was N-myc protein, the blot was re-probed with 
antibody plus the epitope peptide (Figure 6.11 B). From this it can be seen that the 67kDa 
band was blocked, and therefore is specific, confirming its identity as N-myc, but in 
addition a band migrating at around 120kDa also was blocked (band B on the figure). The 
identity of this protein or complex is not clear, but it is also specifically expressed in the N- 
myc only transgenic samples (Figure 6.12) and may represent a dimeric protein. Samples 
from two N-myc mice with tumours were used in this assay and both lymph nodes from 
mouse 41 showed a high level of expression of N-myc (67kDa), whereas the thymus from 
mouse 37 was low (Figure 6.12). This sample was extracted from a thymoma of a 4 month 
old animal showing the early thymoma phenotype described above. However, this sample 
showed high expression of the 120kDa molecular weight protein. The other two samples 
were from lymph nodes of a mouse succumbing to typical B-cell lymphoma. The 
expression level of N-myc in three different bi-transgenic mice was tested in lymph node 
tissues and was high and equivalent to N-myc positive animals. Two EBER1 tumour 
tissues from mouse number 127.49 were used and their level of N-myc expression was 
low. Together these results indicate that the cooperation phenotype of tumourigenesis seen 
in the bi-transgenic mice is not due to an increase of either EBER1 or N-myc expression.
6.3.3.3. Analysis of N-myc DNA binding activity
Another means by which EBER1 could cooperate with N-myc in tumourigenesis is 
by leading to increased N-myc activity by some unknown mechanism. To test this 
hypothesis indirectly, the DNA binding activity of N-myc was studied using an 
electrophoretic mobility shift assay (EMSA). The probe used in this assay was a myc
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Figure 6.10: EBER1 expression in bi-transgenic 96127 mice
Lymphoid tumour tissues from three 96127 bi-transgenic mice (panel A) and from a line 127 
tumour mouse (panel B) were collected. RNA extraction was performed followed by DNAse I 
treatment, acid phenol extraction and RT-PCR. The RT reaction was performed with an 
EBER1 specific primer (CR4) and 5pg of  total RNA. For each sample a minus RT control was 
performed. The PCR was performed with 1 /4th of the RT reaction and CR8 and CR9 primers. 
A no DNA control (H20 )  and a positive plasmid DNA control (PCR control) were also 
performed for the PCR. The RT-PCR products were electrophoresed through an agarose gel 
followed by Southern blotting with an EBER1 probe. ALN: axillary lymph nodes, MLNs: 
mesenteric lymph nodes. Note the gDNA contamination in several samples: 96127.12 MLNs, 
96127.29 spleen, MLN, 96127.10 MLN, 127.49 spleen and MLN.
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Figure 6.11: Western blot for N-myc and its blocking peptide in the bi-transgenic 96127 mice 
Proteins from three different bi-transgenic EBER1/N-myc (line 96127) mice were extracted 
using the high salt nuclear extraction method. lOOpg of proteins were separated by a 7.5% 
SDS-PAGE and the gel was western blotted. The membrane was probed with a rabbit anti-N- 
myc antibody (panel A) followed by a goat anti-rabbit IgG-HRP secondary antibody and 
visualised using ECL+. The membrane was stripped and reprobed with a rabbit anti-N-myc + 
N-myc blocking peptide (panel B) followed by a goat anti-rabbit IgG-HRP secondary antibody 
and visualised using ECL+. Finally, the membrane was stripped and reprobed with a rabbit 
anti-(3tubulin antibody (panel C), as a loading control, followed by a goat anti-rabbit IgG-HRP 
secondary antibody and visualised using ECL+. The molecular weights according to the 
marker lane are shown. The N-myc specific band is indicated at approximately 67kDa. Band B 
indicates a protein running at 120kDa which was also blocked when using the blocking 
peptide. The ptubulin specific band is indicated by an arrow at 55kDa.
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Figure 6 .12: Western blot for N-myc expression in the bi-transgenic 96127 mice 
Proteins from different tumour tissues of EBER1 positive (line 127) bi-transgenic EBER1/N- 
myc (line 96127) and N-myc positive mice (of the same cross) were extracted using the high 
salt nuclear extraction method. lOOpg of proteins were separated by a 7.5% SDS-PAGE and 
the gel was western blotted. The membrane was probed with a rabbit anti-N-myc antibody 
followed by a goat anti-rabbit IgG-HRP secondary antibody and visualised using ECL+. A 
wild-type (Wt) control was used to determine the endogenous level of N-myc in the tissues. 
The molecular weights according to the marker lane are shown. The N-myc specific band is 
indicated at approximately 67kDa. Band B indicates another protein running at 120kDa which 
was not blocked when using the blocking peptide (Figure 6.11). The non-specific bands 
exemplified by the * sign show equal loading of the samples except for the Wt control. S: 
spleen, T: thymus, SILN: superficial inguinal lymph nodes, MLN: mesenteric lymph nodes 
and ALN: axillary lymph nodes.
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binding site oligonucleotide comprising an E box (cacgtg) as the target binding site which 
is specific for all the members of the myc family. Therefore to determine if any shift 
observed was due to N-myc or c-Myc binding, supershift assays were also performed with 
the appropriate antibodies (Figure 6.13). Two EBER1 line 127 tumour tissues, an N-myc 
tumour tissue (line 96127.41) and a bi-transgenic tumour tissue (line 96127.29) were used 
for the assay, as well as a c-Myc tumour sample as a positive control (line 97) to assess c- 
Myc DNA binding. No obvious shift by either antibody was observed (even for the N-myc 
and c-Myc controls), suggesting that either the assay did not work or the antibodies were 
not effective, or the bands observed are not N-myc and c-Myc. Therefore it was not 
possible to determine which proteins are in the complex. The two 127 tumours showed 
different complexes as previously described in chapter 5. When using the same extracts 
with an Spl probe, the bi-transgenic sample and the N-myc and c-Myc samples appeared 
equally loaded (Figures 6.14 and 5.10). However the wild-type sample appeared 
underloaded or degraded and similar for the line 127 samples (as shown in Chapter 5, 
Figure 5.10). This could have been due to repeated freezing and thawing of the samples 
before performing the Spl EMSA. Nevertheless when the band from the bi-transgenic 
sample was compared to that of the N-myc sample they were of similar intensity. This 
result indicates that the cooperation between EBER1 and N-myc in tumourigenesis is not 
due to altered activity of Myc.
6.4. Does EBER1 cooperate with c-Myc in lymphomagenesis?
6.4.1. Generation of EpEBERl and Epc-myc bi-transgenic mice
EpEBERl line 127 and line 136 mice were crossed with EpC-myc mice (Tables 
6.4 and 6.5). Line 136 was chosen instead of line 137 (which was used for the N-myc 
cross-breed study) as it harbours the p670 transgene which incorporates a myc binding site 
5’ to EBER1 (Figure 3.1, Chapter 3). It was therefore hypothesised that this cross might 
lead to increased expression of the EBER1 transgene. The transgenic status of the 97127 
offspring was assessed by Southern blot for EBER1 and by PCR for c-myc (representative 
examples shown in figure 6.15). From the Southern blot and the PCR results, mice 
numbered 39, 40, 45 and 47 were bi-transgenic, mice numbered 42 and 46 were EBER1 
positive, mice numbered 41 and 44 were c-myc positive and finally mice numbered 37, 38
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Figure 6.13: Myc DNA binding activity in the EBERl/N-myc bi-transgenic mouse tissues 
Proteins were extracted from different tumour samples (two line 127 samples, one N-myc 
sample line 96127.41, one line 96127.29 bi-transgenic sample and a line 97 (c-Myc) sample) 
using the high salt nuclear extraction buffer. 10pg of protein extract was used for each sample. 
A sample from line 97 was used as positive control for c-Myc binding. Two, three or four 
reactions were prepared for each sample: one without and one with 200x unlabelled 
competitor (+ track competitor), one with 4pg of N-myc antibody (+ track N-myc antibody) 
and one with 4pg of c-Myc antibody (+ track c-Myc antibody). Labelled myc binding oligo 
was added to each sample and incubated for 20 minutes on ice before loading the samples on 
to a 6% polyacrylamide gel. For the supershift the antibody was incubated at room- 
temperature for 15 minutes with the extract before the addition of the labelled probe. A 
labelled oligo without extract was also used as control (P). The gel was electrophoresed for 3 
hours before being dried and exposed on film for the required amount of time. Panel A shows 
a wild-type sample, a spleen line 127.37 tumour sample, a mesenteric lymph node (MLN) line
96127.29 tumour sample (bi-transgenic N-myc/EBERl) and a spleen line 97 tumour sample. 
Panel B shows the same wild-type sample as panel A, a mesenteric lymph node (MLN) line
127.49 tumour sample, a superficial inguinal lymph node (SILN) line 96127.41 tumour 
sample (N-myc positive only) and a spleen line 97 tumour sample. The arrow in panel A 
indicates the specific band, which is the same as band A in panel B. The B and C bands were 
only detected in this single EBER1 sample. All bands (A, B and C) are completely competed 
out with excess unlabelled oligonucleotide (+ tracks) demonstrating specificity.
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Figure 6.14: Spl DNA binding activity in the EBERl/N-myc bi-transgenic mouse tissues 
Proteins were extracted from different tumour samples (two line 96127 bi-transgenic samples 
and a line 97 (c-Myc) sample) using the high salt nuclear extraction buffer. lOpg of protein 
extract was used for each sample. Two reactions were prepared for each sample: one without 
and one with 200x unlabelled competitor (+ track competitor). Labelled Spl binding oligo was 
added to each sample and incubated for 20  minutes on ice before loading the samples on to a 
6% polyacrylamide gel. A labelled oligo without extract was also used as control (P). The gel 
was electrophoresed for 3 hours before being dried and exposed on film for the required 
amount of time. The arrows indicate specific bands which are competed out with excess 
unlabelled oligonucleotide (+ tracks) demonstrating specificity and the * sign shows a non­
specific band.
Transgene Number
c-Myc 19
EBER1 10
c-Myc and EBER1 19
Negative 7
Table 6.4: Summary of the 97127 cross-breed
Transgene Number
c-Myc 11
EBER1 6
c-Myc and EBER1 4
Negative 8
Not tested 32
Table 6.5: Summary of the 97136 cross-breed
A 97127 97
35 36 37 38 39 40 41 42 43 44 45 46 47 + -
B 97127 127
37 38 39 40 41 42 43 44 45 46 47 + -
Figure 6.15: Genotype of line 97127 offspring
gDNAs were extracted from tails of line 97127 mice. In panel A, 300ng of gDNA was used as 
template for the PCR using c-myc primers. The gDNA from a c-Myc positive mouse (97) was 
used as positive control for the reaction and the track is labelled with a + sign. A reaction with 
water was used as negative control and the track is labelled with a - sign. The PCR products 
were electrophoresed through a 1.5% agarose gel and the O ’GeneRuler™ lOObp DNA ladder 
was used as a marker for size. The sizes are indicated on the left hand-side of the gel. An 
arrow indicates the transgenic c-myc DNA fragment. In panel B, 5pg of gDNA was digested 
with EcoK\, electrophoresed through a 1% agarose gel and Southern blotted. The membrane 
was hybridised with an EBER1 specific probe. gDNAs from known EBER1 positive (+) and 
negative (-) line 127 mice were used as controls. The EBER1 band is indicated by an arrow. In 
both panels the numbers above the tracks indicate the animal number.
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and 43 were negative. Animals numbered 35 and 36 were tested on a different Southern 
blot and number 35 was shown to be EBER1 positive whereas 36 was not; therefore 
number 35 was a bi-transgenic animal and 36 was c-myc positive. The transgenic status of 
the 97136 offspring was assessed by PCR for both EBER1 and c-myc (representative 
examples shown in figure 6.16). From the PCR results, mice numbered 18 and 21 were 
EBER1 positive, mice numbered 17, 20 and 22 were c-myc positive and finally mouse 
number 19 was negative.
6.4.2. Phenotype and survival of the bi-transgenic EBERl/c-Myc mice
The animals were monitored weekly for any sign of phenotype. Once the 
appearance of lymphoma was detected the mice were euthanised and tissues were 
collected. The phenotype for Epc-myc mice has been described previously and is 
characterised by an expansion of the cervical lymph nodes and axillary lymph nodes that is 
externally obvious and has been described as a “water wings” phenotype (Adams et al., 
1985, Harris et al., 1988). Tissues were also placed in formalin for subsequent pathological 
analysis. Figure 6.17 A shows a bi-transgenic (line 97127) mouse compared to a negative 
mouse and a c-Myc positive mouse. The phenotype in the EBERl/c-myc bi-transgenic 
mice was the same as that in c-Myc mouse. In the bi-transgenic animal a clear enlargement 
of the different lymph nodes was observed as well as in the spleen compared to that of the 
wild-type mouse. A comparison of the spleen and the different lymph nodes of a negative, 
a c-Myc and a bi-transgenic mouse (line 97127) is also presented (figure 6.17 B and C). 
The spleens of both the bi-transgenic mouse and the c-Myc positive mouse were enlarged 
compared to that of the wild-type and appeared of the same size. Similarly for the different 
lymph nodes, an enlargement was observed for the bi-transgenic and the c-Myc positive 
lymph nodes compared to that of the wild-type mouse, and also appeared of a similar size. 
The phenotype of the 97136 bi-transgenic mice was similar to that of c-Myc positive mice. 
The thymus was also markedly enlarged in 10/12 of the c-Myc mice that succumbed to 
lymphoma as well as in 13/13 of the bi-transgenic 97127 and 2/2 of the bi-transgenic 
97136 mice, as was described by Adams et a l , (1985). Therefore, the bi-transgenic 
EBERl/c-Myc mice have the same phenotype as Epc-myc mice.
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Figure 6.16: Genotype of line 97136 offspring
gDNAs were extracted from tails of line 97136 mice. 300ng o f  gDNA was used as template 
for the PCR using either c-myc primers (panel A) or EBER1 primers (panel B). In panel A, the 
gDNA from a c-Myc positive mouse (97) was used as positive control. In panel B, the gDNA 
from an EBER1 transgenic positive mouse (136.42) and a negative mouse (136.41) were used 
as positive and negative controls. The PCR products were electrophoresed through a 1.5% 
agarose gel and a Ikb DNA ladder was used as a marker for size. The sizes are indicated on 
the left hand-side of the gels. Arrows indicate the transgenic c-myc or EBER1 DNA 
fragments.
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Figure 6.17: Phenotype of line 97127 bi-transgenic mice
Panel A shows a dissected wild-type mouse, an EBERl/c-Myc bi-transgenic mouse (line 
97127) and a c-Myc mouse. Panel B shows the spleen of a wild-type mouse, an EBERl/c-Myc 
bi-transgenic mouse and a c-Myc positive mouse. Panel C shows the different lymph nodes of 
the same mice. CLNs: cervical lymph nodes, ALNs: axillary lymph nodes, SILNs: superficial 
inguinal lymph nodes and MLNs: mesenteric lymph nodes.
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A Kaplan Meier plot to explore the possible cooperation between EBER1 and c- 
Myc is shown in figure 6.18 A. The study is still ongoing as not all the bi-transgenic (6 
mice remaining) and c-Myc (7 mice remaining) mice had succumbed to lymphoma at the 
time of writing. In the time frame of this study no EBER1 mice developed lymphoma, nor 
did any of the negative controls. 12/19 c-Myc mice developed lymphoma between 60 and 
158 days so far, with a median age of 129.5 days. 13/19 bi-transgenic mice have developed 
lymphoma between 57 and 150 days so far, with a median age of 113 days. The P value 
between the two curves is 0.5744, showing no significant difference in tumour onset 
between bi-transgenic 97127 mice and c-Myc mice. A Kaplan Meier plot was also 
generated for the 97136 mice (Figure 6.18 B) and the study is still ongoing as some of the 
mice have not been genotyped yet and not all the bi-transgenic (2 mice remaining) and c- 
Myc (6 mice remaining) mice have developed lymphoma. 5/11 c-Myc mice developed 
lymphoma between 79 and 117 days so far and 2/4 bi-transgenic mice developed 
lymphoma between 94 and 140 days so far. The P value between the two curves is 0.788, 
and like 97127 mice, the 97136 bi-transgenic mice have a similar tumour onset and 
phenotype as c-Myc mice. However more bi-transgenic mice should be included in the 
study to be able to draw any conclusion.
6.4.3. Characterisation of the EBERl/c-Myc bi-transgenic tumour tissues
6.4.3.1. Analysis of c-Myc DNA binding activity
The expression of c-Myc in the tumours was not investigated thoroughly as several 
antibodies were previously tried, some with their blocking peptides, using c-Myc only 
tumour samples and specific c-Myc bands could not be identified properly (Figure 5.7). 
For instance, several bands were observed at the expected size of c-Myc, and when the 
blocking peptide was used, it resulted in the disappearance of all the bands from the blot.
As an alternative to examining the c-Myc expression level, Myc DNA binding 
activity in the bi-transgenic mice was studied by EMSA in order to determine if this was 
altered compared to c-Myc positive mice. The probe used was same as the one used for the 
EMSA with the N-myc samples. A supershift was also attempted on these samples using 
an anti-c-Myc antibody (Figure 6.19). In this figure the unlabelled oligonucleotide
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Figure 6.18: Kaplan Meier survival curves of line 97127 and 97136 mice 
The graphs show the proportion of mice succumbing to lymphoma (Y axis) over time (X axis). 
The graphs were generated and the data analysed for statistical significance with a log rank 
test using Graphpad Prism 4 software. Panel A shows the survival curve o f  all the offspring 
resulting from the 97x127 cross and panel B shows the survival curve of all the offspring 
resulting from the 97x136 cross (except for the mice that are not yet genotyped).
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Figure 6.19: Myc DNA binding activity in the EBERl/c-Myc bi-transgenic mouse tissues 
Proteins from a wild-type sample, an EBER1 tumour sample (line 127), a c-Myc tumour 
sample and an EBERl/c-Myc bi-transgenic tumour sample (line 97127) were extracted using 
the high salt nuclear extraction method. 10pg of protein extract was used for each sample. 
Three reactions were prepared for the different samples, one without and one with 200x 
unlabelled competitor (+ competitor track), and one with 4pg of anti-c-Myc antibody (+ c- 
Myc antibody tracks). Labeled Myc oligo was added to each sample and incubated for 20 
minutes on ice before loading the samples on to a 6% polyacrylamide gel. For the supershift 
the antibody was incubated at room-temperature for 15 minutes with the extract before the 
addition of the labelled probe. A labelled oligo without extract was also used as control (P). 
The arrow indicates a specific band and the * sign indicates a non-specific band.
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effectively competed for the observed band indicating that it is specific. The Myc DNA 
binding activity in the wild-type sample was low compared to that of the EBER line 127 
extract. It was subsequently discovered that this sample was of not very good quality when 
an Spl EMSA was performed, which provides a normalising control for the quality and 
quantity of the samples (Figure 6.20). From the Spl EMSA, the EBER1 tumour sample was 
underloaded compared to the c-Myc and bi-transgenic samples which appeared of the same 
quality and quantity. The addition of anti-cMyc antibody did not appear to induce a 
mobility shift in the specific band, suggesting that it either did not work or the band 
observed is not c-Myc. Nevertheless, no difference in intensity was observed between the 
specific band in the c-Myc sample and the bi-transgenic sample, suggesting that the DNA 
binding activity of Myc is not increased in the bi-transgenic mice. As only one bi- 
transgenic tumour sample was tested by EMSA, the myc DNA binding activity should be 
explored further using different tumour samples in order to be able to fully conclude on 
this part.
6.4.3.2. Upregulation of Id2 in the bi-transgenic samples and EBER1 tumours
The protein level of Id2 was analysed in the EBER1 tumour samples by western 
blot using an anti-Id2 antibody (Figure 6.21). In order to identify the Id2 specific band, the 
membrane was stripped and re-probed with the anti-Id2 antibody and the Id2 blocking 
peptide. This blocked all bands and therefore specificity of Id2 could not be confirmed; 
however a band at the correct size (around 16kDa) was observed in some of the lanes. No 
Id2 signal was observed in the wild-type, the EBER1 positive young animal sample and 
also in the two tumour tissues of mouse 127.49 (previously described in chapter 5, figure 
5.11). This tumour also showed a different Myc banding pattern on the EMSA (Figure 5.9, 
Chapter 5). However, a 16kDa band was observed for one EBER1 tumour (animal number 
127.37), a pre-tumour sample (127.117), the two c-Myc tumour samples (97.1005 and 
97127.13) and in the bi-transgenic tumour sample (97127.1), indicating that in these 
samples Id2 is upregulated and the signal appears of a similar intensity in these lanes. 
However, a loading control needs to be performed in order to conclude fully.
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Figure 6.21: Id2 western blot of lines 127 and 97127 samples
Proteins from wild-type (Wt), EBER1 positive young animal (N) line 127, EBER1 pre-tumour 
(P) line 127, two EBER1 animals with tumours (T1 and T2), two different c-Myc tumour 
samples (C, line 97.1005 and 97127.13) and bi-transgenic tumour (bi) were extracted using the 
high salt nuclear extraction method. lOOpg of proteins were separated by 12.5% SDS-PAGE 
and the gel was western blotted. The membrane was probed with a rabbit anti anti-Id2 
antibody and followed by a goat anti-rabbit IgG-HRP secondary antibody and visualised using 
ECL+. The molecular weights according to the marker lane are shown. The Id2 band is 
indicated by an arrow and is running at 16kDa. S: spleen, MLN: mesenteric lymph nodes, 
SILN: superficial inguinal lymph nodes.
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6.5. Summary
In this chapter, three cooperation studies are presented, which were undertaken in 
order to investigate if the tumours could develop more rapidly in bi-transgenic mice 
compared to EBER1 mice and also compared to the possible cooperating partner (EBNA1 
or Myc), The first study involved EBNA1, another EBV latent gene which like EBER1 is 
expressed in all latencies. No cooperation was observed between EBNA1 and EBER1 in 
lymphomagenesis as the bi-transgenic mice have the same tumour onset as the EBNA1 
mice. However the absence of the “tail” of the curve in the bi-transgenic mice compared to 
that of the EBNA1 mice suggests a possible additive effect between the two genes. The 
phenotype in the bi-transgenic EBER1/EBNA1 mice was the same as the one observed in 
the EBNA1 mice. This study was only undertaken with line 127.
EpEBERl mice (lines 127 and 137) were crossed with EpN-myc mice, and the bi- 
transgenic mice succumbed to lymphoma on average at 214 days compared to 441.5 days 
for N-myc mice. It should be noted that a biphasic phenotype was observed for the N-myc 
animals, the first phase where a thymoma was detected (possibly indicative of a T cell 
lymphoma) when the mice were young and the second where lymphoma was observed in 
the lymph nodes and spleen, of B-cell type as previously described by Dildrop et al., 
(1989) in older mice. The difference between the B-cell tumour onset of the bi-transgenic 
and the N-myc mice (excluding the presumed T-cell lymphoma) is statistically significant 
suggesting that the two genes cooperate in B-cell lymphomagenesis. The phenotype in the 
EBERl/N-myc bi-transgenic mice is the same as the one observed for the EpN-myc mice. 
It was also shown that the bi-transgenic tumours have a clonal IgH rearrangement, no TCR 
rearrangement and are B220 positive, indicating that they are of B cell origin (however the 
thymomas have not been tested for IgH or TCR rearrangement). The cooperation between 
EBER1 and N-myc is not due to either increased EBER1 or N-myc expression, nor to 
increased Myc DNA binding activity and therefore is due to complementarity in the 
actions of EBER1 and N-myc, No cooperation was yet observed between line 137 and 
EpN-myc; however it should be noted that mice of line 137 express EBER1 in the thymus.
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The last cooperation study was between EpEBERl (lines 127 and 136) and Ep.c- 
myc. In these mice the two genes do not appear to cooperate in disease onset; however the 
studies were still underway at the time of submission. The phenotype observed in the bi- 
transgenic EBERl/c-Myc mice is the same as that of Epc-myc mice. Following EMSA 
analysis the DNA binding activity of Myc was shown not to be increased in the bi- 
transgenic sample compared to the c-Myc sample tested. The expression of Id2 (a c-Myc 
regulated gene) was also similar in the bi-transgenic sample and the c-Myc samples.
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The aim of the work presented in this thesis was to investigate the phenotypic 
consequences of expression of EBER1 in vivo. Before this project was started, reports 
demonstrated that transfection of EBERs into Akata EBV negative cells or BJAB rendered 
them malignant and resistant to apoptosis, suggesting a possible involvement of the EBERs 
in the disease process of EBV (Komano et al., 1999, Yamamoto et al., 2000). For this 
purpose, we sought to explore this hypothesis by generating transgenic mice expressing 
EBER1 and analysing their phenotype.
7.1. EBER1 transgenic mice
The design of the transgene was a critical step as the EBER1 gene promoter 
encompasses both RNA pol II and pol HI elements (Howe and Shu, 1989). Therefore three 
different EBER1 constructs were generated. They each contain different promoter 
elements as it was unknown which construct would lead to in vivo expression. The 
expression of the transgene was targeted to the B cell compartment of the animal using the 
immunoglobulin heavy chain intronic enhancer Ep. Expression of the three EBER1 
constructs, either supercoiled plasmid or linear fragment, was observed in transient 
transfection assays of EBV negative B-cells. However the expression of EBER1 was 
higher from the supercoiled plasmids compared to that of the linear fragments as would be 
expected. This could be due to differences in transfection efficiencies, where transfection 
of a supercoil plasmid is more efficient than that of a linear fragment, or to the presence of 
the CMV promoter upstream of the Ep in the supercoiled plasmids, which could lead to a 
higher expression level. However, these hypotheses were not tested, as this assay was 
performed to establish whether or not the constructs expressed EBER1. For both the 
supercoil and the linear fragments, the expression level of EBER1 was higher for 
constructs p670 and p671 compared to p672. This is in accordance with published work 
where it was shown that deletion of Spl and ATF sites dramatically reduced transcription 
of EBER1 following transfection assays (Wensing et al., 2001).
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Pronuclear microinjections of the three constructs were performed and 19 founders 
were generated (6 for p670, 3 for p671 and 10 for p672). For construct p670, 8.8% of the 
pups bom were transgenic positive, for p671 5.2% pups bom were transgenic positive and 
for p672, 9.8% pups bom were transgenic positive. It has been estimated that 20% of pups 
born after pronuclear injections carry the transgene (Nagy et al., 2003a). However, this 
does vary enormously depending on DNA concentration, lethality of the construct and 
experience of the individual. The low number of transgenic positive founders in this case, 
is reflective of the first few months of microinjection when the technique was learned and 
optimised. The number of founders increased once the technique was mastered.
For constructs p670 and p672, four founders (126, 128, 129 and 130) had a partial 
transgene when checked by PCR. It was subsequently determined that the two transgene 
preparations used for microinjection were partially degraded. New transgene preparations 
were then used for microinjections. The different transgene preparations were subsequently 
frequently checked for degradation.
68% of the founders were established into lines. It is usually estimated that between 
20 to 30% of the founders are mosaic (Wilkie et a l , 1986). This means that the transgene 
integrates after the cell started to divide; therefore not all the cells in the organism will 
carry the transgene. The mosaic founders transmit the transgene at a lower frequency 
(which varies depending on the degree of mosaicism) compared to a non-mosaic animal, 
which transmits the transgene to 50% of the offspring. The founders that were not 
established into lines include the four that had a partial transgene (126, 128, 129 and 130) 
and founders 140 and 144. However founder 144 was sterile as no offspring were 
generated when the mouse was set up in several breeding-pairs. The founders of lines 127 
and 141 could also have been mosaics as only 32% and 11% of the offspring from the first 
generation were transgenic positive respectively.
When pronuclear microinjections are performed both the integration site and the 
copy number of the transgene cannot be controlled. The configuration of the integrated 
transgene is usually in head to tail tandem repeats and with multiple copies. The copy 
number for each line was determined using two different approaches. For lines 136, 141, 
133 and 137 the copy number was found to be similar using both approaches. It was noted 
that the first approach had a maximum threshold and was under-estimating lines that had a
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high copy number. Therefore this technique should be optimised (the enzyme quantity can 
be changed as well as the incubation time) in order to provide a more accurate copy 
number and the results compared to the numbers obtained with the second approach. 
Moreover, the samples could be electrophoresed longer in order to obtain better separation 
of the high molecular weight fragments.
7.2. Does the expression level of the transgene correlate with the 
construct?
The expression analysis was performed using total RNA extracted from different 
tissues followed by RT-PCR and Southern blotting, indicating that EBER1 expression in 
these lines is very low (Chapter 4). This was also observed in tissue culture assay 
following transient transfection of the linear fragments (Chapter 3). Line 133 is the only 
line tested where no expression of the transgene was detected, suggesting that in this line 
the transgene integrated into a “silent region”, such as heterochromatin where the packing 
of the DNA is very dense and therefore proteins required for transcription cannot access 
these regions.
For all the other lines EBER1 expression was detected in the lymphoid tissues with 
different patterns and expression levels. Expression in the lymphoid tissues suggested that 
the Ep enhancer was able to direct expression of a pol HI transcript in a tissue specific 
fashion, especially for line 127 where expression was only observed in the lymphoid 
tissues and the brain. Although the data are not directly comparable and the method used to 
detect expression is not absolutely quantitative, the highest expressing lines from each 
construct were determined to be lines 136 and 142 for p670,127 for p671, 131 and 137 for 
p672. A quantification of EBER1 expression level was then performed using the Peyer’s 
patches and thymus samples of these lines. The results showed that the expression of 
EBER1 was not dependent on the construct; for example in the Peyer’s patches, mice of 
line 127 (construct p671) have a higher expression level than mice of line 131 (construct 
p672) followed by mice of line 142 (construct p670), mice of line 137 (construct p672) and 
mice of line 136 (construct p670). This does not reflect the tissue culture observation 
where constructs p670 and p671 showed a higher level of EBER1 expression than 
construct p672 (Chapter 3) and also previously published data from transient transfection
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assays using deletion mutants (Wensing et a l, 2001). Therefore in these mice, the level of 
EBER1 expression is independent of the different elements present on the promoter. This 
could be explained by the fact that the previous observations were only described 
following transient transfection assays as opposed to a “stable integration” in the mouse. It 
would be of interest to examine EBER1 expression level following stable transfections of 
the three constructs and determine if they are construct dependent or independent. In this 
assay it was also determined that the EBER1 expression level was lower than that of 
established BL cell lines.
7.3. Does the expression pattern of the transgene correlate with the 
construct?
For both lines of construct p670, the highest EBER1 expressing tissue was the 
thymus followed by the peripheral lymph nodes, mesenteric lymph nodes, bone marrow 
and Peyer’s patches for line 136 and bone marrow, spleen and liver for line 142. In 
addition line 136 was shown to express EBER1 in several non-lymphoid tissues at a low 
level. Line 127 (construct p671) was shown to express EBER1 at a relatively high level in 
Peyer’s patches followed by the thymus, peripheral lymph nodes and bone marrow and 
expression was also detected in the brain but not in any other non-lymphoid tissue tested. 
For line 145, the second p671 line, the highest EBER1 expressing tissue was the peripheral 
lymph nodes followed by mesenteric lymph nodes, spleen and thymus. For the p672 
construct (lacking all the EBER1 upstream motifs apart from the TGTA box and only 
including the Ep), the expression patterns were also very variable between the lines, with 
line 131 highest expressing tissues being the peripheral lymph nodes and mesenteric lymph 
nodes followed by bone marrow, spleen, thymus and Peyer’s patches. Expression was also 
detected in several non-lymphoid tissues tested. Line 132 expression was medium in the 
thymus and low in the other lymphoid tissues tested. For line 134 EBER1 expression was 
high in the spleen and low in mesenteric lymph nodes and thymus, whereas line 135 only 
showed high expression in the thymus. The highest EBER1 expressing tissue for line 137 
was the thymus and expression was very low in other lymphoid and non-lymphoid tissues 
tested. Line 138 was shown to express EBER1 at a relatively high level in peripheral 
lymph nodes followed by thymus. As expression was also detected in several non­
lymphoid tissues for a few lines it could suggest that the transgene has integrated near a
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cellular gene which could influence the expression pattern or that the transgene was not 
sufficiently lymphoid specific. However, expression in non-lymphoid tissues is not 
uncommon in Ep, transgenes and was also observed in other studies (Dildrop et al., 1989, 
Wilson et al., 1990, Alkema et al., 1997). Although the Ep enhancer was used to direct 
expression to the B cell compartment, several lines (127, 135, 137, 138) showed relatively 
high expression in the thymus and it is also not unsual for transgenic mice with an Ep 
enhancer to express the transgene in T cells. For instance, EpLmyc mice and Ep-IEX-1 
mice develop T cell lymphomas and EpBiml mice are highly susceptible to both T and B 
cell lymphomas (Moroy et a l, 1990, Zhang et a l, 2003, Alkema et al, 1997). Despite this, 
lymphomas in 127 mice were shown to be of B-cell origin.
In conclusion, the pattern of expression was found to be variable within and 
between constructs, showing no correlation with the transgene construct.
7.4. Does EBER1 expression in vivo affect the dsRNA interferon 
response?
EBERl was shown to have a role in the inhibition of the anti-viral effect of IFN. It 
was demonstrated that EBERl could bind PKR and inhibit its activation both in vitro and 
in vivo (Clarke et a l, 1991, Sharp et al., 1993, Yamamoto et a l, 2000, Nanbo et a l, 2002). 
Thus the possible involvement of EBERl in the inhibition of an IFN response in the 
EpEBERl mouse model was tested following injection of dsRNA (pIC) in the tail vein of 
the animal. In the spleen of line 127 transgenic positive mice a very slight activation of 
PKR was observed and considered negligable compared to that of wild-type mice, which is 
in accordance with previous reports. However, eIF2a, which is a PKR substrate, was 
shown to be phosphorylated in both wild-type and transgenic positive mice treated with 
pIC, suggesting that in this tissue EBERl does not block phosphorylation of eEF2a. The 
DNA binding activity of NFkB remained unchanged following pIC treatment in both wild- 
type and transgenic positive mice, which was surprising as an increase in NFkB DNA 
binding activity was expected at least for the wild-type samples following treatment, 
suggesting that either the EMSA performed was not sufficiently sensitive or that the effect 
of PKR on NFkB occurs at a later time point than the one used for collecting the tissues. In 
order to explore this result further a western blot with an anti-total IkB antibody could be
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performed, as IkB is a PKR substrate, and a decrease in the total level of IkB would imply 
activation of NFkB. Statl, which is invoved in the IFN signalling pathway, was shown to 
be upregulated and activated following pIC treatment in both wild-type and transgenic 
positive mice. However a different result was observed when thymus protein extracts of 
mice of lines 127 and 137 were used. For instance, Statl was not upregulated and activated 
following pIC treatment in the transgenic positive samples when compared to wild-type. 
This would suggest that EBERl is blocking Statl expression and activation by a yet 
unknown mechanism in this tissue. It should be noted that in the thymus of mice of both 
lines 127 and 137 EBERl expression is higher and could explain the different result for 
Statl between the spleen and thymus of line 127. It would be interesting to determine the 
status of PKR and eIF2a in the thymic protein extracts. If both PKR and eIF2a are not 
phosphorylated it would suggest that EBERl does inhibit the IFN response via PKR in this 
tissue and that a higher expression level of EBERl is needed to achieve it. If they are both 
phosphorylated and the inhibition of Statl expression and activation is confirmed, it would 
suggest that EBERl is able block the IFN signalling pathway via Statl by a yet unknown 
mechanism. A report was recently published showing that following IFNa treatment of 
both EBER positive and negative BL cells, PKR was upregulated and activated and eIF2a 
was also phosphorylated (Ruf et al., 2005), suggesting that protection against IFNa 
apoptosis was not due to inhibition of PKR by EBERs and contradictory to previous 
findings by other groups. It could be possible, considering the results presented in this 
thesis, that induction of Statl was inhibited in Ruf and colleagues’ assays and therefore 
lead to inhibition of apoptosis. However, Ruf and colleagues’ experiments were performed 
following IFNa treatment as opposed to pIC treatment as described here. Thus it would be 
interesting to examine the results from the thymocyte and splenocyte explants for lines 127 
and 137 following various treatments (pIC or IFNa) and determine if they follow the same 
trend as the one observed with the tissues. This assay would also enable the direct 
comparison between pIC and IFNa treatment and provide more insight into the 
relationship between PKR and EBERl.
In conclusion, following dsRNA treatment in the spleen of line 127 transgenic 
positive mice, EBERl may be blocking PKR but this is not apparent in its substrates or 
Statl and therefore the IFN response might not be blocked in this tissue. However, with 
higher EBERl expression in the thymus of lines 127 and 137 transgenic positive mice,
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Statl induction is blocked, which may indicate a new mechanism of EBERl action in the 
LFN response. However activation of PKR and its substrates has yet to be analysed in this 
tissue.
7.5. Does EBERl expression in vivo predispose to tumourigenesis?
53% of the transgenic positive mice in the phenotype watch of line 127 animals 
developed lymphomas with a late onset compared to 12.5% in controls. The average age of 
tumour development was 18 months. The late onset could be due to the low expression of 
EBERl in the tissues. However, the development of B-cell lymphomas in these mice 
suggests an oncogenic role for EBERl, independent of the presence of other viral genes 
and thus implicating EBERl in the pathogenesis of EBV associated tumours at least in B- 
cell tumours. The development of lymphomas in other independent lines would further 
support this and the phenotype watches were still underway at the time of writing. As mice 
of line 127 have developed lymphomas so far, the hypothesis that the phenotype could be 
caused by an insertional mutation in this line cannot be excluded. The transgene could 
have inserted near an oncogene or have disrupted a gene. To investigate if this is the case, 
the site of insertion of the transgene could be determined and the genes in close proximity 
to the transgene which could potentially influence the phenotype observed would then be 
identified. Two known oncogenes, Araf and Elkl, and members of the Ras and myc 
families are located on the X chromosome and therefore could influence the phenotype in 
this line as the transgene was shown to be X-linked (Chapter 3).
The animals in the other lines under phenotype watches are now reaching the age of 
lymphoma onset of line 127 and so far one mouse has succumbed to lymphoma at 13.5 
months of age for line 131. The repeated observation of lymphoid expansion in younger 
animals of lines 137 and 136, which is statistically significant (summary in table 7.1), is an 
encouraging sign and one could predict that animals in these 2 lines will develop 
lymphoma, as lymphoid expansion was also observed in young line 127 mice but not in 
any negative controls. In mice of line 145 a phenotype comprising of multiple lymph nodes 
at several locations (instead of the usual one) was observed in young animals (Table 7.1) 
and is statistically significant.
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Chapter /. Uiscussion
Cross-breeding studies have shown that EBERl (line 127) cooperates with N-myc 
in B-cell lymphomagenesis, whereas no cooperation was observed between EBERl (line 
127) and EBNA1 or EBERl (lines 127 and 136) and c-Myc.
Several approaches have been taken to investigate the mechanism of tumour 
formation in mice of line 127. It was shown that it was not likely to be due to increased 
EBERl expression in the tumour samples, although the approach used was not fully 
quantitative. The expression level of c-Myc was shown to be unchanged in pre-tumour and 
line 127 tumour samples as compared to wild-type. No rearrangement in the c-Myc locus 
in the EpEBERl tumours was observed. However, this technique only examines 
rearrangements in close proximity to the myc locus and therefore does not provide any 
information with respect to possible trisomy or translocation at greater distance from myc, 
which could have occurred. Trisomy of chromosome 15 (carrying c-myc) was previously 
observed with EjaEBNAI mice of line 26 (Drotar et a l, 2003). Despite no apparent 
increase in c-Myc expression levels, the DNA binding activity of Myc was increased in the 
two 127 tumour samples tested when compared to wild-type mice. However two different 
results were obtained; the DNA binding activity of sample 127.37 resembled that of the 
transgenic c-Myc control sample, whereas for sample 127.49 two extra specific bands were 
observed suggesting that in this tumour additional protein complexes, such as other 
members of the Myc family, Max, members of the Mad family and Mnt, bind to this oligo.
Id2 is a member of the Id family of genes which are basic helix-loop-helix proteins 
lacking a DNA binding domain (Perk et al., 2005, for review). The Id proteins were found 
to be upregulated in many cancers including BL (Nilsson et al., 2004). Id2 was shown to 
be the only member of the Id family able to bind to hypo-phosphorylated Rb and lead to 
cell cycle progression (Iavarone et al., 1994). As Id2 was shown to be a transcriptional 
target of c-Myc (Lasorella et al., 2000), Id2 expression was analysed in line 127 tumour 
samples. Id2 was found to be upregulated in the sample (127.37) with the same DNA 
binding profile as that of the c-Myc sample by EMSA, whereas no Id2 expression was 
detected for sample 127.49 with the extra EMSA bands. This suggests that for mouse 
127.37 Id2 was implicated in the mechanism leading to tumour formation, possibly by 
enhancing cycle progression. Due to time limitations, other 127 tumour samples were not 
analysed for Id2 expression but it would be interesting to determine in which category they
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fall. However, this result suggests that in some cases EBERl expression could lead to 
upregulation of genes involved in cell cycle progression.
In order to assess if EBERl and c-Myc cooperate in lymphomagenesis EpEBERl 
mice (lines 127 and 136) were crossed with Epc-myc mice. From the data obtained the two 
genes do not appear to cooperate in lymphomagenesis, thus indicating that either the two 
genes have redundant modes of action or that c-Myc is such a powerful oncogene in itself 
that only the presence of another strongly expressed oncogene with a complementary 
function would accelerate tumour onset, as described when Ep,c-myc mice were crossed 
with EpBdh mice (Strasser et al., 1990). With the 97136 cross more bi-transgenic mice are 
needed in order to perform a thorough analysis, but so far the results indicate that the 
presence of the c-Myc binding site on the EBERl promoter does not lead to increased 
tumour onset when c-Myc is over-expressed. However, it would be interesting to 
determine if EBERl expression is changed in the 97136 bi-transgenic mice, which could 
provide more information on the involvement of the c-Myc binding site in EBERl 
transcription. Analysis of a bi-transgenic 97127 tumour sample showed that Myc DNA 
binding activity and Id2 expression were unchanged when compared to a c-Myc (97) 
sample.
As EjiN-myc mice develop B-cell lymphoma with a longer latency than Ep,c-myc 
mice, a cross-breeding programme was undertaken between EpN-myc and EpEBERl 
(lines 127 and 137) to determine if the two genes could cooperate in lymphomagenesis. A 
biphasic phenotype was observed for the N-myc animals, the first phase being a thymoma, 
possibly indicative of a T cell lymphoma, which was detected in young mice and the 
second one being a B-cell lymphoma involving enlargement of the lymph nodes and spleen 
as previously described by Dildrop et al., (1989) in older mice. In their study, N-myc was 
found to be highly expressed in the spleen and to a lower extent in the thymus, which is 
indicative of both B and T cell expression. As N-myc is less oncogenic than c-Myc in B 
cells it could allow for a T cell phenotype to develop. In order to determine if the animals 
succumbing to a thymoma developed a T cell lymphoma, the samples should be analysed 
for T cell receptor rearrangement. The result from this experiment will be used to 
determine if these animals should be excluded from the B-cell lymphoma incidence in this 
study. If they are included the difference in tumour incidence between N-myc mice and bi-
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transgenic mice (96127) was not found to be statistically significant, and therefore would 
indicate that the two genes do not cooperate in lymphomagenesis. However, it should be 
noted that the median age for both groups is very different with the bi-transgenic (96127) 
mice succumbing to lymphoma twice as fast as N-myc mice, which is indicative of an 
accelerated phenotype and would tend to suggest a possible cooperation between the two 
genes. This was supported when the mice with a thymoma were excluded from the B-cell 
lymphoma incidence as the difference between the two curves was found to be statistically 
significant. It would be interesting to compare these results with the 96137 study upon 
completion. If both studies show similar results it will be strongly indicative of a 
cooperation between EBERl and N-myc in B-cell lymphomagenesis. The bi-transgenic 
96127 tumours were shown to be of B cell origin as was previsouly described for N-Myc 
by Dildrop et al., (1989). To investigate the mechanism of cooperation between the 
EBERl and N-myc, expression of EBERl was analysed in bi-transgenic samples and 
compared to EBERl tumour samples and was shown to be unchanged, although the 
method used was not entirely quantitative. N-myc expression level was unchanged when 
the bi-transgenic and N-myc tumour samples were compared. It was noted that the 
expression level of the 66kDa protein in a thymoma (sample 37 T on the blot) was low, 
suggesting that the phenotype in this mouse arose by a different mechanism and would 
favour the removal of the mice succumbing with a thymoma from this study. However in 
order to conclude fully on this, N-myc expression should be analysed in different 
thymomas. A higher band was also observed on the blot (in all N-myc and bi-transgenic 
samples) and like the N-myc band was blocked with the N-myc blocking peptide. One 
hypothesis is that this band could be reflective of an N-myc (homo or hetero) dimer. It 
could also be an N-myc related protein of high molecular weight, as it is specific to the 
peptide. The Myc DNA binding activity was the same in the N-myc and bi-transgenic 
samples. These results suggest that the cooperation mechanism between EBERl and N- 
myc is likely due to the complementary actions of both genes. One could imagine that 
EBERl could complement the action of N-myc with an anti-apoptotic activity.
As mentioned previously, EBERl and EBNA1 do not cooperate in 
lymphomagenesis, thus indicating that the two genes are redundant and possibly activate 
pathways of similar functions in the cell leading to the phenotype observed. It was 
previously shown in the laboratory that EBNA1 expression in transgenic mice lead to 
increased expression of B cIxl  and increased survival via upregulation of a cytokine, IL2
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(Tsimbouri et al., 2002). It was previously observed that EBER expression led to increased 
Bch expression in BL (Komano et al., 1999). Therefore, it is possible that in line 127 
EBERl could lead to the upregulation of an anti-apoptotic gene such as Bch or even B cIx l - 
Hence, it would be of interest to determine the expression level of these genes in different 
EBERl tumours and compare it with pre-tumour samples. Expression of EBERl in 
transgenic positive mice could lead to increased survival and also upregulate a B cell 
growth or survival factor. It was observed in BL cell lines that EBERs increased 
expression of IL10 (Kitagawa et al., 2000). In the serum of mice of lines 127 and 137 
several cytokines were tested and the results may indicate increased levels for some of 
them; however these results need to be confirmed with other serum samples. Amongst 
these cytokines, IL10 level was increased in samples from line 127 young animals and 
from older animals with tumours. This upregulation was not observed in the serum of mice 
of line 137. As EL10 is used as an autocrine growth factor for B-cells (Rousset et al., 1992) 
it is possible that sustained EL10 secretion might promote tumour formation in B-cells. 
EL10 was shown to inhibit NFkB activity (Driessler et a l, 2004) in human monocytic cells 
and it is possible that a similar effect occurs in B-cells. If true, IL10 upregulation by 
EBERl could lead to inhibition of IFN|3 expression and also expression of other essential 
genes involved in apoptosis, for example, which contain an NFkB binding site in the 
promoter. An NFkB binding site was found in the p i00 form of human 2’5’OAS (three 
2’5’OAS isoforms have been identified, p40/46, p69/71 and plOO) (Rebouillat etal., 2000) 
and also in the promoter of the murine PKR gene (Tanaka and Samuel, 1994). Therefore, 
one can hypothesise that inhibition of NFkB by ELIO could block expression of both PKR 
and 2’5’OAS, which would then impair the EFN response. It would be interesting to 
determine by which mechanism EBERl upregulates IL10 expression as it would give 
further insight into its oncogenic role.
Another possibility is via PKR, as it has been shown that EBERl blocks PKR 
actions in vitro and in vivo (Clarke e ta l, 1991, Shaip et al., 1993, Yamamoto etal., 2000, 
Nanbo et al., 2002). This is supported by a report where a mutant PKR was shown to 
enhance tumourigenesis (Koromilas et al., 1992, Meurs et al., 1993). This mechanism 
could involve the extensive enhancement of protein synthesis from both cellular and viral 
mRNA. However, this has yet to be confirmed in the EpEBERl mice as PKR activation 
following pIC treatment was inhibited (in the spleen of mice of line 127) but not
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eIF2a phosphorylation. Moreover a recent report has suggested that the anti-apoptotic 
actions of EBER are not mediated by PKR (Ruf et al., 2005), thus suggesting alternative 
mechanisms independent of PKR. This could be mediated via Statl, as it was not induced 
or activated in the thymus of lines 127 and 137 following pIC treatment and its loss of 
expression has previously been implicated in oncogenesis (Kaplan et a l, 1998). A report 
showed that following dsRNA treatment, PKR induced phosphorylation of p38 (Silva et 
a l., 2004), which then leads to the activation of Statl (Ser 727) (Goh et al., 1999). 
Therefore it is possible that EBER1 acts via p38 and inhibits its phosphorylation, leading 
to inhibition of Statl activation, which would promote anti-apoptotic effects. However p38 
phosphorylation was not analysed in the samples following pIC treatment.
MicroRNA (miRNAs) are derived from long double-stranded transcripts (pri- 
miRNA) with a high degree of secondary structure and are processed by Drosha, an RNase 
n i endonuclease, to generate a precursor miRNA (pre-miRNA), which is then exported to 
the cytoplasm. The pre-miRNA is then processed by Dicer (which is the same enzyme that 
processes dsRNA to siRNAs), another RNase HI endonuclease, to generate a miRNA, 
which will be taken up by the RNA induced silencing complex (RISC) leading to either 
mRNA degradation or translation inhibition (Bartel, 2004, for review). A miRNA 
polycistron (mir-17-92) was recently reported to be acting like an oncogene. It was found 
amplified in different B lymphoma samples as compared to wild-type samples and was 
shown to cooperate with c-Myc to accelerate tumour onset (He et al., 2005). As EBER1 is 
an RNA with a high degree of secondary structure and was shown to cooperate with N- 
myc in B-cell lymphomagenesis, it can be hypothesised that EBER1 could be the precursor 
of a miRNA. It is possible that the EBER1 miRNA could originate from the usual start or 
from the upstream start of EBER1. This was demonstrated in different Ep.EBERl 
transgenic lines (127 and 131, possibly 137) and confirmed in Raji using an RT-PCR 
approach and to date has an unknown function (Chapter 4, Jat and Arrand, 1982, Arrand 
and Rymo, 1982). Therefore future work to test this would be to detect if EBER1 can lead 
to production of a miRNA and also if the level of this EBER1 miRNA increases between a 
pre-tumour tissue and a tumour tissue. If EBER 1 is a miRNA it could also down-regulate 
the expression of genes which negatively regulate anti-apoptotic genes, thus leading to 
overexpression of these anti-apoptotic genes. A recent study has shown that two miRNAs, 
miR-15a and miR-16-1, act as tumour suppressor genes. In chronic lymphocytic leukaemia,
138
Chapter 7. Discussion
miR-15a and miR-16-1 have been shown to either be down-regulated or deleted, which 
leads to the upregulation of Bcl2 (Cimmino et al., 2005). A study using BL41/B95.8 cells 
reported the identification of 5 miRNAs expressed by EBV; however the EBERs were not 
included (Pfeffer et al., 2004). The same group also reported the identification of miRNAs 
from several members of the herpesviridae (Pfeffer et al., 2005).
The development of cancer involves a succession of events and therefore EBERl’s 
actions as an oncogene could combine more than one mechanism suggested here.
7.6. How does EBER1 contribute to the actions of EBV in healthy 
individuals?
Following a viral infection dsRNA is produced, from viral replication and protein 
synthesis, which can trigger the induction of an immune response (eg IFN response) in the 
infected cell. This may lead to death of this cell and neighbouring cells. One of the best 
characterised functions of the EBERs is to block the IFN response via binding of PKR and 
inhibition of its autophosphoiylation. This enables the virus to evade the IFN response and 
also to control protein synthesis, as one of the substrates of PKR is the translation initiation 
factor eIF2a. Therefore viral proteins can be expressed and the infected cell does not die. 
The EBERs have also been reported to inhibit apoptosis under other conditions (Nanbo et 
al., 2002, Wong et al., 2005) and therefore could promote survival of the virus infected 
cells. Recently the EBERs have been suggested to contribute to the immortalisation 
process using EBER-deleted virus and EBV Akata negative cells (Yajima et al., 2005). 
This could be mediated by the expression of IL10, which could provide an autocrine 
growth factor to the infected cells and ensure their longer-lived status. IL10 also inhibits 
Thl response and favours a Th2 response (Kidd, 2003, for review). As IFNy is produced 
by differentiated Thl cells (Murphy and Reiner, 2002, for review) one can hypothesise 
that the IL10 induced skew towards Th2 cells mediated by the EBERs would lead to a 
reduction in IFNy production. Therefore, as well as restricting the production of IFNa and 
IFN($ the EBERs could also control the response mediated by IFNy. For the virus, this 
would provide evasion from the IFN systems and thus contribute to establishing life-long 
viral persistence.
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In this study it was also shown that the presence of EBER1 did not change the 
proportions of B and T cells or their status in the transgenic mice, suggesting that EBER1 
does not interfere with B and T cell development (Chapter 5). However it should be noted 
that in the Peyer’s patches of line 127 transgenic positive mice, there was a skew towards a 
possible B1 population when compared to wild-type animals. This increase in B1 cells was 
also described in LMP2A transgenic positive animals (Ikeda et al., 2004). This skew in 
both cases could be due to the system used (eg expression in transgenic mice) rather than 
to a function that would manifest also during viral infection. However, if  EBER1 and 
LMP2A favour the development of B1 cells as opposed to B2 cells following EBV 
infection, this could be advantageous for virus persistence as B1 cells are longer lived then 
B2 cells (Berland and Wortis, 2002, Martin and Kearney, 2001, for reviews).
It was recently demonstrated that adenovirus VAI and VAII RNA inhibited RNA 
interference (RNAi) resulting from small hairpin RNAs (shRNAs) and pre-miRNAs (Lu 
and Cullen, 2004, Andersson et al., 2005). It was shown that this effect was mediated 
through competitive binding to both exportin 5 nuclear export factor and the RNase HI 
Dicer. The VA RNAs were shown to be processed by Dicer into siRNAs and incorporated 
by RISC. As the EBERs share similar properties with the VAs (pol IQ transcripts with a 
high degree of secondary structure that bind and inhibit PKR) and were shown to 
functionally replace the VAs in a mutant Adenovirus lacking VA genes (Bhat and 
Thimmappaya, 1983, Bhat and Thimmappaya, 1985), one can hypothesise that the EBERs 
could also function as suppressors of RNAi in EBV infected cells and thereby contribute to 
the persistence of the infected cells.
7.7. Future directions
As this is the first report describing the generation of transgenic mice expressing a 
pol III gene following pronuclear microinjection, it is of particular importance to fully 
determine if the transgene produces a pol Q or pol QI transcript. An RT-PCR approach was 
undertaken and showed that the EBER1 transcript in different lines (127, 131, 134, 136 
and 137) does not contain a polyA tail, therefore indicating that it could be a pol QI 
transcript (Chapter 4). To further confirm this in the transgenic mice, a primer extension 
assay using an EBER1 specific reverse primer could be performed. A run on assay could
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also be performed using nuclei isolated from an EBER1 transgenic mouse tissue with and 
without a-amanitin treatment. If EBER1 in the transgene mice is confirmed to be a pol ID 
transcript this study would be the first report describing the generation of transgenic mice 
expressing a pol HI gene.
As EBER1 was previously shown to bind to PKR and inhibit its activation, it would 
be of interest to analyse the kinase activity of PKR in EpEBERl lines and possibly in the 
tumour samples. This would confirm if PKR is involved in the oncogenic properties of 
EBER1. However it should be noted that kinase activity of PKR might be increased in the 
samples, as it has been shown that L22 could regulate PKR activity through its ability to 
sequester EBER1 (Elia et al., 2004). Therefore it would also be of interest to analyse L22 
in these samples. EBER1 has also been shown to bind and activate 2’5’OAS in vitro. It 
would be of interest to assess 2’5’OAS activity in the transgenic positive mice and 
determine if it is also activated in vivo. This could be performed by monitoring RNase L 
activity, as RNase L is activated by 2’5’A which are synthesised by activated 2’5’OAS, 
using one of the protocols described by Player et al., (1998).
The mechanism by which EBER1 exerts its actions remains largely unknown. To 
explore this, the establishement of an EBER1 expressing cell line derived from a tumour 
tissue would be a very useful tool. This has been attempted but has yet to be successful.
If the EBERs can act to suppress RNAi, as hypothesised in section 7.6, it is 
possible to imagine that EBER1 in line 127 mice could compete for Dicer binding and 
therefore inhibit the processing of some transcripts which would normally lead to 
inhibition of their target genes. In this case, the intact target genes would still be present in 
the cells and could therefore lead to a tumour phenotype. Moreover if the EBER1 can be 
processed into a functional siRNA, it could potentially target a tumour suppressor gene and 
lead to its mRNA degradation. Thus it would be interesting to determine if the activity of 
Dicer is changed in EBV positive BL cells as compared to EBV negative BL cells, as well 
as in the mice samples and if the EBERs can be processed into functional siRNAs. EBER1 
could also regulate its own expression with this process, as its high expression could be 
toxic to the cells, and thus modulate its effects.
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As EBER1 might be implicated in the disease process of the virus, it would be a 
good target for therapeutic purposes in EBV infected cells. Therefore the properties of 
EBER1 (and EBER2) can be used to develop assays to either inhibit their expression or to 
use their properties. For instance, one could imagine that the IFN response could be 
restored in EBV infected cells if EBER1/EBER2 expression is inhibited. siRNAs targeting 
both genes could be transfected into EBER expressing cells and followed by either IFNa 
or pIC treatment to induce an IFN response. If the EBERs are inhibited it could lead to 
apoptosis of the cells. If the proof of concept is validated in BL cell lines it can then be 
tested in vivo by injecting the EBER1 siRNA into the tail vein of EpEBERl mice as 
described by Lewis et al., (2002), followed by either IFNa or pIC treatment and analysis 
of the response in tissues expressing EBER1.
This project was conducted using EBER1 and no investigation into the role of 
EBER2 was performed. Due to the similarities between EBER1 and EBER2 one can 
hypothesise that they might act in a similar fashion. Therefore EBER2 could also have 
oncogenic properties in B-cells in vivo. To test this, one could generate EBER2 transgenic 
mice; however tumours might develop with a long latency as was observed for EBER1 
(line 127). The generation of EBER1-EBER2 transgenic mice might provide more 
information on the properties of the EBERs in vivo and it might also lead to shorter tumour 
latency as the expression might be higher in the cells when both genes are present. The fact 
that both EBER1 and EBER2 are present in EBV infected cells (as are VAI and VAR in 
adenovirus infected cells) and also in EBV associated malignancies leads to the hypothesis 
that both genes are needed for a full phenotype. However, the presence of two slightly 
different genes having similar roles is intriguing and could suggest that they might have 
different functions. An upstream transcription start was detected for the EBER1 gene, 
which led to the expression of a minor EBER1 species (Chapter 4, Jat and Arrand, 1982, 
Arrand and Rymo, 1982). However Arrand and colleagues did not observe this minor 
species for EBER2. Therefore, the minor EBER1 species could provide other functions for 
EBER1 that EBER2 would not have. It would be of interest to test if EBER2 is a miRNA 
precursor and therefore can lead to the production of a miRNA. EBER2 could also act to 
suppress RNAi (like the VA RNAs). One could determine if EBER2 can compete for 
Dicer binding and can be processed into a functional siRNA.
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Appendix 1: pcDNA3.1 vector from Invitrogen
The figure shows the pcD N A 3.1 vector which was used to clone the three different EBER1 
inserts. The Ep was first cloned using H ind iII and E coR l restriction sites and the different 
EBER1 inserts were cloned using E co R l  and X h o l  restriction sites. These sites are 
indicated by arrows. The figure o f the vector was taken from Invitrogen’s website.
